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1. SUMMARY 
Pediatric cancer is the most common disease-related form of death in children and adolescents. The 
advent of chemotherapy and radiotherapy in the middle of the last century helped to drastically decrease 
the mortality rate. Yet, the harsh treatment regimens come at the price of developmental defects, 
cognitive impairments, and the increased risk of secondary malignancies even after years of the initial 
treatment. Despite the higher chances of curing patients, many cancers relapse and become resistant 
to the standard-of-care therapy. Thus, both to improve survival rates of patients and to reduce the burden 
of side-effects new treatment strategies need to be found, targeting cancer specific abnormalities. Many 
cancers become so reliant on specific oncogenic signals that withdrawal of these signals has detrimental 
effects on the cancer cells. This, so called oncogene addiction offers opportunities to target cancer cells 
pharmacologically. 
One example of oncogene addiction can be seen in rhabdomyosarcoma (RMS), specifically the alveolar 
subtype. RMS is the most common soft-tissue sarcoma in children, accounting for 3-4% of all pediatric 
cancers. The two major subtypes, embryonal RMS (eRMS) and alveolar RMS (aRMS), have their peak 
of incidence in early childhood and adolescence, respectively. aRMS tumors have the worst prognosis 
of all childhood RMS cases with 5-year overall survival rates of only around 21%.  
The pathognomonic aberration in aRMS is a chromosomal translocation. Most commonly this 
translocation results in the expression of the fusion protein PAX3-FOXO1. This fusion protein is a 
transcriptional activator and the major driver of aRMS tumorigenesis and essential for tumor cell survival. 
Thus, aRMS cells are addicted to the oncogenic features of this fusion protein. As targeting a 
transcription factor directly is near impossible, we wanted to find other strategies to interfere with the 
biology of the fusion protein. 
Hence, our aim in this study was, on the one hand, to characterize the effectors by which PAX3-FOXO1 
prevents cell death in aRMS cells. On the other hand, we aimed to find new ways to pharmacologically 
interfere with PAX3-FOXO1 stability. Based on these findings, the foremost aim was to find a 
combination therapy, priming aRMS cells to cell death resulting from loss of PAX3-FOXO1 activity. 
Here, we demonstrate that aRMS cells upregulate the BH3-only protein NOXA and undergo intrinsic 
apoptosis dependent on NOXA, after genetic silencing of PAX3-FOXO1. In line with these findings we 
show that the BH3-mimetic ABT-263 (Navitoclax) can prime aRMS cells for this mode of cell death in 
NOXA-dependent manner. Furthermore, we demonstrate a novel functional interaction of PAX3-FOXO1 
with Aurora kinase A which stabilizes the fusion protein by phosphorylation. Consequently, inhibition of 
Aurora kinase A, with the small molecule inhibitor Alisertib results in less PAX3-FOXO1 stability. In line 
with these findings, combination of both Navitoclax and Alisertib synergistically induces cell death in 
vitro and with lasting effects reduces xenograft tumor growth in vivo.  
Lastly, we also established a potential novel transcriptional regulation of MDM2 by the fusion protein in 
aRMS. Consequently, we show that aRMS cells from patient-derived xenografts are sensitive to 
pharmacological disruption of the MDM2/p53 interaction by Idasanutlin.  
Taken together, this study reveals new functional interactions of PAX3-FOXO1 and its activities to 
prevent cell death and provides novel strategies for combination therapies. 
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2. ZUSAMMENFASSUNG 
Krebs ist die häufigste krankheitsbedingte Todesursache bei Kindern und Jugendlichen. Die 
Entwicklung von Chemotherapeutika und Strahlentherapie Mitte des vorherigen Jahrhunderts konnte 
die Sterblichkeitsrate drastisch senken. Dennoch führen die harschen Behandlungen bei Kindern zu 
vielen Nebenwirkungen, wie Entwicklungsstörungen, kognitiven Einschränkungen und einem erhöhten 
Risiko sekundäre maligne Erkrankungen zu entwickeln, selbst Jahre nach der ursprünglichen 
Behandlung. Trotz hoher Chancen, Patienten zu heilen, können viele Krebsarten resistent gegenüber 
der Standardbehandlung werden. Es müssen also neue Therapien entwickelt werden, die spezifisch 
gegen Krebszellen gerichtet sind, um die Überlebensraten zu steigern und gleichzeitig Nebenwirkungen 
zu reduzieren. Viele Krebszellen werden abhängig von onkogenen Signalen, dass der Entzug dieser 
Signale vernichtende Wirkungen auf die Zellen hat. Dieses Konzept der Onkogenabhängigkeit bietet 
neue Chancen, Krebszellen pharmakologisch anzugreifen.  
Ein Beispiel der Onkogenabhängigkeit kann in Fällen des alveolären Rhabdomyosarkoms (RMS) 
beobachtet werden. Mit 3-4% aller pädiatrischen Krebsfälle ist RMS die häufigste Form des 
Weichteilsarkoms in Kindern. Die zwei Haupttypen sind das embryonale und das alveoläre RMS 
(aRMS). Das embryonale RMS tritt am Häufigsten im frühen Kindesalter auf, während die meisten 
aRMS-Fälle bei Jugendlichen auftreten. Mit einer 5-Jahres Überlebensrate von gerade einmal 21% 
haben aRMS Tumoren die schlechteste Prognose aller RMS Fälle. 
Typisch für aRMS Tumoren ist, dass sie eine chromosomale Translokation aufweisen. Am Häufigsten 
führt diese dann zur Expression des Fusionsproteins PAX3-FOXO1. Dieses Fusionsprotein ist als 
Transkriptionsfaktor die treibende Kraft in der aRMS Tumorgenese und essentiell für das Überleben der 
Tumorzellen. Daher sind aRMS Zellen von diesem Onkogen abhängig. Leider ist sehr schwierig einen 
Transkriptionsfaktor pharmakologisch zu inhibieren. Daher wollen wir neue Strategien finden, wie man 
die Aktivität des Fusionsprotein unterdrücken kann. 
Das Ziel dieser Studie war daher einerseits, die Effektoren zu charakterisieren, durch die PAX3-FOXO1 
den Zelltod in aRMS Zellen verhindert. Weiterhin wollten wir neue pharmakologische Ansätze finden, 
die Stabilität des Fusionsproteins zu beeinflussen. Letztendlich war das Ziel, eine Kombinationstherapie 
zu finden, die aRMS Zellen für den Zelltod sensitivieren der aus dem Verlust von PAX3-FOXO1 
resultiert. 
In dieser Studie zeigen wir, dass aRMS Zellen das BH3-only Protein NOXA hochregulieren und in 
Apoptose gehen, wenn man das Fusionsprotein mit genetischen Mitteln ausschaltet. Der Wirkstoff ABT-
263 (Navitoclax) sensitiviert aRMS Zellen für diese Form des Zelltods. Weiterhin zeigen wir eine neue 
funktionale Interaktion zwischen PAX3-FOXO1 und Aurora Kinase A, welche das Fusionsprotein durch 
Phosphorylierung stabilisiert. Inhibition von Aurora Kinase A mittels Alisertib reduziert 
konsequenterweise die Stabilität des Fusionsproteins. Die Kombination von Alisertib und Navitoclax 
induziert Zelltod in vitro und reduziert das Tumorwachstum stabil in Xenograft Experimenten in Mäusen.  
Zuletzt zeigen wir noch eine potentielle neue Regulation von MDM2 durch das Fusionsprotein und dass 
Zellen aus Patientenproben sensitiv gegenüber der Inhibition von MDM2 durch Idasanutlin sind. 
Zusammengefasst zeigt diese Studie neue funktionelle Interaktionen von PAX3-FOXO1 auf und wie es 
Zelltod verhindert. Weiterhin zeigen wir neue Ansätze für Kombinationstherapien des aRMS. 
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3. LIST OF ABBREVIATIONS 
ACD Accidental cell death 
ADCC Antibody-dependent cellular cytotoxicity 
ALL Acute lymphoblastic leukemia 
APAF1 Apoptotic protease activating factor 1 
ATM Ataxia telangiectasia mutated 
ATP Adenosine triphosphate 
ATR Ataxia telangiectasia and Rad3 related 
BAK Bcl-2 homologous antagonist killer 
BAX Bcl-2 associated X protein 
BCL-2 B-cell lymphoma 2 
BRAF Rapidly accelerated fibrosarcoma 
BRCA1 Breast Cancer 1, early onset 
CAR Chimeric antigen receptor 
CASP Caspase 
CHK Checkpoint kinase 
CLL Chronic lymphatic leukemia 
CML Chronic myelogenous leukemia 
COG Children’s Oncology Group 
DAMP Danger associated molecular pattern 
DDR DNA damage response 
EGF Epidermal growth factor 
EpSSG European pediatric Soft tissue sarcoma Study Group 
ER Endoplasmic reticulum 
FDA U.S. Food and Drug Administration 
FGF Fibroblast growth factor 
FOXO1 Forkhead box protein O1 
HDAC Histone deacetylase  
IGF Insulin-like growth factor 
IRSG Intergroup Rhabdomyosarcoma Study Group 
mAb Monoclonal antibody 
Mb Mega base 
MDM2 Mouse double minute 2 homolog 
MOMP Mitochondrial outer membrane permeabilization 
mTOR Mammalian target of rapamycin 
OMM Outer mitochondrial membrane 
PARP Poly (ADP-ribose) polymerase 
PAX Paired box gene 
PI3K Phosphoinositide 3 kinase 
PLK1 Polo-like kinase 1 
PMAIP1 Phorbol-12-myrisate-13-acetate-induced protein 1 (NOXA) 
PPTP Pediatric Preclinical Testing Program 
PS Phosphatidyl serine 
RCD Regulated cell death 
RMS Rhabdomyosarcoma 
ROS Reactive oxygen species 
SAC Spindle assembly checkpoint 
VAC Vincristine / Actinomycin D / Cyclophosphamide 
VEGF Vascular endothelial growth factor 
WHO World Health Organization 
 4 
 
4. INTRODUCTION 
4.1 CANCER 
4.1.1 General 
Cancer as a disease has been reported throughout human history. The earliest written reports date back 
to around the year 3000 BC: On an ancient Egyptian papyrus a physician described the resection of a 
tumor in a female breast using a tool called “fire drill”, indicating a cauterizing method. The description 
concludes with the words: “There is no treatment”.1 Later, Hippocrates names the disease Καρκίνος 
(karkinos). Literally translated this name means “crab”, reflecting the resemblance of the tumor and its 
veins to the animal dug in the sand with its legs spread around it.1 Today, cancer is the one of the leading 
causes of death worldwide, second only to cardiovascular diseases.  
However, cancer is not “one” disease, but rather a set of diseases sharing common characteristics: 
They are the result of a process in which a cell sequentially acquires multiple mutations activating 
oncogenes, e.g. BRAF2, or inactivating tumor suppressor genes, e.g. TP533. The altered function of 
these genes leads to dysregulation of proliferation, survival signals, and response to anti-growth 
signals.4 Mutations in stability genes such as BRCA1, which is responsible for DNA damage repair, 
increase the mutation rate in a cell and contribute to tumorigenesis.5 As cells acquire more mutations 
they divide more rapidly and progress from a histological hyperplasia, via dysplasia into a cancer in situ 
that loses its tissue architecture and features but is still confined by the basal membrane (Figure 1). 
Ultimately, through more mutations cancer cells acquire possibilities to breach the basal membrane, 
invade into the surrounding tissue and enter the blood stream or lymphatic vessels to seed into distant 
organs, where they form secondary tumors, called metastases.5 
 
Figure 1: Stages of carcinogenesis from organized tissue to invasive and metastatic cancer. Adapted from6 
 
In the year 2000, Douglas Hanahan and Robert Weinberg proposed a model of oncogenic traits that 
almost every cancer will acquire, irrespective of its origin.7 These hallmarks of cancer are: resisting cell 
death, sustained proliferation, insensitivity to anti-growth signals, invasion and metastasis, replicative 
immortality and sustained angiogenesis. 7 After a revision in 2011, four new traits where added to the 
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hallmarks, acknowledging the interaction of cancer cells with their surrounding environment: evading 
immune destruction, tumor promoting inflammation, deregulating cellular energetics, and genome-
instability (Figure 2).8 While the exact sequence of when these alterations occur can differ, ultimately 
these hallmarks are common to almost all cancers and will dictate their malignancy (Figure 2).7 
 
Figure 2: The hallmarks of cancer as proposed by Hanahan and Weinberg. This revised version also acknowledges 
the influence of the cancer on the microenvironment. The outer circle indicates therapeutic ways to target each 
hallmark. Adapted from8 
4.1.2 Classification 
Tumors can be classified into benign (non-cancerous) and malignant tumors (cancerous). A benign 
tumor grows locally restricted within the boundaries of a basal membrane. Malignant tumors are those 
that breach the basal membrane, invade surrounding tissues, and metastasize.9 These malignant 
cancers account for the majority of cancer-related deaths. Carcinomas are malignant tumors arising in 
the epithelium, while those originating in the connective and supporting tissues (i.e. of mesenchymal 
origin) are called sarcomas. Cancers of the hematological system are called leukemia or lymphomas, 
neuroectodermal cancer arises from cells of the nervous system.4 
4.1.3 Epidemiology 
In the adult population the most common cancers by far are carcinomas, especially those arising in lung, 
colon or stomach, as well as prostate in men and breast and cervix in women. In 2015 8.8 Million people 
worldwide died of cancer. Globally, this number accounts for 1/6 of all deaths.10,11  
4.1.4 Etiology 
Cancer is a genetic but not necessarily inherited disease, involving mutations or other damage at the 
DNA level.2 As oncogenes, tumor suppressor genes, and stability genes are all encoded in the DNA, 
mutations in the gene or other genomic alterations can affect the expression and function of these 
genes. Herein lies the basis of tumorigenesis. Alterations are acquired throughout life, either intrinsically 
through sporadic mutation events or facilitated by extrinsic noxae. These extrinsic factors can be 
grouped into chemical agents (e.g. benzopyrene, aflatoxin), physical agents (i.e. ionizing and non-
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ionizing radiation), and biological agents (viruses, bacteria). Furthermore, personal life style, e.g. 
smoking, diet, alcohol consumption, can contribute to cancer risk. Apart from these acquired alterations, 
mutations can also be inherited, which predisposes the patient to develop cancer. A single mutation 
does not turn a cell cancerous right away but rather provides a selective growth advantage.5 Thus, the 
first mutation in either an oncogene or a tumor suppressor is considered a “gatekeeping” event. Over 
years, through the aforementioned factors, cells can acquire more mutations that further increase their 
proliferation rate or contribute to the tumors invasiveness.5 The sequential acquisition of mutations 
explains why cancer risk increases with age.  
4.1.5 Genomic and genetic alterations in cancer 
Typical genetic aberrations in cancer are point mutations or insertion/deletion events, leading to crucial 
amino acid exchanges (e.g. BRAF V599E in melanoma12) or truncation of proteins (e.g. AR-V7 in 
prostate cancer13). In addition to mutations in the gene sequence, other alterations of the genome can 
contribute to tumorigenesis. Cancer cells also show elevated levels of chromosomal aberrations.14 Large 
portions of chromosomes can be deleted or amplified, which results in loss of tumor suppressor genes 
or increased copy number of oncogenes, respectively. Copy number variations of oncogenes can range 
von 10-100 copies of one oncogene in one cell, compared to two copies in a normal cell.5 Even whole 
chromosomes can be lost (aneuploidy) or duplicated (polyploidy) to a large extend in cancer cells.15 
Apart from these chromosomal anomalies, cancer cells can also harbor chromosomal translocations 
that lead to the fusion of two unrelated genes. In some cases, the result of such a translocation is a 
functional oncogenic fusion protein, for instance BCR-ABL in chronic myelogenous leukemia (CML) or 
PAX3-FOXO1 in rhabdomyosarcoma (see below).16 In other cases, an oncogene is placed under the 
control of a new promotor or obtains new regulatory elements, for instance IG-MYC in Burkitt’s 
lymphoma17 or TMPRSS2-ERG in prostate cancer18. In the case of tumor suppressor genes, 
chromosomal translocations most often lead to the truncation and inactivation.5  
4.1.6 Conventional therapy 
4.1.6.1 Surgery and radiation 
The major goal of cancer therapy was and is, to kill the tumor. Today, in most cases the standard therapy 
comprises surgery, chemotherapy, and radiation. Surgery, to remove the primary tumor, already 
performed in ancient Egypt.1 For benign tumors, this method can be applicable and even curative. 
However, malignant tumors can infiltrate the surrounding tissue making it hard to remove the complete 
tumor mass. To prevent relapse, in the late 19th century, the American surgeon William Halsted 
performed radical mastectomies to make sure that the whole tumor was removed, albeit having 
infiltrated the tissue.19 At that time this harsh treatment went hand in hand with a drastic decrease in 
quality of life of the patients, many of whom succumbed to the treatment rather than the disease. 
Moreover, the greatest risk of aggressive tumors comes from their ability to form metastases. In many 
cases multiple micro-metastases exist in the body, which are not visible by eye and thus impossible to 
resect. Surgery has its limits in conditions where the tumor mass occurs in places that are too dangerous 
to be accessed by the surgeon. Here, additional therapy options were needed. 
The advances on the field of radiation by Becquerel, Roentgen and Curie laid the foundation for a second 
option of cancer treatment: radiation therapy.19 The principle is that the cancer is exposed to high-energy 
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radiation (photons, protons and particle radiation) either from an external beam or from radioactive 
particles (seeds) implanted directly into the tumor.20 The ionizing radiation induces DNA damage in 
cancer cells. Healthy cells are hit as well but are more efficient in repairing damage.21 Cancer cells with 
defects in stability genes like BRCA1 struggle to repair DNA damage adequately, which results in cell 
death or mitotic arrest.21,22 Radiation can be used as adjuvant or neoadjuvant therapy. Adjuvant means 
that after resection of the tumor the area is radiated to kill potential residual cells. Neoadjuvant therapy 
is used before surgery to shrink the tumor mass before resection.20 
4.1.6.2 Chemotherapy 
The term chemotherapy was coined by Paul Ehrlich at the end of the 19th century. Ehrlich originally used 
that word to describe the chemical treatment of a disease.19 The first chemotherapies for cancer 
treatment were used in the 1940s. The basis of anti-cancer chemotherapy is to target rapidly proliferating 
cells. However, these drugs do not distinguish between cancer cells and other rapidly proliferating cells, 
i.e. intestinal epithelium, blood and immune cells.23 Depending on their mechanism of action, 
chemotherapeutic drugs act cell-cycle specifically or non-specifically.23 The following paragraphs 
exemplify the common classes of chemotherapeutics and their respective mechanism of action in a 
dividing cell (Figure 3A). 
 
Alkylating reagents 
Observations during the Second World War showed that soldiers exposed to mustard gas suffered from 
leukopenia, lack of leukocytes. Based on this observation, in 1943 pharmacologists used nitrogen 
mustard, a derivative of mustard gas, to treat lymphomas.19 Following these first treatments, 
cyclophosphamide was synthesized as a nitrogen mustard derivative. Today, cyclophosphamide and 
cisplatin are still used in clinics. Alkylating agents add alkyl groups to both mitochondrial and nuclear 
DNA resulting in strand breaks or in point mutations from C:G to T:A base pairs. Accumulation of these 
DNA alterations results in programmed cell death. This drug acts cell-cycle unspecifically. Adverse 
effects of alkylating agents are male infertility due to reduced sperm production and the risk of secondary 
malignancies due to the mutagenic activity of DNA alkylation.23 
 
Anti-metabolites 
Anti-metabolites were first developed by Sidney Farber in the late 1940s. He treated children suffering 
from acute lymphoblastic leukemia (ALL) with the folate antagonists aminopterin and amethopterin (now: 
methotrexate) and achieved first remissions for this until then incurable disease.19 Anti-metabolites are 
analogs of nucleic acids or their precursors, mimicking purines (6-Mercaptopurine), pyrimidines (5-
Fluoruracil, Cytarabine), or folate (Methotrexate). During DNA replication in S-phase these analogs can 
be incorporated into the DNA or inhibit enzymes that are essential for nucleotide synthesis 
(Methotrexate: dihydrofolate reductase, 5-FU: thymidylate synthetase).23 
 
 
Anthrayclines 
Anthracyclines are molecules derived from actinobacteria. The most commonly used drugs of this class 
are doxorubicin and mitoxantrone. Anthracyclines have three mechanisms of action. One, they generate 
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free oxygen radicals that in turn damage DNA strands and membranes. Second, anthracyclines can 
intercalate into the DNA blocking DNA synthesis in S-phase. Lastly, these drugs can also inhibit 
topoisomerase II, preventing relaxation of supercoiled DNA. Through these effects anthracyclines block 
replication and transcription which induces cell death. Anthracyclines exert cardiac toxicity damaging 
the cardiac muscle.23  
 
Vinca alkaloids 
Vincristine and vinblastine are alkaloids extracted from the periwinkle plant and are M-phase specific 
drugs. Both drugs block tubulin assembly and thus interfere with the spindle apparatus during mitosis.23 
 
Topoisomerase inhibitors 
As the name suggests, these drugs block the supercoiling activity of topoisomerases I or II thus 
preventing DNA transcription and replication. Irinotecan and topotecan are type I inhibitors, etoposide 
and amsacrine (and doxorubicin) are type II inhibitors, targeting the S-G2 transition.23  
 
Figure 3: Targets of anti-cancer drugs: A) common targets of conventional chemotherapeutic drugs in a dividing 
cell. B) Cellular targets for precision medicine in hematological malignancies (shaded yellow) or solid tumors 
(shaded blue). Adapted from24  
4.1.7 Targeted therapies 
Conventional therapy comprises the three options mentioned above and is still the standard of care 
treatment for most cancers. Their advance in the last century increased remission rates and improved 
survival of cancer patients. However, these therapy options come with some major drawbacks. Surgery 
does not affect distant (micro-)metastases and cannot be applied if tumors grow in unfavorable places. 
Radiation, while potent, also damages surrounding tissues and exposes healthy regions to dangerous 
doses of radiation. Chemotherapy does not target cancer cells specifically, and can have adverse effects 
in the whole body, especially on other rapidly dividing cells. While combination of these therapies helps 
to reduce the individual dose of each agent, it still cannot fully reduce severe adverse effects. Studies 
show that the rate of noncancer deaths in cancer patients is increased compared to the healthy 
population. In the case of chemotherapy, a study could show that around 8% of cancer-patient deaths 
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can be attributed to the therapy.25–28 Due to these drawbacks of conventional therapy, the field of 
precision medicine is advancing and already being implemented into the standard of care regimens.  
The goal here is, to find new selective treatment strategies directed against cancer-specific 
vulnerabilities while sparing healthy cells (Figure 3B). These vulnerabilities are reflected in the concept 
of oncogene addiction: In many cases, by massively favoring a single oncogenic pathway through 
mutation or gene amplification, cancer cells gain growth advantages but also become reliant on these 
signals. Interruption of this pathway would have detrimental effects on the cancer cell. Cancer genetics 
and genomics reveal which genes are mutated or aberrantly expressed in an individual cancer cell 
population, thus pinpointing the “Achilles heel” of these cells.29 The sum of these cancer-specific 
pathways and features cumulates in the cancer cell obtaining the hallmarks of cancer, which are 
therefore sought to be targeted (Figure 2).8  
A concept related to oncogene addiction is synthetic lethality. It describes the concept that of two genes, 
loss of either gene can be tolerated if the other gene can compensate. Loss of the second gene is 
detrimental for the cell. Synthetic lethality has been described in BRCA1-deficient tumors. The stability 
gene BRCA1 is important for the repair DNA double-strand breaks through homologous recombination 
(HR). BRCA1-/- cancers adapted to this loss and show genomic instability.30,31 These cancers rely on 
other mechanisms to access this HR for DNA repair, in this case a protein called poly (ADP-ribose) 
polymerase (PARP-1). Thus, inhibition of PARP-1 is well tolerated in healthy cells, as these can still 
compensate loss of PARP-1 activity through BRCA1 (Figure 4).31,32 BRCA1-/- cancer cells however, 
have now lost all their means to activate HR and as a result accumulate too much genomic damage to 
tolerate (Figure 4).31 This overload in DNA damage leads to cell cycle arrest and programmed cell death 
(see below) in cancer cells.30,32 
The next chapters exemplify ways to specifically target proteins in and on cancer cells. 
 
Figure 4: Model of synthetic lethality: Left: in a normal cell, BRCA and PARP can activate homologous 
recombination (HR) or base excision repair (BER) to repair DNA damage. Center: a cancer cell deficient for BRCA 
and thus for the HR pathway relies on PARP and BER to get rid of overwhelming DNA damage. Right: Inhibiting 
PARP rids the cancer of its last mechanism to contain DNA damage and prevent subsequent cell death. A healthy 
cell will still have the BRCA pathway to compensate for loss of PARP activity. Adapted from33 
4.1.7.1 Small molecule kinase inhibitors 
Small molecules are defined by their low molecular weight of less than 900 Da, allowing them to diffuse 
through membranes to reach intracellular and even nuclear targets.34,35 The majority of small molecule 
inhibitors target kinases. Kinases typically have a specific ATP-binding site and several adjacent pockets 
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whose composition differs between different kinases. Thus, the ATP-binding site and the pockets are 
targets for the design of specific competitive inhibitors.36 
One of the most successful inhibitors is imatinib (Glivec® / Gleevec®) used to treat chronic myeloid 
leukemia (CML).23 This inhibitor targets the pathognomonic fusion protein BCR-ABL, a tyrosine kinase 
acting as a strong oncogene (Figure 3B). Imatinib competitively binds to the ATP-binding pocket, 
disrupting the kinase potential. This treatment results in a complete response in 98% of the 
patients.23,37,38 A second BCR-ABL inhibitor is dasatinib (Sprycel®). Dasatinib has a broader target 
spectrum and is used in imatinib-resistant CML.23,39 
Other kinase inhibitors target the intracellular kinase domains of receptor tyrosine kinases like VEGFR 
(sorafenib, Nexavar®) or growth factor receptors like EGFR (gefitinib, Iressa®).23 Several kinase 
inhibitors are currently in pre-clinical development and clinical trials, targeting kinases, like BRAF 
(Vemurafenib)40, AKT (Afuresertib)41, or Aurora kinase (Alisertib)42,43. 
The major drawback of all these inhibitors however is, that they are prone to giving rise to resistance in 
cancer cells, for instance due to mutations in the binding region.  
 
4.1.7.2 Non-kinase inhibitors 
Importantly, also non-kinase targeting inhibitors have been developed and made it into the clinics. A 
prime example here is the PARP-1 inhibitor olaparib (Lynparza®), which has been approved for the 
treatment of BRCA-deficient breast cancer to exploit the very concept of synthetic lethality explained 
above.44  
One crucial problem to date is targeting of transcription factors. Transcription factors lack enzymatic 
activity but rather exert their function through DNA-protein or protein-protein interactions. Thus, on the 
one hand, interaction surfaces are too large for small molecules to cover let alone disrupt.45 On the other 
hand, apart from the DNA-binding domain, transcription factors are known to be intrinsically disordered, 
making it near impossible to obtain a crystal structure needed for drug design.46 The efforts to directly 
target a transcription factor are exemplified by the search for a drug targeting c-MYC which to date, after 
years of research, still remains unfruitful.47,48 
 
4.1.8 Immunotherapy 
While all of the therapies described above directly target the cancer by exogenous means, another 
therapeutic concept is to stimulate the body’s own defenses, the immune system, to fight cancer.  
 
The immune system has a major role in controlling cancer development, as reflected by the increased 
cancer risk in immunocompromised patients. The estimation is, that each cell encounters approximately 
20.000 events of DNA damage each day.49 Most of the damage is repaired by the cell-intrinsic DNA 
damage repair machinery and if not, the cells undergo programmed cell death (see below). Cells that 
acquire a mutation and continue to proliferate however, are in danger of transforming. Here, the immune 
system recognizes these damaged cells and eliminates them. Each cell of the body fragments part of 
its proteins and presents these antigens on its surface using the major histocompatibility complex I 
(MHC-I). Cells of the adaptive immune system, especially CD8+ cytotoxic T-lymphocytes (CTL) scan the 
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cells for foreign antigens.50 A mutated peptide presented on MHC-I is recognized by the T-cell receptor 
(TCR) as a foreign antigen, also called a neo-antigen or tumor-associated antigen (TAA). CTL activation 
needs to be bolstered by co-stimulatory signals present on an antigen-presenting cell (APC) of the 
immune system (e.g. dendritic cell) to reach sufficient activity. Co-stimulatory signals are mediated 
through engagement of CD28 on the CTL surface and B7 ligands (e.g. CD80 or CD86) on the APC. 
Sufficiently active CTLs eliminate the cancer cell by secretion of perforin, granzyme, and interferon-γ, 
as well as expression of FAS-ligand to induce extrinsic apoptosis (see below).50  
However, as described by Hanahan and Weinberg in their Hallmarks of Cancer, evasion from immune 
surveillance is another characteristic of cancer cells.8 Cancer cells can down-regulate MHC-I 
expression, express inhibitory T-cell ligands (e.g. programmed cell death protein ligand 1, PD-L1), or 
secrete immunosuppressive cytokines (e.g. TGF-β). All these mechanisms result in suppression of the 
anti-cancer function of immune cells in the cancer tissue. The following sections will briefly introduce 
new strategies of re-activating the immune response against cancer. 
 
Monoclonal Antibodies / checkpoint inhibitors / BiTEs 
Since the 1980s monoclonal antibodies (mAbs) have been designed to act against a large variety of 
antigens on the surface of or secreted by cancer cells. mAbs work on the one hand by blocking ligand 
binding to important receptors, e.g. growth factor receptors.19 On the other hand, mAbs recruit cells of 
the immune system like lymphocytes and natural killer (NK) cells to the cancer cell to exert antibody-
dependent cellular cytotoxicity (ADCC). The first mAb approved for cancer therapy was rituximab 
(Rituxan®), a mAb directed against CD20, for the treatment of non-Hodgkin lymphoma.19 Other 
important mAbs, approved for cancer therapy are trastuzumab (Herceptin®) targeting EGF-R in breast 
cancer, or bevacizumab (Avastin®), targeting molecules of vascular endothelial growth factor (VEGF) 
released by cells of the cancer microenvironment.19 Thus, bevacizumab prevents binding of VEGF to its 
receptor and blocks angiogenesis, another Hallmark of Cancer.7  
The most recent breakthrough in immunotherapy relies on so-called immune checkpoint inhibitors. 
These mAbs bind and block immunosuppressive checkpoints, like PD-L1 on the cancer cells, PD1 on 
CTLs, or CTLA-4 on APCs that way reactivating CTL function.51 Immune checkpoint inhibitors that have 
already been approved for the clinics in various cancer types are atezolizumab (anti-PD-L1), nivolumab, 
pembrolizumab (both anti-PD1), and ipilimumab (CTLA-4).51 
Another antibody-based approach is the fusion of two scFv-fragments from mAbs to engage two 
different antigens, one on the cancer cells and the other CD3, on the T-cell surface. These so called, bi-
specific T-cell engager (BiTE) work by bringing T-cells into close proximity of a cancer cell to exert their 
function. The first BiTE to be approved for the clinics is blinatumomab (Blincyto®), targeting CD19 on 
acute lymphoblastic leukemia (ALL) cells.19 
 
Chimeric antigen-receptor (CAR) T-cells 
CAR T-cells mark the most recent milestone in cancer therapy. In brief, the principle is based on adoptive 
T-cell transfer where patient T-cells are isolated, primed, and reinjected into the patient. In this specific 
setting, isolated T-cells are genetically modified to express a chimeric antigen-receptor.52 The CAR 
consists of the antigen-binding region of a mAb engineered to the TCR and accessory signaling 
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molecules.52 In this way, CAR T-cells can engage almost any cancer cell expressing the antigen without 
the need for MHC-based presentation. In 2017 the FDA approved the first CAR T-cell therapy 
tisagenlecleucel (Kymriah®), directed against CD19 in ALL.53,54 
 
4.2 PEDIATRIC CANCER 
4.2.1 Statistics adult vs. pediatric cancers 
Pediatric cancers include those affecting patients under the age of 14 years but also adolescents up to 
the age of 19 years. By that definition, with approximately 175.000 new cases per year, pediatric cancer 
only comprises 1% of all cancer cases. Nevertheless, cancer is the most common disease-related cause 
of death in children and adolescents.10 
Pediatric cancer differs from adult cancer in a variety of factors. The most apparent difference is the 
spectrum of cancer types. While the large majority of cancer types in adults are carcinomas (Figure 
5A), these cancers almost never occur in children and adolescents.55 Instead, hematological 
malignancies (e.g. ALL) and cancers of neuroectodermal origin (e.g. neuroblastoma) comprise the 
majority of pediatric cancers compared to the those of the adult population (Figure 5B).55 Importantly, 
the spectrum of pediatric cancers differs also between children (0-14 year) and adolescents (14-19 
years) where non-Hodgkin lymphomas are most prevalent. Moreover, compared to adult cancer the 
spectrum of pediatric cancers consists to a much larger proportion of sarcomas.55  
 
 
Figure 5: Cancer incidence in A) children (0-19 years) and B) adults. Purple: hematological origin, blue: CNS origin, 
green: sarcomas, red: epithelial origin (carcinoma). Adapted from56,57 
 
4.2.2 Etiology 
Also in their etiology pediatric cancers appear profoundly different from adult cancers. In many cases 
the exact etiology of pediatric cancer is unclear. While adult cancers, especially carcinomas have years 
to accumulate mutations, pediatric malignancies understandably do not have this range of years. As a 
result, pediatric cancers in general harbor far fewer mutations than most adult carcinomas (Figure 6A-
B).5,55 While adult cancers, such as lung adenocarcinoma can harbor over 200 nonsynonymous 
mutations, pediatric cancers present on average with 9.6 mutations.5 Another explanation for this low 
mutational burden is that children are not exposed to mutagenic environmental noxae, like tobacco 
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smoke, for as long as adults. Furthermore, in a recent study it was estimated that of over 1100 childhood 
cancer patients only 8% showed a hereditary predisposition.58 In conclusion and with respect to the 
short latency of onset, it is therefore more likely that rather than environmental risk factors these few 
oncogenic aberrations already occur during early development and drive tumorigenesis. The onset of 
disease seems to depend on the differentiation stage of the cell of origin.58 
Strikingly, pediatric cancers often show higher levels of chromosomal aberrations, such as 
translocations.59 This high degree of chromosomal abnormality might indicate that single but drastic 
events of genomic rearrangement could lead to the development of driver aberrations. Indeed, one such 
event, named chromothripsis, has been found to take place in a variety of cancers and in up to 25% of 
all bone cancers. 60,61. Chromothripsis describes a phenomenon of a single cellular crisis where multiple 
chromosomal breaks occur and 10-100 genomic rearrangements take place.61 In medulloblastoma 
chromothripsis has been linked to p53-deficiency, likely as a requirement for cancer cells to survive the 
massive chromosomal damage.62 
 
Figure 6: A) Mutational burden of cancers in children and adults depending on the site of origin. Numbers give the 
amount of non-synonymous mutations. B) Graph exemplifying the mutational burden of mutagen-induced cancers 
(pink), adult solid tumors (yellow) and pediatric cancers (blue). Adapted from5 C) Increase of 5-year survival rates 
of four childhood cancers over the past decades. Adapted from63 
4.2.3 Prognosis & therapy 
In spite of the lower mutational burden of pediatric cancers, their genetic heterogeneity is complex, 
which results in a large intertumoral and intratumoral heterogeneity. The intertumoral heterogeneity 
makes predictions of outcomes between patients very difficult, even though they might share histological 
characteristics. The intratumoral heterogeneity means that in some cases different subsets of the cancer 
of one patient may respond differently to therapy.64  
Nevertheless, the development of advanced standard treatment protocols comprising surgery, 
radiotherapy and chemotherapy in the 1950s-1970s led to an overall increase in cure rates of pediatric 
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cancer of 80%. However, there is a high extent of heterogeneity in 5-year survival rates. Some cancers, 
like Wilm’s tumor or Hodgkin lymphoma show 5-year survival rates over 90%, while metastasizing 
sarcomas still have a dismal prognosis of less than 30% survival after 5 years.65 What is more, in these 
solid tumors the cure rate has stagnated for the last four decades (Figure 6C).65  
Apart from the heterogenous response of pediatric cancers to conventional therapy, another major 
drawback of standard therapy is the adverse effects these aggressive regimens can impose on the 
developing body of young patients. Apart from the immediate adverse effects like nausea, hair loss and 
leukopenia, children suffer from defects in their cognitive development and potential infertility affecting 
their later life. Other adverse effects include cardiopulmonary defects, like lung fibrosis or ventricular 
dysfunction, or central nervous system deficiencies like hearing loss.66 
Most importantly, due to the mutagenic potential of radiation and certain chemotherapeutics, e.g. 
alkylating agents and anthracyclines, surviving patients have a 19-fold increased risk to die from 
secondary malignancies compared to the healthy population.66 These malignancies can occur years if 
not decades after treatment, and most commonly arise as breast, bone and thyroid cancers.66  
In spite of the huge progress in the development of targeted therapies for adult cancer in the last 
decades, bringing these therapies into the clinics for pediatric cancer treatment has proven difficult. The 
reason why only so few targeted therapies can be tested for childhood malignancies is that dosing 
proves difficult, as children over the years of their development undergo several changes in a variety of 
influencing factors, such as activity of metabolizing enzymes, pH of the gastric environment, or the 
biodistribution of drugs.66 Owing to these changes, drug dosing needs to be thoroughly calculated to 
avoid overexposing or undertreatment with the new drug.66 Another issue is that due to the low 
mutational burden of pediatric cancers, many of the precision medicine targets of adult cancer are simply 
not applicable in pediatric malignancies.  
This lack of neo-antigens is also the reason why immunotherapeutic approaches so far have had only 
modest effects. In recent years, only few immunotherapies emerged that made it to the clinics for 
pediatric cancer treatment. One such example is dinutuximab (Qarziba®), a chimeric mAb against 
disialoganglioside GD2, which has been approved in the EU for treatment of neuroblastoma.67 
Furthermore, the CAR T-cell therapy Kymriah® against CD19 has also been approved for childhood 
ALL.54,68 
4.3 RHABDOMYOSARCOMA 
As explained above, sarcomas are much more common in children and adolescents than they are in 
the adult population. Sarcomas are cancers in tissues with mesenchymal origin like bone, muscle and 
soft tissue.9 Soft tissue sarcomas comprise approximately 7% of all pediatric cancer entities and of this 
group, rhabdomyosarcomas (RMS) make up 48% of all cases, thus being the most common soft tissue 
sarcoma (Figure 5).55 Rhabdomyosarcoma belongs to the group of small, round blue cell tumors of 
childhood that also comprises Ewing’s sarcoma, lymphoma, and neuroblastoma.69 
Though mostly a sporadic disease, some studies could link hereditary diseases to the occurrence of 
RMS. These predisposing diseases are Li Fraumeni syndrome (characterized by a loss of p53)70, 
Neurofibromatosis I71, and the Costello syndrome72. In families with Li Fraumeni syndrome, 
rhabdomyosarcoma is the most frequent pediatric cancer.73 
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4.3.1 Subtypes and prognosis 
RMS comprises several subtypes of tumors that received their names from showing characteristics of 
skeletal myogenesis.56 5-year overall survival of patients, irrespective of RMS subtype is estimated to 
be around 65% 74 but there is a big disparity in prognosis between the subtypes (see below).  
According to the WHO, these subtypes are distinguished based on histology, with embryonal RMS 
(eRMS) and alveolar RMS (aRMS) being the most common ones (Figure 7A).11 As the other subtypes, 
like pleomorphic or undifferentiated RMS are less common and mostly occur in the adult population,56 
they will not be focused on in the next paragraphs.  
Approximately 60% of all RMS cases are accounted for by eRMS, which occurs most commonly in the 
head and neck region, as well as in the genitourinary tract. Its histology shows features of 
undifferentiated skeletal muscle. Incidence of eRMS is highest in children under the age of 5 years, with 
a second peak of incidence during adolescence.75 
In contrast, aRMS tumors comprise about 20% of RMS cases and most commonly arise in the trunk 
and extremities. The defining histological features of this subtype are alveoli-like structures in the tissue, 
similar to those of the lung. Occurrence of this subtype is most common in adolescence.75 
Risk stratification at diagnosis is based on the TNM-staging of malignant tumors as well as a system of 
several factors introduced by the Intergroup Rhabdomyosarcoma Study Group (IRSG). Most 
importantly, metastasis status has a huge impact on outcome of the patients.76 
Of all RMS subtypes, eRMS has the most favorable prognosis with a 5-year survival rate of almost 70% 
if not metastasizing. aRMS tumors show a far worse prognosis with 5-year survival only around 34%.77,75 
Irrespective of their subtype, 5-year overall survival of metastasizing eRMS and aRMS cases drops to 
a mere 11% (Figure 7B).78–80 Metastases most commonly occur in lung, lymph nodes and bones.75 
Overall, prognosis is worse for adults and adolescents, as well as infants, while children between 1-10 
years have a better prognosis.75  
 
4.3.2 Molecular characteristics 
The two major RMS subtypes not only differ in terms of their histology and clinical prognosis but also 
their mutational landscapes. Generally, both subtypes have a low mutational burden, with only 0.31 
mutations per mega base (Mb) in protein-coding regions.84  
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Figure 7: Rhabdomyosarcoma. A) Histologies of the four most common subtypes of RMS. Adapted from81,82            
B) Kaplan-Meier survival curves comparing three overall survival of the three given subtypes (left panel), or overall 
survival of non-metastatic vs metastatic diseases (right panel). Adapted from77 C) Schematic of the fusion protein 
PAX3-FOXO1 and its respective wild-type components. Adapted from83 
 In 80% of all aRMS cases, tumor cells harbor a reciprocal chromosomal translocation involving 
chromosomes 1 or 2 and another chromosome which leads to the fusion of one of the paired box genes 
PAX7 or PAX3 with another gene (Figure 7C) (see below).80 With 0.1 protein-coding mutations per Mb, 
fusion-positive aRMS tumors harbor even fewer mutations than RMS tumors overall, accounting for only 
6.4 somatic mutations per tumor, where only a median of 2.5 mutations are in expressed genes.85 
Interestingly, in sequencing studies, no recurrent single nucleotide mutations were found but instead 
genomic amplification of distinct regions was observed.84,85 Most commonly, the regions 2p24 and 
12q13-q14, which code for the oncogenes MYCN and CDK4, respectively, were amplified (Figure 8).86 
In contrast to neuroblastoma, amplification of these genomic loci in aRMS patients is not associated 
with worse outcome and overall survival.87 As the PAX fusion proteins are oncogenic transcription 
factors that significantly influence aRMS biology, this subtype can be classified as a transcriptionally 
driven disease.  
In contrast to aRMS, eRMS tumors harbor more single nucleotide mutations and display a larger amount 
of karyotype complexity and a heterologous histology.84 Most often genes of the RAS pathway are 
mutated, for instance NRAS, KRAS or HRAS.85 Furthermore, fibroblast growth factor receptor 4 
(FGFR4) was found to be mutated in several cases, as well as phosphoinositide-3-kinase (PI3K) (Figure 
8).85 Moreover, among genomic alterations, most frequently loss of heterozygosity 11p15.5 was found 
which is also associated with other tumors, like Wilms tumor or hepatoblastoma.84 Owing to these 
alterations, eRMS is considered a signaling driven disease. 
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Figure 8: Mutational landscape of RMS tumors comparing alveolar RMS (left) and embryonal RMS (right). Each 
column represents one patient sample. Data based on whole-genome and/or whole-exome sequencing. Adapted 
from85 
4.3.3 PAX-FOXO1 fusion genes 
The unique occurrence of the PAX fusion genes in most aRMS cases has drawn attention of researchers 
and made it a well-studied target. Indeed, the importance of these oncogenic transcription factors for 
aRMS tumor progression and maintenance could be demonstrated in several studies.  
Through reciprocal translocation, in most cases, the N-terminal DNA-binding domain of a PAX gene is 
fused in frame to the transactivation domain of the forkhead box gene FOXO1 located on chromosome 
13.88,89 In fewer cases, PAX genes are fused to NCOA190,91 or INO80D85. The most common fusion 
proteins are PAX3-FOXO1 and PAX7-FOXO1, expressed in 60% or 20% of all aRMS cases, 
respectively (Figure 8).85,92,93  
Clinically, fusion-negative aRMS cases have a much more favorable prognosis similar to that of eRMS 
patients. Among fusion-positive cases, patients harboring the PAX3-FOXO1 rearrangement have a 
poorer prognosis than those with the PAX7-FOXO1 fusion, although their transcriptional program does 
not differ.94  
PAX3-FOXO1 drives transcription of several hundreds of genes. Among these genes are markers of 
muscle differentiation, which reflects the natural function of PAX3 in differentiation processes.95 Further 
genes activated by PAX3-FOXO1 are known oncogenic factors like FGFR2, FGFR4, MYCN and ALK.96 
These data indicate that, through its specific transcriptional program, the fusion has a major role in 
driving tumorigenesis of fusion-positive aRMS. Indeed, studies could show that ectopic overexpression 
of PAX3-FOXO1 in non-cancer cell lines and chicken embryonic fibroblasts is sufficient to drive 
transformation and anchorage-independent growth of these cells.97,98 The role of PAX3-FOXO1 for 
tumor maintenance was demonstrated by anti-sense oligonucleotide-mediated knockdown of fusion 
gene expression. This study could show that loss of PAX3-FOXO1 expression resulted in cell death 
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underlining the essential role of the fusion protein for tumor survival.99 In vivo studies demonstrated a 
loss of aggressive growth of aRMS cells after depletion of the fusion protein.100 
PAX3-FOXO1 is post-translationally regulated through a large variety of modifications on sites also 
present in the respective domains of the wild-type proteins (Figure 9A).95 In wild-type FOXO1 
modification of these distinct sites regulates subcellular localization and protein stability.101 One example 
of these regulatory modifications is acetylation of lysines 245 and 248 in wild-type FOXO1 by KAT2B.102 
This modification subsequently allows for phosphorylation of serines 256 and 319 by AKT, which in turn 
facilitates nuclear export and subsequent degradation of wild-type FOXO1.103 Interestingly, while these 
sites also exist in PAX3-FOXO1, acetylation of the corresponding lysines K426 and K429 has been 
found to stabilize the fusion protein rather than lead to its degradation.104  
 
4.3.4 Therapy 
Standard of care therapy for RMS today is the result of numerous studies conducted by the IRSG (now 
Children’s Oncology Group, COG) since 1972 and the European pediatric Soft tissue sarcoma study 
group (EpSSG). 105,106  In general, patients receive a conventional multimodal therapy consisting of 
surgery, radiation and chemotherapy. The exact regimen strongly depends on the individual risk 
stratification of the tumor. Assessment of risks has evolved over the past decades to optimize the 
treatment regimen for each individual patient.76 Apart from TNM staging, the IRSG proposed and refined 
a clinical grouping staging system. This staging system also takes into account the unresectability of 
certain tumors sites, surgical status after surgical intervention, and metastatic status.76 Based on this 
system, tumors are categorized into the four risk groups IRSG-I to IRSG-IV. 
Surgery and radiotherapy are the localized therapies, where radiotherapy is recommended in sites 
where the tumor cannot be completely resected, or not resected at all.76,105 Adjuvant radiotherapy was 
shown to improve outcome in aRMS patients also after complete resection of the primary tumor.107  
However, due to drastic side effects of radiotherapy such as secondary malignancies or fibrosis, 
recommendations for the use of radiotherapy in RMS patients differ between COG and EpSSG. 105,108–
110  
Chemotherapy is still the major systemic means of RMS therapy. Generally the regimen, which was 
implemented in 1974, consists of vincristine, actinomycin D and cyclophosphamide (VAC).111 Since 
then, the regimen has not undergone substantial alterations but was refined in terms of dosage and time 
points based on risk stratification.76 In Europe cyclophosphamide is often replaced by ifosfamide 
(IVA).112 Moreover, these alkylating agents are omitted in case of low risk diseases.105 In certain 
intermediate-risk or high-risk cases topoisomerase inhibitors such as doxorubicin, etoposide, or 
irinotecan, are included in the regimen.105 The EpSSG tried to establish high-dose chemotherapy 
protocols to avoid the need for radiotherapy.76 
Implementation of the VAC regimen has led to a drastic increase in patient survival since the 1970s.113 
However, despite the increase in cure rates of up to 90% in low-risk patients, overall the curve of 
improvement has flattened during the last decades reaching a plateau of an overall of around 70% of  
patients surviving 5 years after localized disease.113 This trend is likely attributed to the fact that the core 
systemic regimen has not changed for over four decades now.113 Moreover, disseminated disease still 
has a dismal prognosis, and 30% of RMS patients experience relapse of the cancer. In these cases, 
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treatment choices are sparse and often consist of increased doses of the first line chemotherapy, with 
meagre outcomes.114 The severity of this situation is reflected in 5-year survival rates that drop down to 
a mere 17% with the median survival time after recurrence being as low as 0.8 years.114 
These dire perspectives substantiate the need for new therapy options in RMS treatment. To date, no 
targeted therapy approaches have entered the clinics, but research is focused on finding new options 
to treat RMS. 
 
Figure 9: Targeting PAX3-FOXO1 biology. A) Schematic of the sites of post-translational modifications and their 
effects on the PAX3-FOXO1 protein. B) Possible levels to interfere with the “life-cycle” of the oncogenic transcription 
factor. Red: Target proteins, blue: targeted drugs available. Adapted from95 
 
4.3.5 Novel therapy approaches 
For adult cancer, a variety of targeted therapy options exist. However, as mentioned before, transitioning 
from approved adult drugs to pediatric cancers proves cumbersome and at times impossible. 
Unfortunately, the same holds true for RMS treatment: Though various promising pre-clinical studies 
exist, in the clinic these drugs face many pitfalls, for instance intrinsic and acquired resistances. Due to 
these resistances, most pre-clinical and clinical studies investigate combination therapy effects rather 
 20 
 
than monotherapy.115 In case of aRMS, among the already low number of mutated genes (median of 
2.5 in transcribed genes), even fewer are cancer-associated or druggable.95 
Most of the recent studies use small molecules to target different receptor tyrosine kinases (RTK) and 
downstream signaling. Only a few examples are presented in the following paragraphs. One strategy 
relies on targeting insulin-like growth factor receptor 1 (IGFR-1) and anaplastic lymphoma kinase (ALK). 
Here, combination of ALK inhibition with the multi-kinase inhibitor sorafenib, or with the src inhibitor 
dasatinib showed synergistic effect in vitro.116,117 Of note, many RMS tumors showed resistance to IGFR 
blockade. In some cases, enhanced activity of src or platelet-derived growth factor receptor beta 
(PDGFR-β) were attributed to this resistance.118 Consequently, simultaneous inhibition of these proteins 
using the inhibitors pazopanib or crenolanib overcame resistance to IGFR blockade in vivo.118 
Resensitization to this IGFR-directed treatment could also be achieved using mTOR inhibitors or PI3K 
inhibitors.119 
Other RTK-directed approaches target fibroblast growth factor receptor 4 (FGFR4), a target gene of 
PAX3-FOXO1, PDGFR, or EGFR.120 Simultaneous treatment of VEGFR using sunitinib and the 
camptothecin analogue namitecan reduced RMS tumor growth in vivo.121  
While most of the inhibitors, mentioned above, target RTKs many targeting approaches for different 
intracellular signaling cascades are being investigated as well. Targeting the PI3K/mTOR pathway 
showed a lot of potential in vitro, especially if combined with inhibition of the RAS/MEK/ERK pathway. 
115,122. Clinical trials however, combining the PI3K inhibitor buparlisip with the MEK inhibitor selumetinib, 
show that although anti-tumor efficacy can be increased this comes at the cost of increased toxicity, 
thus invalidating the idea of targeted therapy as an alternative to conventional therapy.123 The 
RAS/MEK/ERK pathway is especially important in eRMS tumors, which often show mutations in this 
pathway. Among several approaches, one study found that inhibition of MEK acts synergistically with 
radiotherapy in vitro and potently diminishes the pool of cancer stem cells 124. Combination of targeted 
therapy with conventional therapy is a much-pursued goal in pre-clinical research. Synergistic effects 
could be observed when combining inhibitors of the JAK/STAT pathway with doxorubicin or cisplatin in 
vitro.115 Moreover, inhibiting GLI2 in the hedgehog pathway using GANT-61 in combination with mTOR-
inhibitors or vincristine significantly reduced tumor growth in xenograft mouse models.125,126 
Apart from small molecule inhibitors, immunotherapy-based approaches targeting RMS were heavily 
investigated in recent years, although, up until now, to no avail. The COG tried targeting the IGFR axis 
by using monoclonal antibodies (mAbs) against IGF1 in various pediatric sarcomas. However, phase II 
clinical trials showed no objective results on patient outcome.127,128 Another phase I/II study investigates 
effects of combining a mAb against IGF1R with dasatinib (NCT03041701). As of July 2018, no results 
have been obtained. A phase II clinical trial by the EpSSG comparing a combination of the VEGFR-
directed mAb bevacizumab with standard chemotherapy vs. chemotherapy alone showed no effect on 
event-free survival of patients129 In another clinical trial by the COG, bevacizumab + standard 
chemotherapy (vinorelbine and cyclophosphamide) was compared to mTOR inhibition + standard 
chemotherapy. Here, the bevacizumab arm was discontinued due to significantly worse outcome 
compared to mTOR inhibition130 A variety of other pre-clincal studies tried targeting different surface 
proteins on RMS tumors, like FGFR4, glypicans 3 and 5, or folate receptor 1, also with moderate success 
or none at all.131  
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Cell-based immunotherapy approaches are sparse for RMS treatment. Cho and colleagues could 
demonstrate that RMS cells are sensitive to activated NK-cell anti-tumor activity in vitro.132 Another 
approach was to prime immune cells ex vivo using translocation-specific peptides found in different 
pediatric sarcomas, for example PAX3-FOXO1 in aRMS, and then re-introducing them into the patients 
to establish an immune response. The pilot study showed increased immune responses. However, only 
three aRMS patients were included which does not allow for firm conclusions.133 
 
4.3.5.1 Targeting PAX3-FOXO1 biology 
A unique opportunity for targeting aRMS arises from the expression of the oncogenic and crucial fusion 
protein PAX3-FOXO1, which is critical for maintaining tumor cell viability. Similar approaches targeting 
oncogenic fusion proteins, have great success in diseases like CML where the kinase inhibitors imatinib 
or dasatinib potently inhibit the BCR-ABL fusion. However, the case of aRMS, drug design is much more 
challenging owing to the fact that PAX3-FOXO1 is not a kinase but rather a transcription factor. As 
described above, designing small molecules to directly target a transcription factor is nearly impossible 
due to the lack of enzymatic activity (i.e. no ATP-binding pockets), large DNA-protein or protein-protein 
interaction surfaces, and the intrinsically disordered structure of the transactivation domain.45 In order 
to take advantage of the important role of the fusion protein in aRMS, one needs to come up with indirect 
approaches interfering with PAX3-FOXO1 biology. Figure 9B shows possible strategies to indirectly 
target the transcription factor at different stages of its “life cycle”.95  
The first point with which to interfere is to reduce expression of PAX3-FOXO1 for example through 
epigenetic drugs. However, currently not much is known about the exact mechanisms regulating fusion 
gene expression. Still, studies could show that the histone deacetylase (HDAC)  inhibitor entinostat 
could reduce PAX3-FOXO1 gene expression and aRMS tumor growth in vivo. 134 Of those HDAC 
inhibitors that are in clinical trials, panobinostat and vorinostat also showed anti-tumor effects against 
RMS in vivo. 135 Currently, a variety of HDAC inhibitors are in clinical trials for combination therapy of 
RMS with chemotherapeutic drugs. 95,136 
The second step to target PAX3-FOXO1 indirectly addresses its co-factors. Transcription factors work 
in concert with a large variety of epigenetic regulators and complexes to exert their function. Here, it 
could be shown that PAX3-FOXO1 is dependent on chromodomain helicase DNA-binding protein 4 
(CHD4), a multi-domain protein that also has ATPase functions. Depletion of CHD4 was shown to have 
detrimental effects on aRMS viability similar to loss of PAX3-FOXO1.137 However, currently no CHD4 
inhibitor is available.95 Another co-regulator, recently described, is the BET bromodomain protein 
BRD4.138 Inhibition of BRD4 using the small molecule JQ-1 lead to loss of the PAX3-FOXO1 gene 
expression signature and showed anti-tumor effects in xenograft mouse models.138,139  
The third and broadest step to interfere with PAX3-FOXO1 biology is to target its effectors, i.e. its target 
genes. Several of these target genes are known oncogenes and small molecules exist to target them. 
Among many others, these effectors and their inhibitors include RTKs such as IGF1R, FGFR4, met or 
ALK. 140–143. Interestingly, also genes involved in apoptosis belong to the target genes of PAX3-FOXO1. 
For instance, BCL-XL was found to be a target gene.144 Indeed, RMS cells were shown to be susceptible 
to inhibition of BCL-XL in combination therapy.145 Conversely, PAX3-FOXO1 has also been implicated 
in higher expression of NOXA, thus priming RMS cells for cell death and making them sensitive towards 
 22 
 
treatment with BH3-mimetics (see below). 146,147 However, a direct transcriptional upregulation of NOXA 
by the fusion protein has not been established so far.   
Lastly PAX3-FOXO1 biology can be targeted through modulators of the fusion protein. Phosphorylation 
of the fusion protein by CDK4 has been shown to help localize the protein to the nucleus, thus enhancing 
its activity. Consequently, inhibition of CDK4 was shown to reduce transcriptional activity of PAX3-
FOXO1 and delay aRMS xenograft growth in mice.148,149 Furthermore, PAX3-FOXO1 stability is 
regulated through proteasomal degradation of the fusion protein.95,150 It could be demonstrated that 
acetylation of PAX3-FOXO1 at K426/K429 by the acetyltransferase KAT2B (P/CAF) stabilizes the fusion 
protein.104 Another important interactor of PAX3-FOXO1 is polo-like kinase 1 (PLK1), which has been 
shown to phosphorylate the fusion protein at S503 and thereby stabilize it.150 Indeed, inhibition of PLK1 
by volasertib reduced cell viability and diminished tumor growth in vivo.150 
 
Although a large variety of targeting options exist, especially for PAX3-FOXO1 biology in aRMS, so far 
none of these approaches made it past clinical trials and the search for successful a drug combination 
is still a paramount goal in RMS research. 
 
4.4 CELL DEATH 
4.4.1 General 
Cell death belongs to the life cycle of every cell, though how exactly a cell dies varies and depends a lot 
on the circumstances. Historically, scientists distinguished between only two distinct types of cell death: 
necrosis and apoptosis. Here, necrosis described an instantaneous and irreversible process as a result 
of the cell being exposed to injury or other external stresses, disrupting the integrity of its cell membrane. 
Apoptosis, on the other hand was described as an intrinsically regulated process, requiring active protein 
synthesis.151,152 
In recent years however, scientists discovered a variety of distinct modes of cell death of which the 
majority are regulated and not instantaneous. A more fitting classification of cell deaths therefore is to 
distinguish between accidental cell death (ACD) and regulated cell death (RCD). While ACD essentially 
matches with the historical description of necrosis, apoptosis is only one variation of many forms of 
RCD.153 
ACD can occur through physical stress (changes in pressure, temperature, osmotic pressure), chemical 
stress (pH variation), or mechanical (shear force).153 As a result of a ruptured cell membrane, cytosolic 
and nuclear components of the dead cell are now exposed to the environment and thus serve as danger 
signals, so called danger-associated molecular patterns (DAMPs) for surrounding cells and the immune 
system.153–155 
Opposed to ACD, cells have developed various genetically encoded mechanisms to induce RCD as a 
response to different intrinsic or extrinsic stresses to allow for the most adequate response. In the past 
years, more and more distinct modes of RCD have been characterized and will be in future research 
which is why since 2005, the Nomenclature Committee on Cell Death (NCCD) meets on a regular basis 
to define major cell death modalities on a morphological, molecular and genetic basis.156 Knowledge of 
 23 
 
these defined and regulated modes of cell death allows for new strategies of pharmacological 
intervention in various diseases, especially in cancer.  
In the next paragraphs a few types of RCD will be described in more detail. 
 
4.4.2 Apoptosis 
4.4.2.1 Characteristics 
The term apoptosis was first introduced in 1972 by Kerr and colleagues to describe a regulated or 
programmed form of cell death that is important for cell turnover in healthy tissues and for elimination of 
cells in embryonic development.157 The name apoptosis (ἀπόπτωσις) is derived from the Greek word 
describing the falling of leaves from a tree.157  
 
Morphologically, apoptotic cell death is characterized by nuclear condensation (pyknosis) and chromatin 
fragmentation while maintaining an intact cell membrane that herniates into smaller compartments called 
apoptotic bodies (blebbing).9,157 The effect of keeping the cell membrane intact is that no DAMPs are 
released during apoptosis making this an overall immunogenically silent cell death, although there are 
exceptions as demonstrated recently.158,159 Apoptotic bodies release and present “find-me” and “eat-
me” signals to attract macrophages and activate phagocytosis, respectively. That way apoptotic bodies 
are cleared before spilling intracellular DAMPs into the extracellular space. “Find-me” signals, released 
from dying cells, are for example ATP160,161 or sphingosine-1-phosphate (S1P)162. Triggering 
phagocytosis is achieved by presentation of phosphatidyl-serine (PS) on the outer leaflet of the lipid 
bilayer forming the cell membrane. Under normal conditions, PS is distributed asymmetrically only on 
the inner leaflet of the cell membrane. With apoptosis occurring, enzymes named scramblases are 
activated to shuffle PS to the outer leaflet.163 There, PS is recognized by annexin receptors on the 
macrophages, triggering phagocytosis.164 Failure of macrophages to clear apoptotic bodies results in a 
process called secondary necrosis and subsequent inflammation due to the release of DAMPs from 
failing membranes of former apoptotic bodies.165 
 
Apoptosis is an energy-dependent form of cell death and is characterized by the activity of a proteolytic 
cascade of cysteine-aspartate specific proteases, caspases. These endoproteases have a wide variety 
of targets and are synthesized in inactive dimers.166 Caspases are activated through proteolysis by other 
caspases, which is why one distinguishes initiator caspases and executioner caspases.166 The 
executioner caspases 3, 6, and 7 are the convergence of all upstream caspases and cleave several 
hundreds of targets, including other pro-caspases. In this way, the executioner caspases drive the 
apoptotic processes and morphological changes:  
Cleavage of lamins on the nuclear membrane is one factor thought to drive pyknosis. Inactivation of 
inhibitor of caspase-activated DNase (ICAD) releases the respective DNase responsible for DNA 
fragmentation.167 Cleavage of poly (ADP-ribose) polymerase-1 (PARP-1) ensures that energy storages 
of the cell are not consumed due to DNA damage repair activity of PARP-1.168 Cleavage of cytoskeletal 
proteins, like actin, vimentin and others, results in blebbing of the cell membrane and the formation of 
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apoptotic bodies.9,169,170 Lastly, caspase-3 has been found to proteolytically activate Xkr8, the 
scramblase responsible for flipping PS on the outer leaflet.171,172 
 
The executioner caspases can be activated by different initiator caspases depending on the upstream 
cue initiating the activation cascade. These cues can be intrinsic or extrinsic stimuli, which is why the 
following two major forms of apoptosis are distinguished. 
 
4.4.2.2 Intrinsic apoptosis 
Overview 
Intrinsic apoptosis is also called mitochondrial apoptosis, as the signaling program revolves around this 
organelle. It is the most common mode of RCD activated by cells in response to several different 
perturbations comprising growth factor withdrawal, endoplasmic reticulum (ER) stress, overload with 
reactive oxygen species (ROS), mitotic defects, and, importantly, DNA damage.173–175 The pivotal step 
of intrinsic apoptosis is the irreversible mitochondrial outer membrane permeabilization (MOMP) 
resulting in the release of mitochondrial factors triggering formation of a cytosolic caspase-activating 
protein platform that initiates the caspase cascade.153 
 
Interactions at the outer mitochondrial membrane 
MOMP is the result of an interplay between pro-apoptotic and anti-apoptotic members of the B-cell 
lymphoma 2 (BCL2) family, facilitating or antagonizing the formation of pores in the outer mitochondrial 
membrane (OMM), respectively. All members of this family share up to four BCL2-homology domains 
(BH1 to BH4).176–178 The pores are formed by BCL2-associated X apoptosis regulator (BAX) and BCL2 
antagonist/killer1 (BAK).179 While BAX has been found to cycle between OMM and cytosol, BAK stays 
at the OMM. In response to the stress signals mentioned above, BAX and BAK are activated 
transcriptionally or post-translationally at the OMM, either directly or indirectly by pro-apoptotic BH3-only 
proteins.153 BAX, for example, ceases retro-translocation to the cytosol and accumulates at the OMM 
upon apoptosis induction.153,180 
Important members of the BH3-only proteins are p53-upregulated modulator of apoptosis (PUMA), 
BCL2-interacting mediator of cell death (BIM) and phorbol-12-myristate-acetate induced protein 1 
(PMAIP1, NOXA).181,182 These BH3-only proteins are upregulated transcriptionally upon cellular stress, 
for example in response to DNA damage that cannot be repaired.153 Pro-apoptotic BH3-only proteins 
can be sub-grouped into activators and sensitizers. They home to the OMM where activators, like 
PUMA, BIM, and NOXA interact transiently with BAK and BAX to activate them through conformational 
changes.153 BAK and BAX activation allows for the formation of homodimeric and heterodimeric pores 
resulting in MOMP.183–186 Formation of dimers results in release of BH3-only proteins and subsequent 
dimer-by-dimer oligomerization increasing membrane permeabilization through a toroidal pore.187  
The process of BAX/BAK activation is antagonized by the subfamily of anti-apoptotic BCL2 proteins 
comprising BCL2, BCL2 like 1 (BCL-XL), BCL2 like 2 (BCL-W), BCL2 related protein A1 (BCL2-A1, BFL-
1), and MCL1.153 These anti-apoptotic BCL2 family members reside in the OMM and exert their function 
either by sequestrating BAX and BAK, preventing their oligomerization, or by sequestration of activating 
 25 
 
BH3-only proteins.188–191 Some anti-apoptotic BCL2 proteins (e.g. BCL-XL) also function by promoting 
retrotranslocation of BAX from the OMM to the cytosol, thus depleting the pool of mitochondrial BAX.192 
Sensitizing BH3-only proteins, like BCL2 associated agonist of cell death (BAD), BCL2 modifying factor 
(BMF), or hara-kiri, BCL2 interacting protein (HRK), do not physically interact with BAX and BAK to 
activate dimerization, but rather promote MOMP by binding and sequestering anti-apoptotic BCL2 family 
members. This sequestration restricts anti-apoptotic BCL2 protein function.193 However, the distinction 
between activator and sensitizer BH3-only proteins seems to be less stringent than previously 
estimated.194–196 This is reflected in the binding preferences of BH3-only proteins to anti-apoptotic BCL2 
family members. BID, BIM and PUMA can bind all proteins of that family, NOXA preferentially inhibits 
MCL1, and HRK inhibits BCL-XL.194 In certain situations, alternative interacting pairs have been 
described. Some data hint at possible interactions of BCL-XL with NOXA.197 Nonetheless, 
overexpression of sensitizer proteins in absence of activator proteins only induces minimal apoptosis. 
These results suggest that activator BH3-only proteins act downstream of sensitizers.153,198  
Recent evidence also shows that BAX and BAK can self-activate, albeit with much slower kinetics, even 
in absence of pro-apoptotic BH3-only proteins and anti-apoptotic BCL2 family members.198,199 Another 
non-canonical mechanism of BAX/BAK activation is that p53 not only acts as a transcriptional activator 
of pro-apoptotic proteins but also exerts its function by directly activating the pore forming proteins at 
the OMM.200–202  
 
Apoptotic mechanisms after MOMP 
Ultimately, MOMP leads to the release of contents from the mitochondrial intermembrane space, 
allowing movement of proteins such as cytochrome c somatic (CYCS) and second mitochondrial 
activator of caspases (SMAC) to the cytosol. Cytosolic CYCS is bound by apoptotic peptidase activating 
factor 1 (APAF1) creating a supramolecular protein platform called the apoptosome.203 The apoptosome 
can bind pro-caspase 9 through its caspase recruitment domain (CARD).203,204 Proximity of pro-
caspases in the multimeric coordination of the apoptosome induces autocatalytic maturation of caspase 
9 (CASP9)204 which can catalyze the proteolytic activation of CASP3 and CASP7205. Caspase activity 
can be inhibited by X-linked inhibitor of apoptosis (XIAP). Cytosolic SMAC associates with XIAP to 
reduce its activity, thus precipitating apoptosis by allowing caspases to exert their function.206,207 Other 
IAPs exert their function by upregulation of anti-apoptotic factors like CASP8 and FADD like apoptosis 
regulator (c-FLIP), or by ubiquitylation of caspases or the receptor interacting serine/threonine kinase 1 
(RIPK1) triggering pro-survival NF-κB signaling.153  
In spite of these anti-apoptotic mechanisms, evidence suggest that activation of executioner caspases 
marks a point-of-no-return in the apoptotic cascade.208 Under physiological conditions there is an 
equilibrium of pro-apoptotic and anti-apoptotic molecules at the OMM which is sufficient to keep the cells 
from reaching this point-of-no-return. Due to increased metabolism and high levels of replicative stress, 
cancer cells also express higher levels of pro-apoptotic proteins.209 To compensate this shift in the 
apoptotic equilibrium, cancer cells need to upregulate anti-apoptotic BCL2 family proteins and are highly 
dependent on their activity.209 
A specific variant of intrinsic apoptosis is called anoikis, triggered by the loss of integrin-dependent 
extracellular matrix attachment.210 In this way, anoikis prevents anchorage-independent growth and as 
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such is considered oncosuppressive.210 Cancer cells need to become insensitive to this mode of cell 
death when losing contact inhibition and gaining metastatic potential.210 
 
4.4.2.3 Extrinsic apoptosis 
In contrast to intrinsic apoptosis, extrinsic apoptosis is induced by activation of membrane-bound 
receptors. The most common of apoptosis-promoting receptors are death receptors including FAS 
(CD95, APO-1), TNF-receptor 1 (TNFR1), TRAILR-1 and TRAILR-2.153 Generally, ligand-mediated 
activation of death receptors leads to multimerization and the cytosolic assembly of a multiprotein 
complex called death-inducing signaling complex (DISC). DISC recruits CASP8 (and sometimes 
CASP10).153,211 FAS and TRAILRs exist as pre-formed homotrimers stabilized by ligand binding which 
induces conformational changes in the intracellular death domain (DD). These changes allow for 
association of Fas associated via death domain (FADD) to the DISC.212–214 FADD recruits CASP8 and 
facilitates the formation of a linear filament consisting of several CASP8 proteins. The proximity of 
CASP8 leads to homodimerization and autoproteolytic activation.215  
TNFR1 activation results in the association of TNFR-associated death domain (TRADD) which recruits 
a complex consisting of TNFR associated factor 2 (TRAF2), TRAF5, c-IAP1, c-IAP2, and RIPK1.153 
Importantly, here receptor ligation does not necessarily result in cell death, but depends highly on the 
degree of receptor oligomerization and the post-translational modification of RIPK1. Deubiquitylation of 
RIPK1 favors its association with FADD and CASP8, while polyubiquitylation by IAPs results in pro-
survival signaling.153 
Two major pathways downstream of CASP8 activation have been described. In Type I cells (thymocytes 
and mature lymphocytes), CASP8 proteolytically activates the executioner caspases 3 and 7, which is 
sufficient for apoptosis.216 Type II cells (e.g. pancreatic β cells, hepatocytes and most cancer cells) rely 
on XIAP to hamper CASP 3 and 7 activity. In these cases, CASP8 proteolytically activates BID. 
Cleavage of BID results in a truncated form (tBID) which localizes to the OMM where it acts an activator 
BH3-only protein to activate BAX/BAK-dependent MOMP and CASP9 activation.216,217 
 
4.4.3 Necrosis / Necroptosis 
Historically, the only distinction between cell deaths was apoptosis versus necrosis. Apoptosis was 
considered as genetically regulated cell death and necrosis was considered as ACD.157 The necrotic 
morphotype is characterized by swelling and rupturing of the plasma membrane and spillage of the 
cytosolic contents into the surrounding tissue. However, in 1988 it could be demonstrated that treatment 
with TNF results in either apoptosis or necrosis depending on the cellular background.218 Later research 
showed that indeed necrosis could be inhibited chemically and by genetic means, indicating that 
necrosis also is genetically regulated.219 In analogy to apoptosis as RCD but considering its morphotype, 
this mode of cell death was called necroptosis.153 
Similar to extrinsic apoptosis, necroptosis is also initiated by death receptors like FAS and TFNR1. As 
mentioned above, the complex recruited to the receptor contains TRADD and RIPK1. Deubiquitylation 
of RIPK1 results in dissociation from the receptor to form complex II including TRADD, FADD, RIPK1.220 
Here, CASP8 is recruited and its activity is crucial for the decision between apoptosis and necroptosis. 
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As described above, active CASP8 induces the apoptotic cascade. However, if CASP8 is inactive or 
absent from complex II, RIPK3 and mixed lineage kinase domain like pseudokinase (MLKL) are 
recruited to the complex which is then called necrosome.220 RIPK3 phosphorylates MLKL, which induces 
oligomerization and translocation of these oligomers to the plasma membrane where they trigger 
membrane permeabilization.221 
The necrosome can be inhibited chemically by the compound necrostatin-1 (nec-1) inhibiting RIP 
kinases,222 but also intrinsically, for example by Aurora kinase A interaction with RIPK1 and RIPK3.223 
 
4.4.4 Other modes of regulated cell death 
In recent years a variety of distinct modes of RCD have been described with their characteristic features.  
Pyroptosis is an RCD linked to the  innate immune responses. It features formation of an inflammasome 
in response to pattern recognition receptor (PRR) activation by pathogens or DAMPs.224 Assembled 
Inflammasomes recruit and activate CASP1, resulting in maturation of pro-inflammatory interleukins (IL-
1β, IL-18) and their release through permeabilization of the plasma membrane.225  
Ferroptosis only recently emerged as a mode of cell death that does not rely on caspases or necrosome 
components.153 It is induced in response to severe lipid peroxidation as a result of high levels of ROS 
and iron availability.226 
Parthanatos occurs due to hyperactivation of the DNA damage response machinery, specifically 
PARP1, in response to severe alkylating DNA damage but also oxidative stress, hypoxia, or 
inflammatory signals.227 PARP1 hyperactivation leads to rapid depletion of intracellular NAD+ and ATP 
levels, resulting in a bioenergetic and redox collapse, as well as mitochondrial membrane depolarization 
followed by MOMP.227 
 
4.4.5 Cell cycle control 
Each cell can control progression of one phase to the next in order to avoid severe consequences of 
progressing in spite of existing damage. These instances control are called checkpoints. Cell cycle 
checkpoints are mechanisms to halt cell cycle progression upon DNA damage. The three major 
checkpoints are during late G1-phase, late G2-phase, and in mitosis (M-phase) (Figure 10). The G1 
checkpoint controls the size of the cell, whether sufficient nutrients or growth factors are present, and 
whether the DNA is damaged and then allows for progression into the S-phase or subjects the cell into 
G0-phase, a quiescent non-proliferative state.228 The G2 (also G2/M) checkpoint assesses DNA 
damage and replication errors after the S-phase and prevents transition into the M-phase unless 
damage has been repaired.228 Lastly, the M checkpoint makes sure that all spindles are properly 
attached to the kinetochores to prevent errors in chromosomal segregation.228 Both, the G2 and M 
checkpoints will be described in more detail below (chapter 4.5). 
Should errors persist in spite of cell cycle arrest, cells can initiate cellular senescence or apoptosis. Even 
though cellular senescence and mitotic arrest involve the machinery for certain forms of RCD, they 
cannot be considered as cell death.153  
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Figure 10: Cell cycle phases and the major checkpoints. Checkpoints are indicated by red bars and the descriptions 
show what cues are assessed by each checkpoint (red) and what next step is initiated (green). Adapted from228 
 
4.4.5.1 Cellular senescence 
Cellular senescence is a process in which cells permanently stop proliferating while still maintaining 
metabolic activity. In contrast to the quiescent state of G0-phase, senescent cells cannot be reactivated, 
for instance by mitogenic factors.228 This process is thought to be involved in aging and the etiology of 
some age-related diseases. While cellular senescence is thought to be onco-suppressive, evidence 
hints at adverse effects in certain chemotherapeutic regimens and at recurrence of specific 
neoplasms.229 
Senescence occurs in response to a variety of stimuli (see below) and is characterized by the inhibition 
of cyclin-dependent kinases (CDKs), absence of proliferation markers like Ki-67, and activation of the 
DNA damage repair (DDR) machinery.229  
Replicative senescence 
Replicative senescence is induced by telomere erosion due to high number of cell divisions. This 
process triggers the DDR mediated by ATR, ATM, CHK1, and CHK2, which in turn activate p53. As a 
result, cyclin-dependent kinase inhibitor 1A (CDKN1A, also called p21) is expressed to inhibit CDK2. 
Furthermore, the CDKN2A locus is de-repressed, which leads to expression of the tumor suppressors 
p16 and ARF.153 
Oncogene-induced senescence 
This process can function as another delay in early tumorigenesis, as high activity of certain oncogenes 
results in CDKN2A de-repression.229 Moreover, excessive DNA replication and the concomitant errors 
result in DDR activation which in turn leads to p53 activation. Increased proliferation and resulting ROS 
can induce p38 MAPK resulting in increased transcriptional activity of p53.153 
 
4.4.5.2 Mitotic catastrophe 
Mitotic catastrophe is a specific, regulated mechanism that halts proliferation of cells unable to complete 
mitosis, for instance due to severe DNA damage and mitotic checkpoint failure (see below). As such it 
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can also be considered an important onco-suppressive mechanism. Mitotic defects can occur due to 
exogenous and endogenous cues.230 Exogenous cues are drugs such as chemotherapeutics altering 
DNA replication, cell cycle checkpoints, microtubular dynamics, and chromosomal segregation. 
Endogenous sources can be high replicative or mitotic stress due to altered ploidy or due to deregulated 
factors important for DNA replication. While the exact mechanisms of how mitotic alterations are sensed 
are unclear, presumably they require p53 signaling. This hypothesis is supported by data showing that 
cells lacking p53 undergo a necrotic variant of RCD upon encountering mitotic defects.231  
The fate of cells that are confronted with mitotic catastrophe seems to depend on the time spent in 
mitotic arrest. Typically, cells that arrest in mitosis for prolonged time undergo intrinsic apoptosis. Cells 
that escape mitotic arrest and enter interphase can undergo apoptosis later during the cell cycle or can 
enter senescence. Apart from apoptosis, mitotic catastrophe and subsequent senescence are the major 
effects from radiation therapy.232 
Cancer cells require the ability to abrogate mitotic catastrophe to avoid complications when generating 
polyploid and aneuploid cells.  
 
4.4.6 Therapeutic potential of cell death 
Evasion from cell death is one of the original hallmarks of cancer proposed by Hanahan and Weinberg 
in 2000.7 The strategies cancer cells come up with to evade cell death are diverse and offer valuable 
advantages in cancer progression. This evasion of cell death not only influences tumorigenesis but also 
the response of cancer cells to the various therapies available. Thus, knowledge of the specific 
strategies to evade cell death and the possible vulnerabilities can provide important new treatment 
options in cancer therapy. 
 
4.4.6.1 BH3-mimetics 
Cancer cells that regularly face replicative stress due to increased proliferation need to overcome the 
challenge of RCD.209 One mechanism to protect themselves is that cancer cells upregulate anti-
apoptotic BCL2 proteins that sequester stress-induced pro-apoptotic BH3-only proteins, and thus 
dramatically raise the threshold for these pro-apoptotic cues to induce MOMP (Figure 11A).209 Thus, 
these cells not only show resistance against intrinsic stress signals but also against drugs inducing 
apoptosis. However, a major mechanism of action on which many chemotherapy regimens rely, is the 
induction of mitotic catastrophe and subsequent intrinsic apoptosis.153 Therapy resistance, especially in 
relapsed samples, thus is likely explained by the insensitivity of cancer cells to apoptotic cues.154,233–235 
Fortunately, also here the concept of oncogene addiction applies. In this example, cancer cells already 
show a much higher apoptotic potential, they are primed for apoptosis, and rely solely on the anti-
apoptotic function of certain BCL2 family members to prevent MOMP and subsequent caspase 
activation (Figure 11B).209 A new idea for a therapeutic approach therefore has been to inhibit BCL2 
proteins. The first effort in this direction was Genasense (oblimersen sodium), an antisense 
oligonucleotide directed against BCL2 in the treatment of chronic lymphocytic leukemia (CLL).236 
However, this drug showed only modest clinical activity.237 Later, peptides and small molecules were 
designed, so called BH3-mimetics.238,239 As the name suggests, their structures mimic the BH3-domain 
 30 
 
and they insert into the hydrophobic grove of anti-apoptotic BCL2-family proteins, competing with their 
binding to BH3-only proteins and thus releasing the pro-apoptotic proteins.238,240 BH3-mimetics were 
designed to target specific members of the anti-apoptotic BCL2 family. ABT-737 and its orally available 
derivative ABT-263 (Navitoclax) mimic the BH3 domain of BAD and thus target BCL-XL with high affinity, 
but also BCL-2 and BCL-W.241 Both compounds show strong pro-apoptotic effects in various preclinical 
models and in phase I and II clinical trials. However, they do not target A1 and MCL-1, and only showed 
these strong effects if MCL-1 was only weakly or not at all expressed expressed.242–244 ABT-199 
(Venetoclax, Venclexta®) is another derivative of ABT-737 but specifically targets BCL-2.245 In 2016, 
ABT-199 was granted accelerated approval as a breakthrough therapy by the FDA for the treatment of 
patients with CLL harboring a 17p deletion.246–248 In June 2018 approval was extended to second line 
treatment of all patients with CLL, irrespective of 17p status.249,250 Further BH3-mimetics targeting 
different BCL2 proteins are currently under development, for instance the MCL-1 inhibitor S63845.251 
 
Figure 11: Mitochondrial pathway of apoptosis. A) Schematic of interactions between anti-apoptotic BCL-2 family 
proteins and pro-apoptotic proteins. Left: basal condition: the pore-forming units Bak and Bax are held in check by 
BCL-2 proteins. Right: Stress situation, the cell upregulates BH-3 only proteins to sequester anti-apoptotic proteins 
and to activate Bax/Bak dimerization leading to release of cytochrome c into the cytosol. Adapted from252 B) Model 
of cells being primed for apoptosis through high-levels of oncogenic stress. Left: primed cells can easily be “pushed” 
into apoptosis by chemotherapy. Center: Cells high in anti-apoptotic proteins are unprimed and chemotherapy does 
not induce cell death. Right: Through targeted therapy with BH3-mimetics the formerly unprimed cell becomes 
primed and thus sensitive to chemotherapy. Adapted from209 
To find the individual dependency of each cancer on certain anti-apoptotic BCL2 proteins and thus their 
susceptibility to the respective BH3-mimetics, Letai and colleagues designed a screening approach 
called “BH3 profiling”.253,254 Here, they isolate mitochondria from patient cancer cells and treat them with 
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BH3 domain peptides. Induction of MOMP allows identification of the cancer cell’s specific sensitivity 
towards certain BH3-mimetics.255–257 
In other studies, senescence has been proposed as a mechanism to evade cell death and has been 
implicated in the adverse effects of certain chemotherapeutics and the recurrence of cancers. However, 
senescent cells have been shown to be dependent on specific BCL2 proteins, especially BCL-XL. Here, 
BH3-mimetics have been proposed to act as senolytic agents to induce cell death in the senescent 
cells.258–260  
 
4.4.6.2 Immunogenic cell death 
Apart from apoptosis, which is considered silent in terms of evoking immune responses, other cell death 
modalities such as necroptosis or pyroptosis result in the release of intracellular contents. Certain 
molecules among these contents, so called danger-associated molecular patterns (DAMPs), can alert 
the immune system and stimulate its response against cell-antigens. Immunogenic DAMPs have been 
found to be ATP and the chromatin associated protein high-mobility group box 1 (HMGB1), but also 
exposure of calreticulin (CRT) on the plasma membrane due to ER stress.261–264 Due to its immunogenic 
capability, these cell death modalities are also called immunogenic cell death (ICD). In cancer therapy, 
the idea is that after treatment-induced ICD, tumor-infiltrating dendritic cells take up the debris from 
cancer cells, process them and present them, in this way stimulating a systemic, adaptive immune 
response against cancer cells, similar to a vaccination.265 In doing so, ICD is thought to contribute to 
enhanced anti-cancer effects of certain chemotherapeutic drugs. Indeed, studies could show that an 
increased ratio of CD8+ cytotoxic T-cells (CTLs) to regulatory T-cells (Tregs) after chemotherapy predicts 
increased therapeutic responses in patients with colorectal and breast cancer.266–270 Furthermore, 
lymphopenia has been shown to negatively affect the outcome in different solid tumors.266 Of the 
conventional chemotherapeutics, anthracyclines have been shown to be very effective in inducing ICD 
in patients.265 Further knowledge of which DAMPs are released, and which drugs induce ICD, can 
contribute to the development of new combination therapies strengthening the anti-cancer activity of the 
immune system. A study analyzing 1040 FDA-approved drugs for their propensity to enhance ICD found 
that cardiac glycosides were particularly effective in upregulating the DAMPs required for ICD.271 
Another approach in this respect is, to combine epigenetic modulators like histone deacetylase (HDAC) 
inhibitors with common therapies to induce upregulation of the DAMPs described above, thus bolstering 
the effects of ICD.272 
Thus, knowledge of ICD provides tremendous opportunities to enhance chemotherapy efficacy by killing 
cancer cells and vaccinating the immune system.  
4.5 AURORA KINASES 
Aurora kinases are a family of serine/threonine kinases involved in cell division. Originally, the aurora 
allele was discovered in a Drosophila melanogaster mutant (aur) showing defective spindle-pole 
behavior.273 The family was named after the night-sky phenomenon occurring close to the poles.274 A 
fitting name, as Aurora kinases localize at the poles of the cell during mitosis (Figure 12A). 
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The mammalian Aurora kinase family comprises the three paralogues Aurora A, B, and C (gene names 
in humans: AURKA, AURKB, AURKC) of which AURKA corresponds to aurora missing in the aur 
Drosophila mutant.275,276  
While the three mammalian paralogues differ in length and the amino-terminal sequence, the catalytic 
domains of Aurora A and B share 71% amino acid sequence identity (Figure 12B).277 In spite of their 
homology, Aurora kinases have distinct localizations (Figure 12A) and functions. Interestingly, studies 
could show that these differences in location and function of Aurora A and B can be pinpointed to a 
single amino acid. Substitution of Gly198 in Aurora A by asparagine, the corresponding amino acid in 
Aurora B, led to Aurora A taking over functions of Aurora B. This was reflected by Aurora A binding to 
Aurora B binding partners and rescuing Aurora B knock-out phenotypes.278,279  
Aurora A functions primarily during mitotic entry, centrosome maturation and separation, as well as in 
determining spindle bipolarity. It associates with the spindle poles.280,281 Aurora B is part of the 
chromosomal passenger complex (CPC) which, until metaphase, associates with the inner centromere 
and is transferred to the spindle midzone in late mitosis. It is thought to regulate chromosome interaction 
with microtubules, spindle stability, and cytokinesis.282 281. Aurora C closely resembles Aurora B but is 
primarily expressed in testis, indicating an important role in meiosis.283 
 
Figure 12: Aurora A. A) Subcellular localization of Aurora A at different points of mitosis. Adapted from280                     
B) Schematic comparing Aurora A, B, and C. Adapted from274 
 
4.5.1 Interactors 
4.5.1.1 Posititve regulators 
One of the best studied co-factors of Aurora A is the protein TPX2. During mitosis, Ran-GTP is activated 
in the vicinity of chromosomes, creating a gradient of active protein close to mitotic chromosomes.284–
286 Active Ran-GTP leads to the release of microtubule-assembly factors, i.e. TPX2.287–289 TPX2 binds 
Aurora A and through conformational changes allows for its activation by auto-phosphorylation of T288 
in the the Aurora A activation loop. Moreover, binding of TPX2 to Aurora A protects the kinase from 
being inactivated by the protein phosphatase PP-1.290,291 This TPX2 activity is important to target Aurora 
A to the mitotic spindle292 where it in turn activates factors important for chromatin-driven bipolar spindle 
assembly.293–295 
A second important interactor is the Borealis protein (Bora), the function of which is crucial in the role of 
Aurora A in mitotic entry (see below).296  
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Aurora degradation 
During mitotic exit, even while they are still regulating crucial steps of the exit, Aurora kinase A and B 
are targeted to proteasomal degradation through the anaphase promoting complex/cyclosome (APC/C). 
APC/C is a multi-subunit E3-ubiquitin ligase and needs the specificity factor Cdh1.297–300 
 
4.5.2 Functions in cell cycle progression 
Aurora kinases play important roles in the progression of cell cycle. Their expression is upregulated 
transcriptionally during late S and G2 with protein levels and activity peaking at G2 and mitosis.277,301 
During G1 their expression is repressed through CDE/CHR elements.302,303 This specific expression and 
the activity pattern in the G2 and M phase indicate the important role auf Aurora kinases during G2/M 
transition and mitosis. In the next paragraphs the diverse roles of Aurora A and its interactors are 
highlighted in detail. 
 
4.5.2.1 Centrosome maturation and separation 
During Interphase, centrosomes duplicate through semi-conservative duplication of the centrioles. 
Maturation of centrosome maturation starts in G2. Through the interplay of the kinases Pak1, Plk-1 and 
Cdk-11, Aurora A accumulates close to the centrosome whereas Pak1 phosphorylates Aurora A at 
Thr288 in the activation loop the kinase.304–306 307–310 This accumulation causes the growth of the 
pericentrosomal material (PCM), increasing centrosomal microtubule nucleation activity.281 Aurora A in 
turn orchestrates and activates components for centrosome maturation, i.e. centrosmin311 or NDEL1312. 
Furthermore Aurora A also activates proteins important for microtubule nucleation such as LATS313,314 
or TACC proteins315.  
 
4.5.2.2 Mitotic entry / G2 checkpoint recovery 
Mitotic entry is controlled directly by the mitotic cyclin-B and the cyclin-dependent kinase 1 (Cdk1), as 
well as the phosphatase cdc25.316 During S and G2 phase the catalytic activity of Cdk1 is inhibited by 
phosphorylation through the kinases Wee1 and Myt1. This phosphorylation is removed by cdc25. Active 
cylin-B/Cdk1 in turn, inhibits Wee1 and Myt1 and activates cdc25, thus creating a positive, so called 
“inner” feedback loop.317,318  
The “outer” feedback loop comprises several feedback mechanisms, most importantly through Polo-like 
kinase-1 (Plk-1) and Aurora A, which strengthen the inner loop (Figure 13A). Here, Aurora A promotes 
the mitotic entry by controlling the Plk1-dependent activation of Cyclin-B/Cdk1.319 Aurora A 
phosphorylates T210 in the Plk-1 kinase domain thus activating it.320 A critical co-factor for this reaction 
is the Borealis protein (Bora). Binding of Bora to the phosphate-binding domain (PBD) of Plk-1 interferes 
with the intramolecular interaction of the PBD and kinase domain which renders T210 accessible for 
Aurora A-mediated phosphorylation (Figure 13B).296 Active Plk-1 phosphorylates Cdc25c, increasing 
nuclear accumulation of the phosphatase. Plk-1 can further phosphorylate Myt1 and Cdk1-
phosphorylated Wee1 leading to its degradation.318,321,322 Thus, Aurora A, through Plk-1296, facilitates 
the inner feedback loop, shifting the equilibrium towards active Cyclin B/Cdk1. Active Cdk1 contributes 
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to this feedback loop by, on the one hand stabilizing Bora and enhancing its binding to Plk-1, allowing 
for efficient Aurora A-mediated activation of Plk-1.323,324 On the other hand Cdk1 also regulates the 
function of the phosphatase PP1, which is known to inactivate Aurora A through dephosphorylation of 
T288.319,325,326  
Aurora A in turn, can also directly influence the inner feedback loop through phosphorylation of 
Cdc25b.327 
 
Figure 13: Regulatory loops involving Aurora A. A) Inner (blue) and outer (yellow) loop of CDK1 activation. Green: 
positive regulators, orange: negative regulators. B) Aurora A-dependent regulation of PLK-1 activity. Adapted 
from328 
 
While the inner feedback loop is the major driver of mitotic entry, the regulation through the outer 
feedback loop with Aurora A and Plk-1 shows redundancy and seems to be not essential. Depletion of 
single factors has no or little effect on mitotic entry but leads to abnormal cell division and mitotic 
abnormalities. These findings underscore the redundant role of many factors for mitotic entry but also 
their critical role in the orchestration of mitotic events. However, while factors like Aurora A, Plk-1 or 
Cdc25 are redundant in normal mitotic entry, their specific activity is essential for G2 checkpoint 
recovery.296,318,325,329,330  
The G2 checkpoint is the last instance for a cell to avoid transmission of mutations to the daughter 
cells:331 DNA damage or stalled replication forks after S-phase are sensed by the proteins ataxia 
telangiectasia mutated (ATM) and ataxia telangiectasia and Rad3-related protein (ATR), which activate 
checkpoint kinases (Chk) 2 and 1, respectively. Chk1/2 regulate p53 activity and DNA-repair 
pathways.332 p53 transcriptionally represses cyclin B expression.331 Moreover, Chk-dependent 
phosphorylation stabilizes Wee1, destabilizes Cdc25A, and sequesters Cdc25C in the cytoplasm, 
resulting in reduced Cyclin B/Cdk1 activity (Figure 14A). Due to these activities, the inner feedback loop 
is halted, and mitotic entry is prevented. This so called G2/M arrest allows for efficient DNA repair.331 If 
the DNA damage burden is too high and exceeds the capacity of repair mechanisms, cells are removed 
from cell cycle in a p53-dependent manner, either by entering senescence or by undergoing intrinsic 
apoptosis.331,333 In many cases however, DNA lesions are efficiently repaired and cells can safely re-
enter the cell cycle in a process called checkpoint recovery. 
In this process, Plk-1 activity mediated by Aurora kinase A plays a crucial role. During DNA damage, 
Plk-1 activity is low. For checkpoint recovery Aurora kinase A activity increases and thereby regulates 
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Plk-1 activity. Plk-1 in turn targets both Wee1 and Claspin (an important co-factor of ATR) for 
degradation and has been found to directly inhibit Chk2. Together with the effects of Plk-1 and Aurora 
kinase A on Cdc25 activity (Figure 14B), these mechanisms result in re-activation of Cyclin B/Cdk1 
activity, thus allowing for the G2/M-transition. Due to the drastic alterations during cell cycle arrest 
compared to normal progression, protein balance and activity is still perturbed after checkpoint 
recovery.333,334 In this scenario activity of Aurora kinase A and Plk-1 is essential.331 
 
Figure 14: Roles of Aurora A and PLK1 in recovery from G2/M arrest. A. G2/M checkpoint: The DNA damage 
response inhibits PLK1 and Cdc25 and Wee1 inhibits Cyclin B/CDK1 to induce a G2/M arrest. B. Checkpoint 
recovery: After successful DNA repair, PLK1 is activated in an Aurora A-dependent manner, allowing for mitotic 
entry. Adapted from335 
 
4.5.2.3 Bipolar spindle assembly / M checkpoint control 
After maturation, in late G2 the centrosomes migrate to define the two poles of the bipolar mitotic spindle. 
The phenotype of the Drosophila aurora mutants and other models systems showed high frequency of 
monopolar spindles indicating a crucial role of Aurora kinase A not only for centrosome maturation but 
also for segregation.273,336–338 Studies in C. elegans showed that upon RNAi-mediated silencing of 
Aurora kinase A, centrosomes indeed first separated but later collapse back.339 336 Further studies 
indicate that Aurora A affects the occurrence of astral microtubules which connect centrosomes to the 
cell cortex and are important for spindle bipolarity.340 
The M checkpoint, also called spindle assembly checkpoint (SAC), is important during mitosis, in the 
prometaphase.341 It is activated when kinetochores of the chromosomes are not properly attached to 
the mitotic spindle: Unattached kinetochores facilitate the formation of the mitotic checkpoint complex 
(MCC) that blocks activity of the APC/C. This lack of APC/C activity results in the cohesin rings around 
sister chromatids to remain closed, thereby preventing segregation, thus halting the mitotic process.341 
The process of “switching on” the SAC relies on Aurora kinase B as part of the CPC.341,342 While the 
role for Aurora kinase B in SAC-control has been established, the role of Aurora kinase A for SAC activity 
remains controversial.343 Some studies demonstrated that Aurora kinase A is dispensable for SAC 
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activity.344,345 Other studies, in turn, could show that Aurora kinase A regulates SAC inactivation346 and 
Aurora B feedback loops.343  
 
4.5.3 Aurora Kinases in cancer 
4.5.3.1 Oncogenic potential of Aurora A 
The AURKA gene is located on a chromosomal region known to be intrinsically unstable, frequently 
mutated and amplified in many tumors.347 Among the first reports on Aurora A functions were studies 
describing its overexpression and oncogenicity in colorectal cancer277 and breast cancer.348,349 The latter 
study also coined one of the other names of Aurora A: breast tumor activated kinase (BTAK).349 
In the past decades Aurora A has been found to be overexpressed or mutated in a variety of different 
cancers such as lung, cervical, prostate, and oral cancer, melanoma, glioma, and acute myeloid 
leukemia (AML).347,350  
Regarding function, increased activity of Aurora kinase A can drive premature G2 checkpoint recovery 
resulting in mutations being more frequently passed on, thereby promoting tumorigenesis. 
Consequently, overexpression of Aurora A has been shown to promote colony formation, centrosome 
amplification, chromosomal instability, and tumor growth in mouse xenograft studies.277,349,351,352 While 
amplification of Aurora A has been shown to be correlated with the p53 status of the cancer cell, 
tetraploidisation as a result of centrosome amplification also is p53-dependent.351,353 Furthermore, 
Aurora kinases are implicated in resistance of tumors against chemotherapy (i.e., taxols or cis-
platin)354,355 or radiotherapy356.  
While overexpression of Aurora A alone is sufficient to transform certain cells, the process is not 
consistent, indicating that additional oncogenic events are required, for example aberrant Ras-
signaling.357 The exact contribution of Aurora A to transformation has not been solved yet, although 
there is evidence that Aurora A interferes with spindle assembly checkpoint (SAC) activity, thus 
increasing genome instability.355 Furthermore, Aurora A overexpression promotes EMT in transformed 
cells.358–360 In this way, Aurora A overexpression contributes to malignancy and results in worse 
prognosis for patients with hepatocellular carcinoma or gastric cancer.361,362 
 
4.5.3.2 Interaction of Aurora A with tumor suppressors 
Aurora A can directly phosphorylate p53 at Ser215 and Ser315, and thus control p53 stability and 
transcriptional activity.346,350,363 p53 in turn, can inhibit Aurora A function by directly binding to the 
catalytic domain.364 Moreover, Aurora A has been shown to phosphorylate BRCA1 at Ser308 while 
located at the centrosome suggesting that disruption of the G2/M transition by BRCA1 and Aurora A 
predisposes to carcinogenesis.365 
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4.5.3.3 Interaction of Aurora A with oncogenes 
Aurora A expression can be upregulated by c-myc, which in turn can upregulate myc expression, 
creating a positive feedback loop.366,367 Also, as shown in Figure 15, Aurora A stabilizes n-myc by 
protecting it from FBXW7-mediated degradation.368–370  
 
In ovarian and breast cancer, Aurora A has been linked to the RAS/RAF/MEK/ERK pathway, through 
which it stimulates telomerase activity in a c-myc-dependent manner.371 Later it could be shown that the 
small GTPase RalA is a direct target of Aurora A phosphorylation, linking the kinase to the Ras 
pathway.372 Aurora A can also modulate Ras signaling through phosphorylation of the tumor suppressor 
RAS-association domain family 1, isoform A (RASSF1A), thereby disrupting microtubule stabilization 
and M-phase cell cycle arrest.373 
Furthermore, it could be shown that Aurora A inactivates apoptotic signaling through upregulation of 
NFkB activity.374 Aurora A was also shown to modulate the equilibrium of anti-apoptotic (Bcl-2, Mcl-1) 
and pro-apoptotic proteins (Bax, Bim, PUMA) at the mitochondrial membrane.375–378 
 
Figure 15: Interaction of Aurora kinases with MYC oncogenes and the influence on tumorigenesis. Adapted from347  
 
4.5.3.4 Aurora A as a therapeutic target in cancer 
Pre-clinical data shows that inhibition of Aurora A leads to suppression of cell proliferation, migration 
and invasion.347,379–381 Treatment of tumor cells with a selective Aurora A inhibitor resulted in defective 
bipolar spindle assembly and chromosome separation. As a result, cancer cells either underwent mitotic 
arrest and when exiting mitosis showed aneuploidy and centrosome amplification382, or Aurora A 
inhibition induced senescence383. Mitotic arrests after combination with spindle poisons indicate a 
compromised SAC.384 
In the past decade, first clinical trials have started with different inhibitors (see Table 1). The most 
promising of them is MLN8237 (Alisertib) which has shown mild effects on solid tumors.385. In 
hematological cancer it was already studied in a phase III clinical trial.386. 
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Clinical trials so far show that single-agent treatment against Aurora A has modest effects and is still 
subject to toxicity.347,387 However, due to the contribution of Aurora kinases to therapy resistance, Aurora 
kinase inhibition has been proposed to work in combination with conventional therapies. Indeed, pre-
clinical data shows synergy of Aurora A inhibition in combination with Paclitaxel in pancreatic cancer 
cells388 or in combination with cis-platin389. Aurora kinase inhibition can sensitize androgen-resistant 
prostate cancer or atypical teratoid rhabdoid tumor cells to radiotherapy.390–393 Moreover, targeted 
therapy approaches such as the use of monoclonal antibodies proved to be effective in combination 
with Aurora A inhibition. It could be shown that Aurora A inhibition overcomes cetuximab-resistance in 
squamous cell cancer of the head and neck.394 
In a recent high-throughput study using genetic and pharmacological compound screens, Wang and 
colleagues could show that Aurora kinase inhibition leads to senescence in Ras-mutated lung cancer 
and melanoma cell lines, thus describing another mechanism of action of Aurora inhibition. 395 
Furthermore, that study could show that cells rendered senescent through Aurora kinase inhibition, 
become susceptible to treatment with BH3-mimetics which act as senolytic agents. Wang and 
colleagues thus proposed a combination therapy of Aurora kinase inhibitor as a senescence inducer 
and ABT-263 as a senolytic drug.395 
 
While the role of Aurora kinases has been extensively investigated in various carcinomas or 
hematological diseases, only few studies looked at Aurora kinases in sarcomas. Pre-clinical studies 
showed anti-tumor effects of Aurora kinase A inhibition in xenograft models of liposarcoma396 or human 
synovial sarcoma397. Furthermore, Aurora kinase A has been investigated as a target in osteosarcoma 
and proposed as a tumor marker.398,399 
Research of Aurora kinases in pediatric malignancies mainly focused on hematological diseases or 
neuroblastoma. The pediatric pre-clinical testing program (PPTP) tested Aurora kinase A inhibition in 
2010 in a variety of their xenograft models. They could show complete responses in almost half of their 
neuroblastoma models, all of their acute lymphoblastic leukemia models, and a variety of other tumor 
models, featuring also rhabdomyosarcoma, Ewing’s sarcoma, and osteosarcoma models.42. 
In 2011 a pre-clinical study has been conducted, showing that Aurora A inhibition reduced proliferation 
of MYCN-amplified childhood neuroblastoma cells and decreased tumor growth in a MYCN 
neuroblastoma mouse model.400   
Despite promising pre-clinical data, in recent years only four clinical trials have been conducted 
investigating Aurora kinase inhibition in childhood malignancies. Currently there is one study recruiting 
patients for a phase II study of Alisertib in rhabdoid tumors (https://clinicaltrials.gov NCT02114229).  
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Table 1: Current status of Aurora kinase inhibitors in clinical trials. Data obtained from https://clinicaltrials.gov in 
June 2016. Table adapted from401  
Name 
Clinical 
trial 
Disease condition 
Starting 
date 
Sponsors 
Current 
status 
Alisertib 
(MLN8237) 
Phase 3 
NCT01482962 
Relapsed or refractory peripheral T-Cell 
lymphoma 
June 2012 
Millennium 
pharmaceuticals, inc. 
Takeda 
Ongoing 
Phase 2 
NCT02560025 
Induction Chemotherapy in patients with 
High-risk acute myeloid Leukaemia 
December 
2015 
Millennium 
pharmaceuticals, inc. 
Takeda 
Ongoing 
Phase 2 
NCT01316692 
Patients with unresectable stage iii-iv 
melanoma 
October 2011 
Vanderbilt-ingram 
cancer centre 
Terminated 
(April 2016) 
Phase 2 
NCT02038647 
Small-cell-lung Cancer (SCLC) treatment in 
combination with paclitaxel 
February 2014 
Millennium 
pharmaceuticals, inc. 
Takeda 
Ongoing 
Phase 1 
NCT02551055 
Neoplasms, Advanced or Metastatic October 2015 
Millennium 
pharmaceuticals, 
inc.|takeda 
Ongoing 
Phase 1 
NCT02214147 
Advanced solid tumors or 
Relapsed/Refractory lymphoma 
September 
2014 
Millennium 
pharmaceuticals, inc 
Completed 
Tozasertib 
(VX-680, 
MK0547) 
Phase 2 
NCT00290550 
Non-small-cell lung carcinoma June 2006 
Merck sharp & dohme 
corp. 
Terminated 
Phase 2 
NCT00405054 
Leukaemia 
December 
2006 
Merck sharp & dohme 
corp. 
Terminated 
Phase 1 
NCT00500006 
Chronic myelogenous leukaemia, 
lymphoblastic, acute, philadelphia-positive 
October 2007 
Merck sharp & dohme 
corp. 
Terminated 
Phase 1 
NCT00111683 
Chronic Myelogenous leukaemia in blast 
crisis, lymphocytic leukaemia, B Cell acute 
and chronic myelogenous leukaemia 
June 2005 
Merck sharp & dohme 
corp. 
Completed 
August 2015 
Phase 1 
NCT02532868 
Advanced solid tumors May 2005 
Merck sharp & dohme 
corp. 
Terminated 
Phase 1 
NCT00099346 
Colorectal cancer January 2005 
Merck sharp & dohme 
corp. 
Terminated 
Berasertib 
(AZD1152) 
Phase 3 
NCT00952588 
Acute myeloid leukaemia July 2009 Astrazeneca 
Completed 
February 2014 
Phase 2 
NCT01354392 
Diffuse large B-cell lymphoma 
September 
2011 
Oxford university 
hospitals nhs trust 
Completed 
July 2014 
Phase 1 
NCT00338182 
Advanced solid malignancies May 2006 Astrazeneca 
Completed 
March 2017 
Phase 1 
NCT00497991 
Patients with relapsed acute myeloid 
leukaemia 
May 2006 Astrazeneca 
Completed 
December 2010 
Phase 1 
NCT00497731 
Advanced solid malignancies-study 3 August 2006 Astrazeneca Terminated 
MLN8054 
Phase 1 
NCT00249301 
Advanced solid tumors October 2005 
Millennium 
pharmaceuticals, inc 
takeda 
Terminated 
Phase 1 
NCT00652158 
Advanced malignancies April 2006 
Millennium 
pharmaceuticals, inc 
Takeda 
Terminated 
Danusertib 
(PHA739358) 
Phase 2 
NCT00872300 
Multiple myeloma October 2008 
Nerviano medical 
sciences 
Completed 
May 2014 
Phase 2 
NCT00766324 
Hormone refractory prostate cancer 
September 
2007 
Nerviano medical 
sciences 
Completed 
May 2014 
AT9283 
Phase 2 
NCT01145989 
Patients with relapsed or refractory multiple 
myeloma 
June 2010 
Ncic clinical trials 
group 
Completed 
November 2015 
Phase 2 
NCT00522990 
Leukaemia 
September 
2006 
Astex pharmaceuticals Terminated 
Phase 1 
NCT00985868 
Relapsed and Refractory Solid Tumors 
September 
2009 
Cancer research uk 
Completed 
April 2013 
Phase 1 
NCT01431664 
Patients With Relapsed or Refractory Acute 
Leukaemia 
September 
2011 
Cancer research uk 
Completed 
December 2014 
Phase 1 
NCT00443976 
Advanced or metastatic solid tumors or non-
hodgkin's lymphoma 
January 2007 
Ncic clinical trials 
group 
Completed 
January 2012 
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Name 
Clinical 
trial 
Disease condition 
Starting 
date 
Sponsors 
Current 
status 
AMG-900 
Phase 1 
NCT00858377 
Advanced solid tumors August 2009 Amgen Ongoing 
Phase 1 
NCT01380756 
Acute myeloid leukaemia July 2011 Amgen 
Completed 
February 2015 
VX-689 
(MK-5108) 
Phase 1 
NCT00543387 
Advanced and/or Refractory solid tumors March 2008 
Merck sharp & dohme 
corp. 
Completed 
April 2011 
TAK-901 
Phase 1 
NCT00807677 
Advanced hematologic malignancies March 2009 
Millennium 
pharmaceuticals, inc. 
Takeda 
Completed 
March 2013 
Phase 1 
NCT00935844 
Advanced solid tumors or lymphoma October 2009 
Millennium 
pharmaceuticals, inc. 
Takeda 
Completed 
November 2011 
GSK1070916 
Phase 1 
NCT01118611 
Advanced solid tumors March 2010 Cancer research uk 
Completed 
March 2013 
ENMD-2076 
Phase 2 
NCT01914510 
Ovarian clear cell cancers 
September 
2013 
University health 
network, toronto 
Ongoing 
Phase 2 
NCT01639248 
Previously treated locally 
advanced + metastatic tnbc 
July 2012 
Casi pharmaceuticals, 
inc 
Ongoing 
Phase 2 
NCT02234986 
Advanced fibrolamellar carcinoma October 2015 
Casi pharmaceuticals, 
inc. 
Ongoing 
Phase 2 
NCT01104675 
Patients with ovarian cancer April 2010 
Casi pharmaceuticals, 
inc. 
Completed 
December 2012 
Phase 1 
NCT00658671 
Advanced cancer April 2008 
Casi pharmaceuticals, 
inc. 
Completed 
June 2012 
Phase 1 
NCT00806065 
Multiple myeloma 
December 
2008 
Casi pharmaceuticals, 
inc. 
Completed 
January 2012 
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5. AIM OF THE THESIS 
As described above, the overall survival of patients with aRMS is still low, especially in disseminated 
disease. The standard of care therapy is harsh and comes with many side effects for the young patients. 
To reduce the burden of therapy side effects and increase overall survival in these patients, we need to 
find new strategies to target aRMS.  
To this end, we focused on interfering with the biology of the pathognomonic fusion protein. The 
therapeutic potentital of targeting PAX3-FOXO1 activity has been demonstrated before in different 
approaches of our group.137,150 Earlier studies could already demonstrate that genetic depletion of 
PAX3-FOXO1 leads to cell death in aRMS, presumably by apoptosis.99 However, the exact mechanism 
of cell death has not been characterized so far.  
Hence, in this thesis we used unbiased drug screens and genetic means to unravel the exact mode of 
cell death, the role of PAX3-FOXO1 in preventing it, and to convert these finding into a new targeted 
combination therapy approach.  
The aims of this thesis are as follows: 
 
1) Characterize cell death in aRMS cells after loss of PAX3-FOXO1 and find a combination therapy 
interfering with fusion protein biology while simultaneously enhancing cell death. (Manuscript I) 
2) Investigate the PAX3-FOXO1-dependent regulation of NOXA in aRMS and its implications for 
new therapy approaches. (Manuscript II) 
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Abstract 
Rhabdomyosarcoma is the most common soft tissue sarcoma in children. The aggressive 
alveolar subtype (aRMS) is characterized by chromosomal translocations, most often a t(2;13) 
resulting in the expression of the oncogenic fusion protein PAX3-FOXO1 which is critical for 
tumorigenesis and cell survival.  
Our aim here was to identify a pharmacological combination therapy approach interfering with 
PAX3-FOXO1 biology at different levels. Since loss of the fusion protein results in cell death, 
we first aimed to pharmacologically enhance this effect. To this end, we screened aRMS tumor 
cells with a library of 208 drugs while simultaneously silencing PAX3-FOXO1 by shRNA. This 
identified the BH3-mimetic ABT-263 to sensitize aRMS cells to cell death after PAX3-FOXO1 
depletion. To further characterize the cell death mechanisms we used combined shRNA and 
CRISPR approaches to perform a BH3 protein profiling. In accordance with identification of 
ABT-263 we demonstrate that aRMS cells undergo intrinsic apoptosis in a NOXA-dependent 
manner upon depletion of PAX3-FOXO1. In a parallel approach, and to identify drugs altering 
PAX3-FOXO1 protein stability, we screened the same drug library directly measuring fusion 
protein levels as read-out. This revealed that inhibition of Aurora kinase A negatively affects 
PAX3-FOXO1 protein levels. Furthermore, we demonstrate that Aurora kinase A stabilizes 
MYCN, both an oncogene and target gene of PAX3-FOXO1 in aRMS, and that inhibition of the 
kinase also destabilizes MYCN. 
Finally, using both aRMS cell lines and patient-derived xenografts we demonstrate that 
combination treatment of Aurora kinase A inhibitors together with ABT-263 synergistically 
induces cell death and greatly slows tumor growth in vitro and in vivo.  
Taken together, these data show a novel functional interaction of Aurora kinase A with both 
PAX3-FOXO1 and its effector MYCN, and suggest new opportunities for targeted combination 
treatment of aRMS. 
 
Keywords: PAX3-FOXO1, MYCN, drug screening, BH3-mimetics, Aurora kinase A, apoptosis 
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Introduction 
Rhabdomyosarcoma is the most common pediatric soft tissue sarcoma. The most aggressive subtype, 
alveolar rhabdomyosarcoma (aRMS), is characterized by the occurrence of balanced reciprocal 
translocations resulting in the expression of oncogenic fusion proteins [1,2]. The most common fusion, 
PAX3-FOXO1, is the result of a translocation between chromosomes 2 and 13. aRMS has a high 
propensity to metastasize and resistances to standard-of-care treatments are common, resulting in the 
worst prognosis for all rhabdomyosarcoma types, with 5-year survival rates of only about 30% [3]. The 
search for novel targeting strategies is difficult as pediatric tumors generally harbor fewer somatic 
mutations than adult tumors [4]. Especially the aRMS subtype harbors very few mutations as opposed 
to other rhabdomyosarcoma subtypes [5].  The lack of other somatic mutations underscores the 
important role of PAX3-FOXO1 in aRMS tumor development and maintenance. Its function as 
transcriptional activator results in activation of multiple oncogenic pathways [6]. Our group showed that 
antisense-mediated loss of PAX3-FOXO1 results in cell death, underlining the addiction of aRMS cells 
to the fusion protein. However, so far the exact mechanism by which the cells die has not been described 
[7].  
Due to its importance in tumor survival, targeting PAX3-FOXO1 has become a paramount goal in 
rhabdomyosarcoma research in recent years. However, since PAX3-FOXO1 is a transcription factor 
lacking enzymatic activity, targeting the fusion protein directly is challenging. Recently, new strategies 
have been developed targeting PAX3-FOXO1 indirectly by inhibiting its stabilizer Polo-like kinase 1 
(PLK1) [8] or its co-factors, like bromodomain-containing protein 4 (BRD4) [9] or chromodomain-helicase 
DNA-binding protein 4 (CHD4) [10]. Further strategies to target PAX3-FOXO1 are reviewed in [11]. 
While single-target therapies have been shown to be efficient in pre-clinical models and clinical 
treatment, they tend to be prone to therapy resistance. One way to circumvent this problem would be to 
use drugs in combination, thus targeting different pathways and making it harder for cancer cells to 
escape. 
Aurora kinases are a family of serine-threonine kinases that are involved in cell cycle progression, most 
importantly during mitosis. The family consists of three homologues Aurora A, B and C encoded by the 
genes AURKA, AURKB and AURKC, respectively [12]. Each kinase serves distinct and tightly regulated 
functions during mitosis or meiosis. Aurora kinase A is highest expressed at the G2/M transition [13]. 
Here, its function is to phosphorylate PLK1 at threonine 210, thus activating it which is a crucial step for 
checkpoint recovery [14,15]. Furthermore, Aurora kinase A serves important roles in centrosome 
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maturation and mitotic entry [16]. During prometaphase it also localizes to spindle poles facilitating 
bipolar spindle assembly [17]. These functions for cell cycle progression indicate an important role for 
Aurora kinases in cancer. Indeed, Aurora kinase A has been found to be upregulated in a variety of 
tumors and has thus been a focus of novel preclinical therapy approaches in the recent years [18–21]. 
Apart from its mitotic function, Aurora kinase A has been shown to phosphorylate AKT and mTOR 
indicating a role in promoting resistance of cancer cells towards chemotherapy [22].  
Its close relation to PLK1 also makes Aurora kinase A an interesting target in rhabdomyosarcoma. 
Recently, we showed that PLK1 stabilizes PAX3-FOXO1 in aRMS tumors through phosphorylation of 
serines 503 and 505, protecting the fusion protein from proteasomal degradation [8]. While single-agent 
inhibition of PLK1 proved very effective in reducing tumor growth in vivo, resistance against this 
treatment was common. Our goal was thus to find a novel effective combination therapy approach to 
treat aRMS.  
To this end, we first aimed to characterize the exact mode of cell death after silencing of PAX3-FOXO1. 
Then, based on our findings, we aimed to find drugs enhancing this mode of cell death as well as more 
drugs interfering with PAX3-FOXO1 biology.  Our goal was, we wanted to find a novel synergistic 
combination.  
Here, we demonstrate that aRMS cells undergo intrinsic apoptosis in a NOXA-dependent manner after 
loss of PAX3-FOXO1. Using a drug library, we found that BH3-mimetics, especially ABT-263, can 
efficiently enhance cell death in a NOXA-dependent fashion. Moreover, we established a novel 
functional link between Aurora kinase A and PAX3-FOXO1 stability. Combination of ABT-263 and the 
Aurora A inhibitor Alisertib have synergistic effects tumor in vitro and in vivo and thus provide the basis 
for a promising new combination therapy approach in aRMS treatment. 
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Results 
Silencing of PAX3-FOXO1 expression induces intrinsic apoptosis in a NOXA-dependent manner 
Since it was previously shown that silencing of PAX3-FOXO1 expression results in FP-RMS cell death 
(Bernasconi et al., 1996), we aimed first to further elucidate the precise mechanism of this cell death.  
To this end, we generated FP-RMS cell lines expressing an inducible shRNA (shP3F) or control (shsc) 
to specifically silence PAX3-FOXO1 expression upon doxycycline treatment (Suppl.Fig.1A). After 
confirming that the system significantly downregulates the fusion protein both on the mRNA and protein 
level in four different cell lines (Suppl.Fig.1B-D), we assessed whether cells would undergo apoptosis. 
We observed a significant increase in caspase 3/7 activity in Rh4 and Rh30 cells 48 hours and 72 hours 
after P3F depletion compared to control (Fig.1A, Suppl.Fig.1E). This increase was also reflected on the 
protein levels of the cleaved products of PARP, caspases 3, 7, and 9 after 48h of shRNA induction 
(Fig.1B). To exclude off-target effects of the shRNA, we overexpressed a non-targetable PAX3-FOXO1 
mutant which indeed could rescue cells from apoptosis despite silencing of the endogenous fusion 
protein as shown by reduced caspase 3/7 activity (Suppl.Fig1F) and decreased levels of cleaved PARP 
and caspase 3 protein products (Suppl.Fig1G).  
To further confirm this notion, we also treated cells after fusion protein depletion with increasing 
concentrations of the pan-caspase inhibitor zvad-FMK which indeed could restore viability of Rh4sh 
cells (Fig.1C) and reduce cleaved PARP and caspase 3 protein levels (Suppl.Fig1H). To exclude other 
modes of cell death, we treated shP3F-Rh4 cells with different cell death inhibitors. Interestingly, 48h 
fusion protein depletion only zvad-FMK could rescue viability but none of the other inhibitors (Fig.1D). 
These data indicate that apoptosis is the major mode of cell death activated in FP-RMS cells upon 
depletion of PAX3-FOXO1. 
 
Next, we sought to identify the pro-apoptotic protein(s) responsible for initiating apoptotic cell death. To 
this end, we performed a small scale CRISPR/Cas9 screen in shP3F-Rh4 cells using the construct 
depicted in Suppl.Fig.2A to knock-out pro-apoptotic genes either individually or in combination and 
measured cell viability upon P3F depletion. Knock-down efficiencies of Bax, Bak, Bad, Bim as examples 
are shown in Suppl.Fig.2B-C. In control cells (shsc-Rh4), only depletion of caspase 9, but not caspase 
8 and the combination of Bax/Bak, were able to significantly reduce caspase 3/7 activity (Suppl.Fig.2D). 
This indicates that activation of the extrinsic pathway is less important in PF-RMS cells. Upon depletion 
of PAX3-FOXO1, NOXA was the only BH3-only protein capable to reduce caspase 3/7 activity 
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significantly (Fig.1E, Suppl.Fig.2E) and similar to knock out of the pore forming proteins BAX and BAK. 
These results were also confirmed in three additional FP-RMS cell lines (Suppl.Fig.2F) indicating that 
NOXA in general plays an important role in initiating apoptosis after PAX3-FOXO1 depletion. Moreover, 
this is in line with the observation that both mRNA and NOXA protein expression are upregulated upon 
silencing of the fusion protein in all cell lines tested (Fig.1F-G, Suppl.Fig.2G). Taken together, our results 
demonstrate that FP-RMS cells undergo intrinsic apoptosis upon silencing of PAX3-FOXO1 which 
depends on upregulation of the BH3-only protein NOXA.  
  
The BH3-mimetic ABT-263 enhances cell death after PAX3-FOXO1 depletion 
Next, we aimed at finding drugs that would enhance apoptosis induced by PAX3-FOXO1 depletion. For 
this, we set up a compound screen of 205 drugs at a final concentration of 500 nM and cotreated shP3F-
Rh4 cells together with doxycycline mediating induction of fusion protein directed shRNA (Suppl.Fig.3A, 
Supplemental table 1). Results are depicted as ratio of viability comparing shP3F versus shsc cells. The 
screen identified 13 candidate drugs that decreased viability of shP3F cells by at least an additional 50% 
while remaining unchanged in control shsc cells (Fig.2A). Classification of the top hits according to their 
mechanism of action revealed that 8 out of the 13 drugs were either Aurora kinase A inhibitors (5) or 
BH3-mimetics (3) (Fig.2B) with ABT-263 being the most potent drug, also when validating each as single 
agent (Fig.2C, Suppl.Fig.3 B-M). To directly compare BH3-mimetics that act more specifically on Bcl-2 
itself or more broadly on the family, we generated dose-response curves of ABT-263 and ABT-199 on 
shP3F-Rh4 cells (Fig.2D-E). Interestingly, while both ABT-263 and ABT-199 showed a further reduction 
of IC50 upon silencing of PAX3-FOXO1, ABT-263 reduced IC50 to at least ten times lower concentration 
(reduction of 3.0M to 0.18M) than ABT-199 (reduction of 9.6uM to 5.6uM). These findings indicate 
that inhibition of BCL-2 itself might be less important than other family members. Hence, we treated cells 
with increasing concentrations of the BCL-XL specific inhibitor A1331852 and S63845 which is MCL-1 
specific.  While A1331852 showed comparable effects to ABT-263 (Fig.2F), while treatment with S63845 
did not further increase cell death (Suppl.Fig.3O). These results support the notion that PAX3-FOXO1 
silencing primes FP-RMS cells to inhibition of BCL-xl via upregulation of NOXA. 
To demonstrate this directly, we treated shP3F-Rh4-NOXA-/- cells (Suppl.Fig.2E) with ABT-263 and 
found indeed reduced sensitivity upon silencing of PAX3-FOXO1 (Fig.2G). Finally, expression analysis 
of different datasets in the r2 database (R2: Genomics Analysis and Visualization Platform: 
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http://r2.amc.nl) revealed that NOXA expression was elevated in all rhabdomyosarcoma datasets 
compared to healthy skeletal muscle tissue (Suppl.Fig.3P).  
These findings suggest that rhabdomyosarcoma cells might be already primed towards a pro-apoptotic 
state through higher basal NOXA expression which can be further enhanced by reduction of fusion 
protein levels and subsequently renders them more sensitive towards ABT-263 treatment.  
 
Aurora kinase A inhibition reduces PAX3-FOXO1 protein stability 
In a next step, we therefore aimed to pharmacologically reduce PAX3-FOXO1 protein levels in FP-RMS 
cells. To this end, we treated wild type Rh4 cells with the same drug library (Supplemental Table 1) and 
analyzed cell lysates by Western Blot to identify drugs that have the potential to reduce PAX3-FOXO1 
protein levels (Suppl.Fig.4A). To exclude that reduced fusion protein levels were due to general toxic 
effects all signals were densitometrically digitalized and normalized to the house keeping protein 
GAPDH. Hits were called when lowering fusion protein levels below 80%, a criterion fulfilled by 43 
compounds (Fig.3A-B). When classifying these hits according to their drug targets we identified five 
epigenetic regulators, five proteasome, five Aurora kinase A, and three CDK9 inhibitors (Fig.3C). Of 
these, aurora kinase A caught our attention because of its ability to stabilize the NMYC protein [31]. 
Hence, we individually validated AURKA inhibitors at increasing doses to reduce PAX3-FOXO1 protein 
levels and identified alisertib as being the compound active at the lowest doses tested (Fig.3D, 
Suppl.Fig.4B-C). Strikingly, treatment of patient-derived primary cells with alisertib also reduced fusion 
protein levels (Suppl.Fig.4C). 
Previous work from our laboratory demonstrated a direct interaction between PAX3-FOXO1 and the 
Polo-like kinase 1 (PLK1) which stabilizes the fusion protein via phosphorylation at S503 [8]. PLK1 in 
turn is known to be activated by AURKA [15]. Hence, we were interested to study the mechanism 
underlying the functional interaction of AURKA and PAX3-FOXO1. We treated Rh4 cells with alisertib 
and analyzed PLK1 protein levels and activity by Western Blot after 48hrs. This revealed increased 
protein levels of both PLK1 and Aurora kinase A. In addition, we observed a reduction of PLK1 
phosphorylation at threonine 210 as expected (Fig.3E). Since AURKA has been described to influence 
phosphorylation of S256 in wild type FOXO1 [23], we also investigated phosphorylation of PAX3-FOXO1 
at serine 437 (corresponding serine 256 in wild-type FOXO1). Indeed, we also observed a clear 
reduction at this site in the fusion protein upon Alisertib treatment (Fig.3E). As this region of PAX3-
FOXO1 has been described to be relevant for protein stability (reviewed in [11]), we next studied whether 
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phosphorylation of serine 437 would contribute to fusion protein stability by replacing serine with alanine 
at this position (S437A). Interestingly, and even more pronounced than the S503A mutant, also the 
S437A mutant significantly reduced fusion protein stability compared to wild-type as revealed by 8hr 
treatment with cycloheximide (Fig.3F-G).  
Lastly, to investigate a potential direct interaction of AURKA and PAX3-FOXO1 we fused PAX3-FOXO1 
to the bacterial biotin-ligase BirA  [24] and expressed it ectopically in HEK293T cells. After pull down of 
biotinylated proteins using streptavidin coated beads, PLK1 was identified on Western Blots to be 
selectively biotinylated in fusion protein samples but not in the BirA-only control as shown before [25] 
(Fig.3H). Strikingly, also AURKA was identified in this assay as being selectively biotinylated, suggesting 
a novel direct interaction of this kinase and the fusion protein (Fig.3H).  
Taken together, our results indicate that AURKA inhibition can decrease fusion protein stability through 
reduced phosphorylation of serine 437 which might contribute to its ability to induce apoptosis in FP-
RMS cells. 
 
Alisertib and ABT-263 act synergistically in vitro 
Since it is unlikely that single agents will be able to provide significant clinical benefit, we next aimed to 
investigate whether a combination of synergistically acting drugs could be identified. To do this in an 
unbiased way, we screened our library for compounds that would synergistically reduce cell viability in 
conjunction with a non-effective concentration of ABT-263 (IC20) (Suppl.Fig.5A-B). We assessed cell 
viability after 48h of combination treatment and ranked the results according to synergistic reduction in 
viability. Strikingly, out of the 28 hits identified, seven were AURKA inhibitors (Fig.4A). Six of these seven 
AURKA inhibitors were also identified in a similar screen carried out in a second FP-RMS cell line 
(Suppl.Fig.5C-D). Hence, AURKA inhibitor might act in synergy with ABT-263. To test this, we selected 
Alisertib and treated FP-RMS cells with increasing concentrations of both Alisertib and ABT-263 to 
obtain a combination matrix. Indeed, both drugs in combination were able to induce cell death even at 
low concentrations (Fig.4B). This combination was highly synergistic as assessed by the SynergyFinder 
web tool [26] (Fig.4C). Importantly, we observed comparable synergistic effects not only in cell lines but 
also using cells from patient-derived xenografts (PDX) (Fig.4D-E). This synergy was tumor specific as 
non-tumorigenic cells (human foreskin fibroblasts and myoblasts) were not sensitive towards the 
combination treatment (Suppl.Fig.6A-D), whereas we observed a less pronounced synergy in the FN-
RMS cell line RD (Suppl.Fig.6E-F). 
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As AURKA is plays an important role for cell cycle progression during G2/M phase, we also were 
interested to assess the effects of Alisertib alone or in combination on cell cycle in FP-RMS cells by flow 
cytometry. When we analyzed cells treated with 50 or 100 nM Alisertib, we observed an increasing 
proportion of cells arrested in G2/M phase (Fig.4F). Additional treatment with 800nM ABT-263, however 
strongly reduced the G2/M peak and increased the sub-G1 fraction (Fig.4F, Suppl.Fig.6G). This suggests 
that Alisertib induces a cell cycle arrest in G2/M while in combination with ABT-263 engages apoptosis. 
These findings are also supported by a synergistic increase in caspase 3/7 activity (Suppl.Fig.6H). 
Taken together, our data indicate that AURKA inhibitors act synergistically in combination with ABT-263 
in vitro as observed not only in cell lines but also in cells from PDXs, while the drug combination had no 
major effects in non-tumorigenic cells.  
 
Combination of Alisertib and ABT-263 synergistically reduces tumor growth in vivo 
Having confirmed a synergistic action of Alisertib and ABT-263 in vitro, we next aimed to assess an anti-
tumorigenic response to the drug combination in vivo. We injected NOD/Scid il2rg-/- (NSG) mice 
subcutaneously with either Rh4 or patient-derived IC_pPDX35 cells. After tumors were palpable, mice 
were randomized into four groups and treated daily over three weeks with either vehicle, ABT-263 alone 
(30 mg/kg), Alisertib alone (80 mg/kg), or combination of both drugs (Suppl.Fig7A). While continuous 
tumor growth was observed in Rh4 cells in vehicle and ABT-263 only treated mice, Alisertib treatment 
slightly delayed tumor growth but failed to induce lasting effects (Fig.5A). In contrast, combination 
therapy resulted in slight tumor regression and lasting stable disease even after the treatment period 
(Fig.5A). This reduction in tumor growth was also reflected in the survival of mice, where only animals 
in the combination group survived (Fig.5B). In the PDX, Alisertib treatment alone provoked a stronger 
delay in tumor growth whereas also in this setting, combination treatment showed the most stable growth 
control (Fig.5C) and survival was still significantly increased in combination treated mice (Fig.5D). We 
also isolated tumors after one week of treatment. Histological analysis after one week of treatment 
revealed a markedly increased number of apoptotic cells in combination treated tumors (Fig.5E). which 
was also reflected by increased staining for cleaved caspase 3 (Fig.5E). Consequently, proliferation in 
combination treated tumors was reduced as reflected by reduced signals of Ki67 and increased 
expression of p21 (Suppl.Fig.7D-E). Furthermore, increased effector caspase cleavage was also found 
in Western Blot analysis of lysates from tumor tissue (Fig.6F) which showed downregulation of PAX3-
FOXO1 (Fig.6F). 
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Finally, to underscore the clinical relevance of AURKA inhibition, we noticed that AURKA expression is 
significantly higher in three independent rhabdomyosarcoma datasets compared to biopsies from 
healthy skeletal muscle (Fig.5G) (data from R2 database: Genomics Analysis and Visualization 
Platform: http://r2.amc.nl).  
 
Discussion 
 
Our aim for this study was to characterize cell death in alveolar rhabdomyosarcoma (aRMS) following 
silencing of PAX3-FOXO1 and to translate this knowledge into novel combination therapy approaches. 
Here, we show that aRMS cells undergo intrinsic apoptosis in a NOXA-dependent manner upon loss of 
PAX3-FOXO1 expression. In accordance with these findings, we show that BH3-mimetics, especially 
ABT-263 (Navitoclax), can efficiently facilitate this mode of cell death. Furthermore, we demonstrate a 
novel functional interaction between Aurora kinase A and the fusion protein. Consequently, we observe 
strong synergy in vitro and in vivo between the Aurora kinase A inhibitor Alisertib and the BH3-mimetic 
ABT-263. 
We could establish a functional link between the PAX3-FOXO1 and the BH3-only protein NOXA. 
However, we were unable to show exactly how the fusion protein regulates NOXA expression. In ChIP 
experiments, we could not find binding of PAX3-FOXO1 to the genomic NOXA locus (unpublished), 
excluding a direct role of the fusion protein in NOXA regulation. NOXA is well described as a target of 
p53 signaling [27], but as most other cell lines, the ones we used for our experiments are p53 deficient 
[28]. However, we observe MYCN-dependent regulation of NOXA expression, in accordance with what 
has been described recently [29]. While MYCN is known target gene of PAX3-FOXO1 [30], this does 
not sufficiently explain NOXA upregulation upon silencing of the fusion protein, indicating that there 
might still be another regulatory pathway involved.  
Conversely, we found that combination of Navitoclax with Alisertib reduced NOXA proteins levels after 
one week of treatment in vivo. This finding indicates that although PAX3-FOXO1 is destabilized, further 
mechanisms, independent of NOXA contribute significantly to the synergistic effect of the combination. 
For instance, Aurora kinase A is known to stabilize MYCN [31]. As described above, we found that 
NOXA expression in aRMS cells is transcriptionally regulated by MYCN (unpublished data). 
Consequently, Aurora kinase inhibition would reduce MYCN activity and thereby also reduce NOXA 
expression. This mechanism of action seems to outweigh the upregulation of NOXA after silencing of 
PAX3-FOXO1. 
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We found that phosphorylation of PAX3-FOXO1 at serine 437 is important for fusion protein stability. 
This site corresponds to serine 256 in wild-type FOXO1. Upon phosphorylation of this residue, FOXO1 
is excluded from the nucleus and subsequently degraded [32]. Strikingly, phosphorylation of S256 in 
wild-type FOXO1 and S437 in PAX3-FOXO1 respectively, seem to have opposite effects on protein 
stability. A similar effect has already been described for acetylation of lysines 426 and 429 that increases 
stability in PAX3-FOXO1 [33]. Matsuzaki and colleagues could show that acetylation of these 
corresponding sites in wild-type FOXO1 results in subsequent phosphorylation at S256 [34]. 
Considering that a similar mechanism is involved in the fusion protein, we can now assume how 
K426/K429 acetylation contributes to stability: through priming the fusion protein for S437 
phosphorylation. 
Taken together, we found a previously undescribed site in PAX3-FOXO1 that is important for fusion 
protein stability. With Aurora kinase A inhibition, we found a therapeutic option to target this site. 
Furthermore, characterization of the exact cell death mechanism allowed us to find drugs enhancing 
this mode of cell death. When used in combination, both drugs show a high degree of synergy in vitro 
and in vivo. These findings shed more light on a devastating disease and may offer novel therapeutic 
options in the treatment of alveolar rhabdomyosarcoma.  
 
Material & Methods 
Cell lines 
Rhabdomyosarcoma cell lines RD, Rh4 (both received from Peter Houghton, St. Jude Children’s 
Hospital, Memphis, TN), RhJT (Scott Diede, Fred Hutchinson Cancer Research Center, Seattle, WA), 
RMS (Janet Shipley, Sarcoma Molecular Pathology, The Institute of Cancer Research, London, UK), 
KFR (Jindrich Cinatl, Frankfurter Stiftung für krebskranke Kinder, Frankfurt, Germany), Rh30 as well as 
HEK293T cells (both ATCC LGC Promochem) were cultured in high glucose DMEM (Sigma-Aldrich), 
supplemented with 100 U/mL penicillin/streptomycin, 2 mmol/L L-glutamine, and 10% FBS (Life 
Technologies) at 37°C and 5% CO2 .  
 
Cells from patient-derived xenografts (PDX) 
PDX tumors were dissociated as described before [35]. In brief, tumor tissue was minced with scalpels 
under sterile conditions and suspended in Hanks’ Balanced Salt Solution (HBSS, Sigma-Aldrich) 
supplemented with 1 mmol/L MgCl2, 200 g/mL Liberase, and 200 U/mL DNase I (both Roche). Tissue 
 55 
 
was digested for 30 minutes at 37°C and filtered twice through 70 m cell strainers (BD Biosciences). 
Dissociated cells were washed with phosphate-buffered saline (PBS, Sigma-Aldrich) before freezing or 
resuspending for further culture. 
Cells derived from PDX tumors were cultured in Neurobasal medium (Life Technologies) supplemented 
with 2x B-27™ Supplement (Life Technologies), 20 ng/mL EGF and 20 ng/mL basic FGF (Peprotech) 
on plates coated with Matrigel® (Corning Life Sciences). 
 
Virus production and transduction 
Lentiviral particles (for stable integration of shRNA or CRISPR/Cas9 constructs) were produced in 
HEK293T cells. In brief, cells were transfected with Pax2 (Addgene #12259) and VSV-G plasmids 
(Addgene #12259) as well as with the respective transfer plasmid using calcium phosphate transfection. 
Virus containing supernatant was concentrated using Amicon Ultra centrifugal filter units (Merck 
Millipore). aRMS cell lines were transduced with the virus particles in presence of hexadimethrine 
bromide (Sigma-Aldrich). Transduced cells were selected with puromycin (shRNA constructs) or sorted 
by flow cytometry for expression of blue fluorescent protein (BFP) (CRISPR constructs). pLentiCRISPR-
tagBFP (Addgene #75160) was a gift from Beat Bornhauser, Zurich. 
 
In vitro drugs treatments / drug library screenings 
Cells were seeded in the respective plate format needed for downstream analysis (i.e. 384-well plate for 
viability or caspase 3/7 assays). shRNA was induced by diluting doxycycline (Sigma-Aldrich) into the 
culture medium at a final concentration of 100 ng/mL. Drugs were added to the cells using the HP D300 
Digital Dispenser (Tecan) and the corresponding software. 
Drug library (Supplemental table 1) was purchased from Selleckchem as pre-dissolved stocks of 10 
mmol/L and was stored at -80°C. 24h after seeding cells, medium was changed to 19 L culture medium 
(for experiment in Fig. 2 +/- 100 ng/ml doxycycline / for experiment in Fig. 4 +/- 800 nmol/L ABT-263). 
Library was thawed and pre-diluted to 10 mol/L in culture medium. From pre-dilution, 1 L of each drug 
was added to the wells for a final concentration of 500 nmol/L. Cells were incubated for 48h and viability 
was measured by WST-1 assay. For results in Fig. 2 in each condition (Rh4 shsc - dox, Rh4 shsc + dox, 
Rh4 shP3F - dox, Rh4 shP3F + dox) relative cell viability compared to DMSO treatment (= 100%) was 
calculated for each drug. Relative viability effect was calculated as the ratio between relative viability 
+dox vs –dox.  
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For protein screen in Fig. 3, cells were seeded in 24-well plates. 24h later medium was changed to 495 
L culture medium. Library was pre-diluted as described above and 5 L of pre-dilution was added to 
each well to reach a final concentration of 100 nmol/L. Cells were prepared for Immunoblot analysis 
after 48h of incubation. 
 
Antibodies 
Antibodies are listed in the Supplemental Material and Methods section.  
 
Viability and caspase assays 
WST-1 assay (Roche Diagnostics) to assess cell viability was used according to manufacturer’s 
protocol. In brief, Assay solution was diluted 1:2 in culture medium and added directly into the wells. 
Cells were incubated at 37°C / 5% CO2 for 30 minutes and absorption of 440nm was measured against 
640nm.  
Caspase activity was assessed using Caspase-Glo® 3/7 Assay (Promega) according to manufacturer’s 
protocol. In brief, Assay solution was added directly to each well, plate was covered and shaken, 
followed by incubation at room temperature for 45 minutes. Signal was assessed by measuring 
chemiluminescence.  
 
Mouse xenograft experiments 
NOD/Scid il2rg-/- (NSG) mice were 8-12 weeks old for the experiments. 5x106 Rh4 cells or IC_PPDX35 
cells, respectively, were injected subcutaneously into the flanks NSG mice and allowed to engraft. After 
engraftment mice were randomized into 4 groups (5-6 mice per group) for a group mean in tumor size 
of 100 mm3. The groups were treated with vehicle, Alisertib alone, ABT-263 alone, or the combination 
of both drugs, respectively, according to the regimen shown in Supplemental Figure 7A. Tumor growth 
was assessed by caliper measurements and the volumes were calculated using the formula  
V= (4/3) π r3; r=(d1+d2)/4). Mice were sacrificed when the tumor volume reached 1000 mm³. All animal 
experiments have been approved by the Swiss veterinary authorities and were performed according to 
the animal license ZH206/15 
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Expression analysis using the R2 database 
All datasets are available on the open access platform R2 Genomics and Visualization Platform 
(http://r2.amc.nl).  
 
Statistics 
Data analysis was performed with GraphPad Prism 7. Significance was calculated using unpaired two-
tailed Student’s t-test or Welch’s two-tailed test. Two-way ANOVA was used for multiple comparisons. 
Differences were considered statistically significant with p<0.05. Drug synergy was calculated using the 
Bliss independence model in the free SynergyFinder WebApp [26].  
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Figure legends 
 
Figure 1: Silencing of PAX3-FOXO1 induces apoptosis via NOXA 
 
A. Caspase activity after silencing of PAX3-FOXO1. Caspase 3/7 activity was assessed 24, 48 and 72 
hours after induction of shRNA expression. Mean of three independent experiments; bars, SD; 2-way 
ANOVA, ***, P ≤ 0.001. B. Western blot analysis of whole cell lysates from Rh4 shsc or shP3F 48h after 
shRNA induction with doxycycline (+) or no induction (-). C. z-vad mediated rescue from cell death. 
WST-1 assay of Rh4 shsc or shP3F treated with doxycycline as before and additionally treated with 
increasing concentrations of z-vad FMK. Mean of two independent experiments; bars, SD; Student’s t 
test, *, P ≤ 0.05, **, P ≤ 0.01. D. Rescue experiment after shRNA-mediated silencing of PAX3-FOXO1 
mRNA. Rh4 cells expressing either scrambled shRNA (shsc) or shRNA targeting PAX3-FOXO1 mRNA 
(shP3F) were treated for 48h with 0.1 µg/mL doxycycline to induce shRNA expression. Viability was 
assessed using WST-1 assay and shown relative to non-treated cells. Additionally, cells were treated 
with either DMSO or a cell death inhibitor at the given concentration. Mean of two independent 
experiments; bars, SD. E. BH-3 only rescue screen. Caspase 3/7 activity of Rh4 shP3F cells harboring 
CRISPR/Cas9-induced knockouts of the indicated genes (sc = scrambled sgRNA). White bars, no 
shRNA induction; black bars, 48h after doxycycline-induced shRNA expression. Mean of two 
independent experiments; bars, SD. F. NOXA expression after PAX3-FOXO1 silencing. Western blot 
analysis of whole cell lysates from Rh4 shsc or shP3F 48h after shRNA induction with doxycycline (+) 
or no induction (-). G. Relative mRNA expression of the PMAIP1 gene in Rh4 shsc or shP3F 48h after 
induction of shRNA with doxycycline. Gene expression was normalized to GAPDH. Mean of two 
independent experiments. 
Each experiment was performed in triplicates. 
 
Figure 2: ABT-263 sensitizes cell to cell death after silencing of PAX3-FOXO1 
A. Drug screen to enhance cell death after silencing of PAX3-FOXO1. Rh4 shsc and Rh4 shP3F cells 
were treated with drugs from a library (Supplemental table 1) while simultaneously inducing shRNA 
expression with 0.1 µg/mL doxycycline for 48h. Viability was measured by WST-1 assay and the relative 
viability effect of each drug was calculated (see Method section). Plot shows the mean viability effects 
from 3 independent experiments performed in duplicates. B. List of the top hits according to the ratio of 
relative viability effects of drugs on shP3F over shsc. Ranked according to their targeting class. SD = 
standard deviation; Welch’s two-tailed t-test, *, P ≤ 0.05, **, P ≤ 0.01, ***, P ≤ 0.001. C. Individual effect 
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of ABT-263 on relative cell viability of Rh4 shsc or Rh4 shP3Fcompared to DMSO; SD; Welch’s two-
tailed t-test, **, P ≤ 0.01. D-F. Relative cell viability of Rh4 shsc or Rh4 shP3F cells after 48h with or 
without shRNA induction and simultaneous treatment with increasing concentrations of ABT-263 or 
ABT-199, respectively. Mean +/- SD from three independent experiments performed in triplicates. IC50 
values were calculated from non-linear regression analysis using GraphPad Prism® 7. G. Relative cell 
viability of Rh4 shsc PMAIP-/- or Rh4 shP3F PMAIP-/- cells treated with increasing concentrations of 
ABT-263 for 48h. 
 
Figure 3: Inhibition of Aurora Kinase A leads to reduced PAX3-FOXO1 protein stability 
A. PAX3-FOXO1 protein levels were assessed by Western Blot 48h after treatment with 100 nmol/L of 
each compound of a drug library (Supplemental table 1). Protein bands were analyzed by densitometry 
and normalized to GAPDH levels. Treatment effect was compared to DMSO treatment. B. Exemplary 
blot of one set of drugs. Aurora Kinase A inhibitors are labelled in red. C: Chart showing the classes of 
inhibitors found among the top candidates. Red: Aurora Kinase A inhibitor, green: CDK9 inhibitors, grey: 
epigenetic modulators. D. Western Blot of lysates from Rh4 cells treated for 48h with increasing 
concentrations of the given drug. Left panel: Alisertib, right panel: AT9283. E. Immunoblot for 
phosphorylation at the given sites. Cells were incubated for 24h with Alisertib and lysed with Co-IP 
buffer. F. Western Blot of RD cells transiently transfected with the respective overexpression plasmid 
for PAX3-FOXO1 mutants or wild-type (wt). 8h before lysis cells were treated with either 10 µg/mL 
cycloheximide (CHX) or DMSO to block protein synthesis. G. Densitometric quantification of the fusion 
protein levels, normalized to GAPDH. Mean of three independent experiments; bars, SD; two-way 
ANOVA, *, P < 0.05, **, P < 0.01. H. Western Blot analysis of streptavidin pull-down experiments. 
HEK293T cells were transduced with a PAX3-FOXO1 expression plasmid fused to BirA biotin ligase 
(P3F-BirA) or with GFP or BirA alone. Cells were incubated with biotin (+) or not treated (-) and lysed. 
Pull-down was performed with beads coated with streptavidin. 
 
Figure 4: ABT-263 and Alisertib synergistically induce cell death in vitro 
A. Synergy screen. Rh4 cells were incubated with each drug of a library (Supplemental table 1) at a 
concentration of 500 nmol/L and additionally with either 800 nmol/L ABT-263 or DMSO. After 48h 
viability was assessed by WST-1 assay. Left y-axis: black bars, compound; grey bars, compound + 
ABT-263. Right y-axis, red bars: viability ratio (+ABT-263/+DMSO). Top hits with a viability ratio < 0.7 
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are shown and ranked according to viability of each drug alone. Red stars: Aurora Kinase A inhibitors. 
Circle plot: 28 top hits were classified according to their target spectrum: red, Aurora Kinase A inhibitors. 
B. Relative cell viability in % after cross-titration of Alisertib against ABT-263 in Rh4 cells. Viability 
relative to DMSO control after 48h. Color scheme: high viability, blue; low viability: red. Mean values of 
three independent experiments performed in duplicates. C. 3D representation of synergy scores of 
cross-titration experiments. Synergy was calculated according to the Bliss independence model using 
the SynergyFinder WebApp  [26]. Positive values (red) indicate synergy, negative values (green) 
indicate antagonism. D. Cross-titration of Alisertib against ABT-263 in IC_PPDX35-derived PDX cells. 
Mean values of three independent experiments performed in duplicates.E. Synergy scores of 
IC_PPDX35 cross-titration. F. Rh4 cells were treated with given concentrations of Alisertib and 
additionally with either DMSO or 800 nmol/L ABT-263. After 24h cells were stained with propidium iodide 
(PI) and cell cycle was analyzed by flow cytometry. Mean of two independent experiments.  
 
Figure 5: Combination of ABT-263 and Alisertib reduces tumor growth in vivo 
Rh4 or IC_pPDX35 cells were injected s.c. into the flanks of NSG mice. After engraftment, mice were 
randomized and assigned into one of four treatment groups: Vehicle (black), ABT-263 only (grey, 3d / 
week 80 mg/kg), Alisertib only (beige, 5d / week 30 mg/kg), ABT-263 + Alisertib combination (red). Mice 
were treated for 3 weeks with the respective regimen through administration p.o. (see also Suppl.Fig.7A) 
and sacrificed when tumors reached a size of 1000 mm3.  
A. Tumor growth of Rh4 cells in vivo. Black arrow: start of treatment. Red box indicates treatment period. 
Per group: n = 6; error bars, S.E.M. B. Kaplan-Meier graph showing percent survival of different 
treatment groups. Mantel-Cox test for comparison of survival curves, ***, p = 0.001 C. Tumor growth of 
IC_pPDX35 tumors. Black arrow: start of treatment. Red box indicates treatment period. Per group: n = 
5; error bars, S.E.M. D. Kaplan-Meier graph showing percent survival. E. Histology of engrafted 
IC_pPDX35 tumors after one week of treatment with either vehicle control (left panel) or combination of 
ABT-263 (80 mg/kg) and Alisertib (30 mg/kg) (right panel). N = 3. Upper panel: Hematoxylin & Eosin 
(HE) staining. Bars = 20 µm. Black arrows: apoptotic cells, red arrow: mitotic cell. Lower panel: 
Immunohistochemical staining against cleaved caspase 3. Bars = 50 µm. Representative images of 
sections from 3 different mice per group. F. Western Blot analysis of protein lysates from IC_pPDX35 
tumors after one week of treatment. Mice were treated either with vehicle or the combination of Alisertib 
(30 mg/kg) and ABT-263 (80 mg/kg) for one week. Mice were sacrificed, and proteins were extracted 
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from tumor tissues G.  AURKA gene expression in rhabdomyosarcoma biopsies and healthy skeletal 
muscle tissue as determined in different datasets using the r2 database (R2: Genomics Analysis and 
Visualization Platform: http://r2.amc.nl). Violin box-plots, minimum to maximum; unpaired t-test, ****, p 
< 0.0001. 
 
Supplemental figure 1:  
A. Schematic of the expression construct showing promoters (pink) and the following ORFs (light blue). 
hPGK promoter is constitutively active, U6Tet is inducible through tetracycline / doxycycline. B. Relative 
mRNA expression of the PAX3-FOXO1 gene in Rh4 shsc cells (beige) or Rh4 shP3F cells (red). Gene 
expression has been normalized to GAPDH and is shown as % of un-induced shRNA (Ctrl); error bars, 
SD; student’s t-test, *** p < 0.001. C. Relative mRNA expression of PAX3-FOXO1 gene in the given 
aRMS cell lines after 48h of shRNA induction with 0.1 µg/mL doxycycline. Beige: shsc, red: shP3F. 
Expression was normalized to GAPDH and shown relative to un-induced control (Ctrl); error bars, SD, 
student’s t-test, * p < 0.05. D. Western Blot analysis of PAX3-FOXO1 (P3F) protein expression in the 
given cell lines after 48h of shRNA induction (+) or control (-). E. Caspase activity after silencing of 
PAX3-FOXO1 in Rh30 shsc (beige) and shP3F (red) cells. Caspase 3/7 activity was assessed 24, 48 
and 72 hours after induction of shRNA expression. Mean of three independent experiments performed 
in triplicates; bars, SD. F. Caspase activity in Rh4 cells after silencing of endogenous PAX3-FOXO1 and 
rescue with over expression of either mutated PAX3-FOXO1 cDNA (silent single base mutations, not-
targetable by shRNA, P3F mut, red) or empty vector (pRR, red). Caspase activity was assessed after 
48h for three different targeting shRNAs and a scrambled control (sh scr). Error bars, SD; student’s t-
test, * p < 0.05, ** p < 0.01, *** p < 0.001. Mean of three independent experiments performed in 
triplicates. G. Western Blot analysis of rescue experiment. 
 
Supplemental Figure 2: 
A. Schematic of the lentiviral CRISPR construct: pink: LTRs and U6-promoter, blue: sgRNA and Cas9 
cDNA + EGFP cDNA fused via a P2A self-cleavage site. B-C. Immunoblots to confirm CRISPR-
mediated knockout of gene expression in Rh4sh cells. D. BH-3 only rescue screen corresponding to 
Fig. 1E. Caspase 3/7 activity of Rh4 shsc cells harboring CRISPR/Cas9-induced knockouts of the 
indicated genes (sc = scrambled sgRNA). White bars, no shRNA induction; black bars, 48h after 
doxycycline-induced shRNA expression. Mean of two independent experiments; bars, SD. E. 
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Immunoblot of both Rh4shsc and Rh4shP3F lysates to confirm NOXA knockout. Each cell was tested 
with scrambled sgRNA (scr) or one of two different sgRNAs targeting the PMAIP1 (NOXA) gene (NOXA1 
and NOXA2). In addition, cells were treated for 6h with 10 µmol/L MG-132 to inhibit proteasomal 
degradation and stabilize potential NOXA proteins. F. Rescue experiment measuring caspase activity 
in 3 aRMS cell lines 48h after induction of shP3F (black bars) or shsc (white bars). In addition to shRNA 
cells were transduced with either non-targeting sgRNA (sc) or two different sgRNAs targeting the 
PMAIP1 (NOXA) gene. Mean of two independent experiments performed in triplicates; bars, SD. G. 
upper panel: immunoblot for NOXA protein expression; lower panel densitometric quantification of 
NOXA protein levels normalized to GAPDH and relative to uninduced shRNA (-). 
 
Supplementary Figure 3:  
A. Schematic of the drug screen setup. Rh4sh cells were plated in 384-well plates, treated with 500 
nmol/L of each drug and 0.1 µg/mL doxycycline to induced shRNA. After 48h WST-1 assay was 
performed to assess viability. B-M. Individual effect of drugs on relative cell viability of Rh4 shsc or Rh4 
shP3F compared to DMSO; SD; Welch’s two-tailed t-test, *, P < 0,05; **, P ≤ 0.01. N-O. Relative cell 
viability of Rh4 shsc or Rh4 shP3F cells after 48h with or without shRNA induction and simultaneous 
treatment with increasing concentrations of TW-37 or UMI-77, respectively. Mean +/- SD from three 
independent experiments performed in triplicates. IC50 values were calculated from non-linear 
regression analysis using GraphPad Prism® P. PMAIP1 (NOXA) gene expression in rhabdomyosarcoma 
biopsies and healthy skeletal muscle tissue as determined in different datasets using the r2 database 
(R2: Genomics Analysis and Visualization Platform: http://r2.amc.nl). Violin box-plots, minimum to 
maximum; unpaired t-test, ****, p < 0.0001. 
 
Supplemental Figure 4: 
A. Screening setup for the library screen to assess PAX3-FOXO1 protein levels. Rh4 cells were plated 
in 24-well plates and incubated with 100 nmol/L of each drug. Cells were lysed after 48h and processed 
for western blot analysis. B. Immunoblot performed with individual hits from drug screen to assess dose 
dependent effects on PAX3-FOXO1 protein levels normalized to GAPDH. C. Immunoblot for MAST60 
PDX cells treated for 48h with the given drug and concentration. 
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Supplemental Figure 5: 
A. Relative cell viability of Rh4 and RHJT cells after 48h of treatment with increasing concentrations of 
ABT-263 (Navitoclax) to determine IC20. Mean of five (Rh4) or two (RHJT) independent experiments 
performed in triplicates. Bars, SD. IC20 values were calculated from non-linear regression analysis using 
GraphPad Prism® C. Synergy screen. RHJT cells were incubated with each drug of the drug library 
(Supplemental table 1) at a concentration of 500 nmol/L and additionally with either 250 nmol/L ABT-
263 (= IC20) or DMSO. After 48h viability was assessed by WST-1 assay. Left y-axis: black bars, 
compound; grey bars, compound + ABT-263. Right y-axis, red bars: viability ratio (+ABT-263/+DMSO). 
Top hits with a viability ratio < 0.7 are shown and ranked according to viability of each drug alone. Red 
stars: Aurora Kinase A inhibitors. D. Venn diagram with top hits from the synergy screens in both Rh4 
(red) and RHJT (blue) cells. Overlap shows common top hits of both cell lines. 
 
Supplemental Figure 6: 
A, C, E. Relative cell viability in % after cross-titration of Alisertib against ABT-263 in myoblasts, human 
foreskin fibroblasts and RD cells, respectively. Viability relative to DMSO control after 48h. Color 
scheme: high viability, blue; low viability: red. Mean of two independent experiments performed in 
duplicates. B, D, F. 3D representations of synergy scores of corresponding cross-titration experiments. 
Synergy was calculated according to the Bliss independence model using the SynergyFinder WebApp  
[26]. Positive values (red) indicate synergy, negative values (green) indicate antagonism. G. Brightfield 
microscopy of Rh4 cells treated with increasing doses of Alisertib and a fixed concentration of 800 
nmol/L ABT-263 or DMSO. Representative pictures of three independent experiments. H. Relative 
caspase 3/7 activity in Rh4 cells after cross-titration of Alisertib against ABT-263 in Rh4 cells after 48h 
of incubation. Mean of two independent experiments. 
 
Supplemental Figure 7: 
A. Experimental setup for in vivo combination treatment. NSG-mice were injected with 5*106 tumor cells 
(Rh4 or IC_PPDX35). After engraftment mice were randomized into four groups and treated with either 
vehicle, ABT-263 alone, Alisertib alone, or the combination of both for three weeks. Arrows indicate the 
days of treatment. At tumor volumes of 1000 mm3 mice were sacrificed. B-C. Weight curves of mice 
during the experiment. D-E. Histology of engrafted IC_pPDX35 tumors after one week of treatment with 
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either vehicle control (left panel) or combination of ABT-263 (80 mg/kg) and Alisertib (30 mg/kg) (right 
panel). N = 3. D: Ki67. E: p21. Bars = 50 µm. Representative images of sections from 3 different mice 
per group. 
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Supplemental Material and Methods 
 
Site-directed mutagenesis 
Site-directed mutagenesis was performed using the GeneArt Site-Directed Mutagenesis System 
(Thermo Fisher Scientific) according to manufacturer’s protocol. 
 
Immunoblot 
Cells were lysed with RIPA buffer (see below), suspended in 4xLDS loading buffer (Thermo Fisher 
Scientific) supplemented with 250 mmol/L 1,4-Dithiothreitol (DTT, Sigma-Aldrich). After boiling the 
samples at 70°C for 5 minutes, proteins were separated by electrophoresis on 4-12% gradient 
polyacrylamide gels (Life Technologies). Proteins were transferred onto a Protran™ nitrocellulose 
membrane (GE Healthcare). Membranes were blocked in 5% (w/v) milk powder in Tris-buffered saline 
(TBS)/0.01% Tween20 (Sigma-Aldrich) and incubated overnight with primary antibodies at 4°C. 
Membranes were washed in TBS/Tween and incubated with horseradish peroxidase (HRP)-coupled 
IgG secondary antibody for 1h at room temperature. Membranes were washed in TBS/Tween and 
proteins were detected using ECL detection reagent (Thermo Fisher Scientific) in a ChemiDoc™ Touch 
Imaging system (BioRad). 
 
RIPA buffer 
Before use, buffer was supplemented with protease inhibitor (Roche Complete Mini) 
Tris-Cl pH=7.5 50 mmol/L 
Sodium chloride 150 mmol/L 
NP-40 1% 
Sodium deoxycholate 0.5% 
Sodium dodecyl sulfate 0.1% 
EGTA 1 mmol/L 
Sodium fluoride 50 mmol/L 
Beta glycerolphosphate 10 mmol/L 
Sodium pyrophosphate 5 mmol/L 
Sodium ortho vanadate  1 mmol/L 
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Co-Immunoprecipitation 
Cells were lysed in ice cold Co-IP buffer (see below) and disrupted using syringes. Lysates were 
incubated with Protein G Dynabeads (Thermo Fisher Scientific)/antibody conjugates or beads alone for 
3h at 4°C. Beads were washed and bound protein was released by boiling the beads in LDS buffer (as 
described above) at 70°C for 5 minutes. 
 
CoIP buffer 
Before use, buffer was supplemented with protease inhibitor (Roche Complete Mini) 
Tris-Cl pH=7.5 50 mmol/L 
Sodium chloride 80 mmol/L 
NP-40 0.3% 
Glycerol 10% 
Magnesium chloride 1.5 mmol/L 
Sodium fluoride 25 mmol/L 
Beta glycerolphosphate 10 mmol/L 
Sodium pyrophosphate 5 mmol/L 
Sodium ortho vanadate  2 mmol/L 
 
 
Generation of shRNA cell lines 
Custom designed shRNAs in Lentiviral vectors (Cellecta) to transduce target cells with either the 
targeting shRNA plasmid (shP3F) or the non-targeting control shRNA plasmid (shscr) were ordered 
(Suppl.Fig.1A) (Cellecta):  
HEK293T cells were co-transfected with the transfer plasmid, the envelope plasmid, and packaging 
plasmids. 48h after transfection viral supernatant was collected and concentrated using Amicon® Ultra 
Centrifugal Filters (Merck Millipore) according to manufacturer’s protocol. Cell lines were transduced 
with viral concentrate in medium containing 8 g/mL Hexadimethrine bromide (Sigma). Cells from PDXs 
were transduced without Hexadimethrine bromide. After 72h cells were selected with 0.5 g/mL 
Puromycin (Sigma). In advance we tested three different shP3F sequences targeting the breakpoint 
region for knockdown efficiency and toxicity and continued with shP3F #3. 
Targeting sequences 
#1 CCTCTCACCTCAGAATTCAAT 
#2 CTCTCACCTCAGAATTCAATT 
#3 GGCCTCTCACCTCAGAATTCA 
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qRT-PCR 
RNA was isolated from cells using the RNeasy Mini Kit (Qiagen). 1 µg of RNA was transcribed into 
cDNA using the High Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific). Real-time 
PCR was performed using TaqMan probes (see below) and the TaqMan Gene Expression Master Mix 
(both Thermo Fisher Scientific). Expression changes were calculated using the ΔΔCt method with 
GAPDH as internal control.  
TaqMan probes 
All probes were ordered as Assay-on-Demand mix (Thermo Fisher Scientific) containing specific primers 
and FAM/BHQ-1 probe. 
Gene Assay ID 
PAX3-FOXO1 Hs03024825 
GAPDH Hs02758991_g1 
PMAIP1 (NOXA) Hs00560402 
MYCN Hs00232074 
MDM2 Hs01066930 
 
 
Antibodies 
Antigen  Manufacturer   Host (Clone)  Dilution 
AURORA A  Genetex  ms mono (35C1) 1:1000 
BAD 
BAK 
BAX 
BIM   Santa Cruz  ms mono (H-5)  1 :500  
CASP9 
Cl. CASP3  Cell signaling  rb mono (D175) 1:1000 
Cl. CASP7  Cell signaling  rb poly (D198)  1:1000 
FOXO1   Santa Cruz  rb poly (H-128)  1:500 
GAPDH  Cell signaling  rb mono (14C10) 1:1000 
MYCN   Cell signaling  rb mono  1:1000 
NOXA   Cell signaling  rb mono (D8L7U) 1:1000 
P21   Cell signaling  rb mono (12D1) 1:1000 
P53   Thermo Fisher Sc ms mono (DO-1) 1:1000 
PARP   Cell signaling  rb poly   1:1000 
PLK1   Merck Millipore  ms mono  1:1000 
pFOXO1(S256 ≙ S437) Cell signaling     1:750 
pPLK1(T210)  Cell signaling     1:750 
XIAP 
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Supplemental Table 1: Drug library content 
Product Name Target 
Veliparib (ABT-888) PARP 
Axitinib VEGFR, PDGFR, c-Kit 
Saracatinib (AZD0530) Src, Bcr-Abl 
FG-4592 HIF 
Afatinib (BIBW2992) EGFR 
Bortezomib (PS-341) Proteasome 
Bosutinib (SKI-606) Src 
Dovitinib (TKI-258, CHIR-258) c-Kit, FGFR, Flt, VEGFR, PDGFR 
Dasatinib Src, Bcr-Abl, c-Kit 
Erlotinib HCl (OSI-744) EGFR 
Gefitinib (ZD1839) EGFR 
Lapatinib (GW-572016) EGFR, HER2 
Lenalidomide (CC-5013) TNF-alpha 
Nilotinib (AMN-107) Bcr-Abl 
Pazopanib HCl VEGFR, PDGFR, c-Kit 
Rapamycin (Sirolimus) mTOR 
Sorafenib Tosylate VEGFR, PDGFR, Raf 
Sunitinib Malate VEGFR, PDGFR, c-Kit, Flt 
Vandetanib (ZD6474) VEGFR 
Vorinostat (SAHA, MK0683) HDAC 
VX-680 (Tozasertib, MK-0457) Aurora Kinase 
Y-27632 2HCl ROCK 
Elesclomol (STA-4783) HSP 
Entinostat (MS-275) HDAC 
Enzastaurin (LY317615) PKC 
Olaparib (AZD2281, Ku-0059436) PARP 
GDC-0941 PI3K 
SB431542 TGF-beta/Smad 
Crizotinib (PF-02341066) c-Met, ALK 
AUY922 (NVP-AUY922) HSP 
PHA-665752 c-Met 
SB216763 GSK-3 
MK-2206 2HCl Akt 
Vismodegib (GDC-0449) Hedgehog, P-gp 
KU-55933 (ATM Kinase Inhibitor) ATM 
GSK1904529A IGF-1R 
MLN8054 Aurora Kinase 
Danusertib (PHA-739358) Aurora Kinase, FGFR, Bcr-Abl, c-RET, Src 
GSK690693 Akt 
JNJ-38877605 c-Met 
Palbociclib (PD-0332991) HCl CDK 
Cabozantinib (BMS-907351) VEGFR, c-Met, Flt, Tie-2, c-Kit 
Everolimus (RAD001) mTOR 
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BMS-754807 IGF-1R 
YM155 (Sepantronium Bromide) Survivin 
Alisertib (MLN8237) Aurora Kinase 
AT9283 Bcr-Abl, JAK, Aurora Kinase 
Barasertib (AZD1152-HQPA) Aurora Kinase 
Roscovitine (Seliciclib,CYC202) CDK 
Lenvatinib (E7080) VEGFR 
Valproic acid  GABA Receptor, HDAC 
CYC116 Aurora Kinase, VEGFR 
XAV-939 Wnt/beta-catenin 
Thalidomide Others 
Decitabine DNA/RNA Synthesis 
PIK-75 PI3K, DNA-PK 
2-Methoxyestradiol (2-MeOE2) HIF 
Vemurafenib (PLX4032, RG7204) Raf 
Rigosertib (ON-01910) PLK 
Ruxolitinib (INCB018424) JAK 
Resveratrol Sirtuin 
Ispinesib (SB-715992) Kinesin 
AEE788 (NVP-AEE788) EGFR, Flt, VEGFR, HER2 
PHA-793887 CDK 
Ponatinib (AP24534) Bcr-Abl, VEGFR, FGFR, PDGFR, Flt 
AT7519 CDK 
MK-1775 Wee1 
Quizartinib (AC220) Flt 
AZD7762 Chk 
R406 (free base) Syk 
Org 27569 Cannabinoid Receptor 
EX 527 (Selisistat) Sirtuin 
Pomalidomide TNF-alpha, COX 
KU-60019 ATM 
BIRB 796 (Doramapimod) p38 MAPK 
RO4929097 Y-Secretase 
Tie2 kinase inhibitor Tie-2 
Azacitidine  DNA/RNA Synthesis 
Acadesine AMPK 
Nicorandil Others 
PF-573228 FAK 
Lovastatin HMG-CoA Reductase 
LDE225 (Erismodegib) Smoothened 
PF-4708671 S6 Kinase 
MLN2238 Proteasome 
MLN9708 Proteasome 
SGI-1776 free base Pim 
AZ 960 JAK 
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Apatinib VEGFR 
Volasertib (BI 6727) PLK 
Degrasyn (WP1130) DUB, Bcr-Abl 
BKM120 (Buparlisib) PI3K 
Imatinib (STI571) PDGFR,c-Kit, v-Abl 
Mifepristone Estrogen/progestogen Receptor 
LY2603618 Chk 
NU7441 (KU-57788) DNA-PK, PI3K 
MK-0752 Gamma-secretase 
Trametinib (GSK1120212) MEK 
Ibrutinib (PCI-32765) Src 
NVP-BSK805 2HCl JAK 
GDC-0980 (RG7422) mTOR, PI3K 
A-769662 AMPK 
AMG-900 Aurora Kinase 
Crenolanib (CP-868596) PDGFR 
AZ 3146 Kinesin 
PHA-767491 CDK 
CUDC-907 HDAC, PI3K 
NVP-BVU972 c-Met 
SB705498 TRPV 
Tofacitinib (CP-690550) JAK 
Dabrafenib (GSK2118436) Raf 
GDC-0068 Akt 
Torin 2 mTOR 
TAE226 (NVP-TAE226) FAK 
TPCA-1 IKK 
Carfilzomib (PR-171) Proteasome 
T0070907 PPAR 
WZ811 CXCR 
IOX2 HIF 
Evacetrapib (LY2484595) CETP 
Pazopanib VEGFR 
Rimonabant Cannabinoid Receptor 
Cabozantinib malate  c-met, VEGFR2 
Spironolactone Androgen Receptor 
JNK-IN-8 Free Base 
QNZ (EVP4593) NF-κB 
Tofacitinib (CP-690550) Citrate JAK 
GDC-0152 IAP 
AZD3514 Androgen Receptor 
AZ20 ATM/ATR 
GSK126 Histone Methyltransferase 
EPZ5676 Methyltransferase 
GSK J4 HCl Others 
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LDK378 ALK 
IWP-2 Wnt/beta-catenin 
GSK2334470 PDK-1 
PF-3758309 PAK 
HSP990 (NVP-HSP990) HSP (e.g. HSP90) 
AZD3463 ALK 
EPZ-6438 Histone Methyltransferase 
PYR-41 E1 Activating 
PR-619 DUB 
P5091 (P005091) DUB 
BMS-833923 Hedgehog/Smoothened 
AZD1080 GSK-3 
C646 Histone Acetyltransferase 
10058-F4 c-Myc 
AVL-292 BTK 
IOX1 Histone demethylases 
OG-L002 Histone demethylases 
SGC-CBP30 Epigenetic Reader Domain 
CNX-774 BTK 
MM-102 Histone Methyltransferase 
JIB-04 Histone demethylases 
PFI-2 Histone Methyltransferase 
CPI-203 Epigenetic Reader Domain 
GSK2606414 PERK 
6H05 Rho 
K-Ras(G12C) inhibitor 9 Rho 
SH-4-54 STAT 
OTX015 BET 
LEE011 CDK 
LDC000067 CDK 
PI-1840 Proteasome 
JNK Inhibitor IX JNK 
GNF-5837 Trk receptor 
Afuresertib (GSK2110183) Akt 
GDC-0994 ERK 
UNC0379 Histone Methyltransferase 
GSK-LSD1 2HCl Histone Demethylase 
GSK J1 Histone Demethylase 
INCB024360 IDO 
BRD4770 Histone Methyltransferase 
BV-6 IAP 
EI1 Histone Methyltransferase 
MI-2 (Menin-MLL Inhibitor) Histone Methyltransferase 
LDC1267 Axl 
CPI-360 Histone Methyltransferase 
CH5183284 (Debio-1347) FGFR 
YK-4-279 DNA/RNA Synthesis 
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AZD6738 ATM/ATR 
Verdinexor (KPT-335) CRM1 
EPZ015666 Histone Methyltransferase 
Pexmetinib (ARRY-614) p38 MAPK 
Pexidartinib (PLX3397) CSF-1R 
BI-847325 MEK 
PFI-4 Epigenetic Reader Domain 
Epacadostat (INCB024360) IDO 
NSC 23766 Rac 
BMS-345541 IκB/IKK 
Pacritinib (SB1518) JAK 
Idasanutlin MDM2/p53 
iBet762 BET 
ABT-263 BCL2, BCL-XL, BCL-w 
ABT-199 BCL2 
Obatoclax BCL2-family 
Dynasore Dynamin 
Dyngo4a Dynamin 
GDC-0973 MEK 
Fenretinide Retinoid Acid Receptor 
JQ-1 BET 
Birinapant IAP 
Doxorubicine DNA  
Vincristine Microtubuli 
Etoposide Topoisomerase 
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Abstract 
Alveolar rhabdomyosarcoma (aRMS) is an aggressive subtype of the most common soft tissue 
sarcoma in children. 5-year overall survival in aRMS patients is as low as 30%. High tendency 
to metastasize and resistance to standard of care therapy are factors contributing to the 
malignancy of this cancer. The major driver of tumorigenesis and maintenance in aRMS is the 
fusion protein PAX3-FOXO1, a strong transcriptional activator. Knowledge of how PAX3-
FOXO1 contributes to the ability of aRMS cells to evade cell death could provide novel insights. 
Recently, we demonstrated that PAX3-FOXO1 depletion results in NOXA-dependent 
apoptosis. Our aim here was therefore, to investigate the PAX3-FOXO1-dependent regulatory 
network of NOXA to find new tumor-specific vulnerabilities. 
Here, using gene expression analysis and chromatin immunoprecipitation sequencing (ChIP-
Seq) experiments we show that in aRMS cell lines NOXA expression is activated by MYCN, a 
PAX3-FOXO1 target gene. Furthermore, using ChIP-Seq analysis we found a novel putative 
regulation of the p53 regulator MDM2 by the fusion protein. Accordingly, patient-derived 
xenograft cells from aRMS patients are sensitive to pharmacological disruption of the 
MDM2/p53 interaction using Idasanutlin.  
Taken together, these data shed light on the regulatory pathways controlling NOXA expression 
in aRMS cell and offer novel opportunities for cell death-directed therapy. 
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Introduction 
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children. The alveolar subtype 
is the most aggressive form of RMS, showing a high tendency to metastasize. Patients with metastatic 
aRMS have a 5-year overall survival rate of 30% [1]. Molecularly, aRMS tumors are characterized by 
reciprocal translocation resulting in the expression of oncogenic PAX-fusion proteins [2]. The most 
common fusion protein is PAX3-FOXO1 and has been shown to be essential for tumor maintenance 
[3,4]. Therapeutic options for aRMS patients comprise surgery, radiation, and chemotherapy, which 
cannot overcome the dismal prognosis [5].  
Resistance towards standard-of-care therapy is one of the major problems in clinics today and calls for 
novel approaches targeting cancer-specific vulnerabilities [6]. Evasion from cell death is one of these 
cancer-specific traits, a hallmark of cancer [7]. Thus, knowledge of the molecular basis of cell death 
resistance could help improve outcome of both standard-of-care therapies and potential novel targeted 
approaches. Typically, mutations and oncogene overexpression result in activation of cell-intrinsic 
countermeasures preventing proliferation or inducing programmed cell death [8]. Thus, cancer cells 
have to develop strategies to circumvent these intrinsic anti-cancer mechanisms.  
The tumor suppressor p53 integrates stress signals such as DNA-damage, metabolic stress, 
translational stress and activates adequate responses, such as cell cycle arrest or apoptosis. Here, pro-
apoptotic proteins are transcriptionally upregulated and localize at the outer mitochondrial membrane 
(OMM) [8]. At the OMM, pro-apoptotic BH3-only proteins, such as NOXA exist in an equilibrium state 
with anti-apoptotic proteins of the BCL-2 family [9]. A shift of this equilibrium towards pro-apoptotic 
results in activation of BAX and BAK which homodimerize and form a pore in the OMM thus initiating 
the apoptotic caspase-cascade [8].  
In many cancers one way to prevent apoptosis therefore is to upregulate anti-apoptotic BCL-2 proteins, 
increasing the threshold of apoptosis induction [9]. Another way for cancer cells to avoid apoptosis is to 
interfere with p53 activity [10]. P53 stability regulated by the ubiquitin-ligase MDM2. The MDM2 locus 
was found to be amplified in certain RMS tumors which results in reduced p53 functionality [11]. In aRMS 
tumors PAX3-FOXO1 was shown to be critical for tumor cell survival [4]. Recently, our group could 
demonstrate that knockdown of PAX3-FOXO1 leads to intrinsic apoptosis in aRMS cells, dependent on 
the BH3-only protein NOXA (unpublished). However, exactly how PAX3-FOXO1 regulates NOXA, could 
not be established.  
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Therefore, in this follow-up study we aimed to characterize the mechanisms by which PAX3-FOXO1 
regulates NOXA and thereby prevents cell death.  
Here, we show that NOXA expression is upregulated upon knockdown of PAX3-FOXO1 and that MYCN 
is the major driver of NOXA expression under basal conditions. Furthermore, we found indications for a 
direct transcriptional regulation of MDM2 by PAX3-FOXO1. Consequently, we demonstrate that aRMS 
cancer cells from patient-derived xenografts were sensitive to pharmacological disruption of MDM2/p53 
interaction. 
 
Results 
NOXA expression is upregulated after silencing of PAX3-FOXO1 
Our recent studies revealed that after silencing of PAX3-FOXO1 cells undergo intrinsic apoptosis 
dependent on NOXA.  We engineered aRMS cell lines to express either small hairpin RNA targeting 
PAX3-FOXO1 mRNA (shP3F) or a non-targeting control (shsc). To gain further insights into the 
regulation of pro-apoptotic mechanisms in aRMS, we analyzed differential expression of NOXA in RNA-
Seq data of both Rh4 and Rh30. In both Rh4 and Rh30 cells we observed upregulation of NOXA by 1.3-
fold, 24h after knockdown of PAX3-FOXO1 and by 1.8-fold after 48h in Rh4 (Fig. 1A, Suppl. Fig. 1A-B). 
We confirmed this upregulation in Rh4 cells using qRT-PCR and western blots. 48h after shRNA-
mediated silencing of PAX3-FOXO1 NOXA mRNA expression increased 2.8-fold compared to the 
scrambled control (shsc) (Fig. 1B). Knockdown of PAX3-FOXO1 mRNA resulted in loss of PAX3-FOXO1 
protein levels and concomitant increased wild-type FOXO1 (Fig. 1C). We also confirmed increased 
NOXA protein levels (Fig. 1C). To confirm these findings in other cell lines, we analyzed NOXA protein 
expression by western blot. Here, we found that in three out of four aRMS cell lines 48h after PAX3-
FOXO1 knockdown, NOXA protein levels were 2-4-fold higher (Fig. 1D). Only Rh30 cells showed no 
upregulation of NOXA. Next, we wanted to confirm these findings in primary tumor material. To this end, 
we cultivated cells obtained from patient-derived xenografts (PDX) and stably transduced them to 
express the inducible shRNA system described above. As shsc showed toxicity in MAST118 PDX cells 
(data not shown), we utilized shRNA directed against luciferase (shluc) as a control. We confirmed 
knockdown of PAX3-FOXO1 by western blot 48h after shRNA induction and observed increased levels 
of NOXA protein, as well as cleaved caspase 7 (Fig. 1E), indicating that these cells react the same ways 
as the cell lines used above: by initiating apoptosis after silencing of PAX3-FOXO1. 
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Taken together, these findings show that NOXA expression is upregulated after silencing of PAX3-
FOXO1 not only in cell lines but also in PDX-derived cells. 
 
MYCN drives NOXA expression in aRMS cells 
Next, we aimed to characterize NOXA regulation in aRMS. To this end, we first established whether 
PAX3-FOXO1 could bind directly to the PMAIP1. ChIP-Seq data from Rh4 cells revealed that there was 
no enrichment of PAX3-FOXO1 binding to the PMAIP1 promoter, neither in Rh4 cells lines nor in 
MAST118 cells from patient-derived xenografts (Fig 2A). These findings indicate that NOXA expression 
is not directly regulated by PAX3-FOXO1. 
Therefore, we aimed to find potential direct regulators of NOXA expression that could contribute to 
increased NOXA expression after silencing of PAX3-FOXO1. To this end, we used both the Rh4 and 
RHjT cell lines expressing the inducible shRNA constructs. In these cells we simultaneously induced 
shRNA and used siRNA mediated knockdown of factors known to regulate NOXA expression in other 
cells: We focused our attention on p53 and wild-type FOXO1. We chose p53, as it is the most 
characterized regulator of NOXA expression and FOXO1 because we observed upregulation of FOXO1 
after silencing of PAX3-FOXO1 indicating that it might play a role in contributing to cell death. Western 
blot analysis showed that neither knock down of p53 nor FOXO1 respectively, abrogated NOXA 
expression (Fig. 2B-C, Suppl. Fig. 2A). We also investigated the effects of siRNA mediated knock downs 
on caspase 3/7 activity to establish the influence on cell death. Neither p53 knock down nor FOXO1 
knockdown rescued aRMS cells from apoptosis after silencing of PAX3-FOXO1 (Fig. 2D-E, Suppl. Fig. 
2B-C). These findings indicate that in cell lines neither p53 nor FOXO1 contribute substantially to NOXA 
upregulation after silencing of PAX3-FOXO1. A recent study demonstrated that NOXA expression is 
driven by MYCN in neuroblastoma [12]. Therefore, we investigated whether such regulation could also 
be observed in aRMS cells. Indeed, analyzing ChIP-Seq data from Rh4 cells, we observed enrichment 
of MYCN at the PMAIP1 promoter in addition to peaks of both H3K4me3 and H3K27ac, indicating active 
transcription and not repression by MYCN (Fig 2A). Furthermore, siRNA-mediated knockdown of MYCN 
abrogated NOXA protein levels in both aRMS cell lines (Fig. 2B-C). Additional silencing of PAX3-FOXO1 
lead to an increase of NOXA protein expression, albeit far weaker than after knockdown of p53 or 
FOXO1 (Fig. 2B-C, Suppl. Fig. 2A), indicating that MYCN is the major driver of NOXA expression in 
aRMS. Depletion of MYCN rescued RHJT cells from cell death (Fig. 2E), however it did not rescue Rh4 
cells from cell death (Fig. 2D).  
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These findings demonstrate that MYCN binds to the PMAIP1 promoter in aRMS cell lines and positively 
regulates NOXA expression. However, the exact contribution of MYCN to cell death after silencing of 
PAX3-FOXO1 remains to be demonstrated.  
 
MDM2 is a potential new target gene of PAX3-FOXO1 but has no influence on NOXA expression 
During our investigations we analyzed RNA-Seq data and found that expression of MDM2, a negative 
regulator of p53 stability, decreased after silencing of PAX3-FOXO1 in Rh4 cells (Fig. 1A, Suppl. Fig 
1A-B). In Rh30 cells after 24h, this decrease was comparable to that of MYCN, a known target gene of 
PAX3-FOXO1 (Suppl. Fig 1B). In Rh4 cells, both after 24h and 48h the decrease of MDM2 expression 
was even more pronounced as that of MYCN (Fig. 1A, Suppl. Fig 1A). These findings led us to 
hypothesize that MDM2 expression might be regulated by PAX3-FOXO1. We analyzed MDM2 mRNA 
expression by qRT-PCR after silencing of PAX3-FOXO1 in 5 different aRMS cell lines and found that 
MDM2 expression was reduced in all samples after 48h. The Rh4 and KFR cell lines showed significant 
reductions to under 40% compared to shsc (Fig. 3A). We observed the same effects on protein levels 
of MDM2 after silencing of PAX3-FOXO1 (Fig. 3B). To investigate whether MDM2 expression was 
directly regulated by the fusion protein we analyzed ChIP-Seq data and found that in Rh4 cells but not 
in MAST118 cells PAX3-FOXO1 binding is enriched at the P1 promoter region of the MDM2 gene in 
concert with marks for active transcription (Pol II binding, histone marks) (Fig. 3C). Interestingly, we also 
found enrichment of MYCN at the P1 promoter of MDM2 (Fig. 3C). This finding suggests that PAX3-
FOXO1 drives MDM2 expression. We hypothesized that MDM2 as a potential target gene of PAX3-
FOXO1 could destabilize p53 and thus negatively affect NOXA expression. Conversely, siRNA-
mediated knockdown of MDM2 (Suppl. Fig. 3A-B) had only minor to no effects on NOXA expression in 
Rh4 cell or RHjT cells, respectively (Fig. 3D). These data indicate that in aRMS cell lines MDM2 does 
not affect NOXA expression. 
Lastly, like most cell lines, Rh4 and RHjT cell lines are deficient for p53 signaling [13]. Therefore, we 
reasoned that these cell lines might not reflect the biology of primary aRMS tumors which are almost 
exclusively known to express wild-type p53 [11]. To investigate the implications of MDM2 as a putative 
new target gene of PAX3-FOXO1, we analyzed whether aRMS cells derived from PDXs were 
susceptible to pharmacological disruption of the MDM2/p53 interaction. Indeed, treatment with 
increasing concentrations of Idasanutlin in MAST60 and MAST118 cells resulted in stabilization of p53 
and increased protein levels of p21 and cleaved caspase 7, indicating active apoptosis (Fig. 3E-F). As 
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expected, Rh4 cells were not sensitive at all to Idasanutlin treatment (Fig.3G). To exclude that this 
treatment could affect non-tumor cells, we treated immortalized myoblasts. Here, Idasanutlin treatment 
also resulting in p53 stabilization, however caspase activation was not detected (Fig. 3H). 
 
Discussion 
In this study, we aimed to characterize mechanisms driving NOXA expression in aRMS cells. Here, we 
show that, conversely not classical tumor suppressor proteins, such as p53 or FOXO1, drive NOXA 
expression but MYCN, an oncogene. Furthermore, we identified MDM2 as a potential new target gene 
of PAX3-FOXO1 which makes primary aRMS tumor cells sensitive to pharmacological disruption of 
MDM2/p53 interaction. 
We found that NOXA was upregulated after silencing of PAX3-FOXO1 indicating that the fusion protein 
while active suppresses NOXA expression. While we could confirm this connection in 5 cell lines, we 
were only able to generate transgenic clones of one patient-derived xenograft, MAST118. Given the 
large heterogeneity among rhabdomyosarcoma tumors, these results would need to be bolstered by 
experiments with further PDX samples. A major complication for this idea however, is that primary 
patient materials are hard to come by, given the few aRMS cases occurring per year [14]. Furthermore, 
it is complicated to establish the perfect conditions for PDX-derived cells to grow in culture without losing 
its primary tumor traits [15,16].  
Interestingly, we found that MYCN drives NOXA expression in aRMS cell lines. This phenomenon was 
recently described for neuroblastoma, where MYCN amplification is common [12]. While, we did observe 
the high dependency of NOXA expression on MYCN both in the Rh4 and RHjT cell line, this regulation 
seems to contribute to apoptosis only in RHjT cells. In Rh4 cells knockdown of MYCN could not rescue 
the cells from cell death after silencing of PAX3-FOXO1, indicating that both cell lines differ in their 
apoptotic potential. One major difference is, that RHjT cells are known to harbor MYCN amplification. 
Thus, this cell line might rely more on MYCN function and already express higher levels of NOXA, 
making them primed for apoptosis. To compensate for higher NOXA levels, RHjT cells would need to 
express higher levels of anti-apoptotic BCL-2 proteins to increase the apoptotic threshold. Loss of MYCN 
expression and resulting lower levels of NOXA could therefore result in anti-apoptotic proteins 
outnumbering the pro-apoptotic factors leading to less apoptosis. Here it would be interesting to analyze 
the expression levels of anti-apoptotic proteins, like MCL-1, the canonical interactor of NOXA [17], 
between different cell lines to explain differences in apoptotic priming. Furthermore, the subgroup of 
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MYCN-amplified aRMS tumors might therefore be sensitive to therapy with BH3-mimetics, like ABT-199 
or ABT-263 which would provide clinicians with targeted therapy options to combine with standard-of-
care therapy.  
Although our findings provide a mechanism of NOXA regulation in aRMS under basal conditions, the 
results are contradictory when it comes to NOXA-dependent cell death after silencing of PAX3-FOXO1. 
Silencing of PAX3-FOXO1 results in reduced expression of its target genes, which also contain MYCN. 
Lower levels of MYCN result in lower levels NOXA, as we could demonstrate using siRNA. However, 
what we observe is, that silencing of PAX3-FOXO1 results in strong upregulation of NOXA despite 
abrogated MYCN expression. Here clearly, we have not characterized all mechanisms driving NOXA 
expression in aRMS. There must be another regulator that is potentially shut down by PAX3-FOXO1 
and therefore only becomes active after silencing of the fusion protein. Finding this elusive regulator 
would require unbiased screening approaches with cells being deficient for individual candidates. 
However, NOXA is a protein that is commonly upregulated upon a wide variety of cellular stresses [18]. 
Therefore, many factors can contribute to its expression and increased NOXA expression after silencing 
of PAX3-FOXO1 might simply reflect cellular stress after loss its critical oncogene. 
Lastly, we identified MDM2 as a putative new target gene of PAX3-FOXO1. This relation has not been 
demonstrated so far and provides insight into further options how aRMS could avoid apoptosis. We 
demonstrate a fusion protein dependent expression of MDM2 which alone would not allow the 
conclusion of a direct regulation. ChIP-Seq analysis provides evidence of PAX3-FOXO1 binding to the 
promoter region of the MDM2 locus and an active signature. However, these results were only obtained 
from one cell line and the results from the PDX tumor differ. Our findings thus might not reflect the 
majority aRMS tumors. Therefore, it would be necessary to prove this direct regulation using further cell 
lines or better PDX cells. An indication for the validity of our findings is, that the P1 promoter region of 
MDM2 contains a PAX3-FOXO1 consensus motif which also overlaps with the ChIP-Seq binding peak 
(Suppl. Fig. 3D). Interestingly, we also found binding of MYCN at the P1 promoter of MDM2 indicating 
that also MYCN drives MDM2 expression. This MYCN-dependent regulation of MDM2 has already been 
described in neuroblastoma [19,20]. In the context of aRMS this finding indicates that apart from a 
potential direct regulation of MDM2 by PAX3-FOXO1, this regulation could also be indirect via MYCN 
as a target gene of PAX3-FOXO1. Thus, to conclusively support the hypothesis of direct MDM2 
regulation by the fusion protein, more functional tests, for instance luciferase promoter assays, need to 
be established. 
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Although MDM2 was not connected to NOXA expression in the cell lines we investigated, in primary or 
PDX derived cells the MDM2/p53 is still intact and might well contribute to NOXA expression. Thus, 
upregulation of MDM2 by PAX3-FOXO1 could indicate at an important role of MDM2 in preventing cell 
death in aRMS tumors. In other rhabdomyosarcoma tumors the MDM2 locus is often found to be 
amplified [11] further underpinning the important role of MDM2 as an oncogene in rhabdomyosarcoma. 
We therefore reasoned that primary aRMS tumors might respond to pharmacological disruption of the 
MDM2/p53 interaction. Indeed, in line with our hypothesis, cells from MAST60 and MAST118 PDX 
tumors were sensitive to Idasanutlin treatment in vitro. We demonstrate, for the first time the sensitivity 
of patient-derived aRMS cells to this treatment. 
Taken together, we demonstrate that NOXA expression is driven by MYCN in aRMS cell lines. 
Furthermore, we show PAX3-FOXO1 dependent regulation of MDM2 expression and sensitivity of 
aRMS PDX tumors to MDM2-directed therapy strategies which could provide further combination 
options to boost efficiency of standard-of-care treatment. 
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Material and Methods 
Cell culture 
Cell lines: Rhabdomyosarcoma cell lines RD, Rh4 (both received from Peter Houghton, St. Jude 
Children’s Hospital, Memphis, TN), RhJT (Scott Diede, Fred Hutchinson Cancer Research Center, 
Seattle, WA), RMS (Janet Shipley, Sarcoma Molecular Pathology, The Institute of Cancer Research, 
London, UK), KFR (Jindrich Cinatl, Frankfurter Stiftung für krebskranke Kinder, Frankfurt, Germany), 
and Rh30 (ATCC LGC Promochem) were cultured in high glucose DMEM (Sigma-Aldrich), 
supplemented with 100 U/mL penicillin/streptomycin, 2 mmol/L L-glutamine, and 10% FBS (Life 
Technologies) at 37°C and 5% CO2 . Immortalized myoblasts (Vincent Mouly, UPMC Université de 
Paris, France) [21] were cultured in Skeletal Muscle Cell Basal Medium (Life technologies) 
supplemented with 10 ng/ml EGF and 0.1 ng/ml bFGF (both Peprotech Inc.).  
PDX cells: PDX tumors were obtained from St.Jude’s Children’s Hospital, Memphis dissociated as 
described before [22]. In brief, tumor tissue was minced with scalpels under sterile conditions and 
suspended in Hanks’ Balanced Salt Solution (HBSS, Sigma-Aldrich) supplemented with 1 mmol/L 
MgCl2, 200 µg/mL Liberase, and 200 U/mL DNase I (both Roche). Tissue pieces were digested for 30 
minutes at 37°C and filtered twice through 70 µm cell strainers (BD Biosciences). Dissociated cells were 
washed with phosphate-buffered saline (PBS, Sigma-Aldrich) before freezing or resuspending for further 
culture. 
Both MAST60 and MAST118 cells derived from the respective PDX tumors were cultured in Neurobasal 
medium (Life Technologies) supplemented with 2x B-27™ Supplement (Life Technologies), 20 ng/mL 
EGF and 20 ng/mL basic FGF (Peprotech) on plates coated with Matrigel® (Corning Life Sciences). 
 
Virus production and transduction 
Lentiviral particles (for stable integration of shRNA) were produced in HEK293T cells. In brief, cells were 
transfected with Pax2 and VSV-G plasmids (both Addgene #12259) as well as with the respective 
transfer plasmid using calcium phosphate transfection. Virus containing supernatant was concentrated 
using Amicon Ultra centrifugal filter units (Merck Millipore). aRMS cell lines were transduced with the 
virus particles in presence of 8 µg/mL hexadimethrine bromide (Polybrene, Sigma-Aldrich). Transduced 
cells were selected with 0.5 µg/mL puromycin). MAST118 cells were transduced without Polybrene. 
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RNA-Sequencing 
Inducible shRNA was induced in Rh4 cells with 0.1 µg/mL doxycycline. After 48h and 72h RNA was 
extracted and processed for RNA-Seq analysis as described before [23]. 
 
Chromatin immunoprecipitation (ChIP)-Seq 
Chromatin immunoprecipitation and subsequent sequencing analysis was performed as described 
before [23]. In brief: ChIP assays were performed by using the ChIP-IT High Sensitivity kit (#53040, 
Active Motif) according to the manufacturer’s instructions. Briefly, cells were grown to confluence, fixed 
with 1% formaldehyde (Sigma-Aldrich) for 13 min, harvested and sonicated with the EpiShear™ 
ProbeSonicator (#53052, Active Motif) for 27 cycles (30% amp, 30sec ON, 30sec OFF). Sonicated 
lysates were then quantified and 30ug of chromatin were incubated overnight at 4°C with 5-10ug of 
antibody (antibodies listed in Supplementary Table 5). DNA was purified according to the manufacturer’s 
instructions. 
 
TaqMan qRT-PCR 
RNA was isolated from cells using the RNeasy Mini Kit (Qiagen). 1 µg of RNA was transcribed into 
cDNA using the High Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific). Real-time 
PCR was performed using TaqMan probes (Supplemental Materials) and the TaqMan Gene Expression 
Master Mix (both Thermo Fisher Scientific). Expression changes were calculated using the ΔΔCt method 
with GAPDH as internal control.  
 
Immunoblot 
Cells were lysed with RIPA buffer, suspended in 4xLDS loading buffer (Thermo Fisher Scientific) 
supplemented with 250 mmol/L 1,4-Dithiothreitol (DTT, Sigma-Aldrich). After boiling the samples at 
70°C for 5 minutes, proteins were separated by electrophoresis on 4-12% gradient polyacrylamide gels 
(Life Technologies). Proteins were transferred onto a Protran™ nitrocellulose membrane (GE 
Healthcare). Membranes were blocked in 5% (w/v) milk powder in Tris-buffered saline (TBS)/0.01% 
Tween20 (Sigma-Aldrich) and incubated overnight with primary antibodies at 4°C. Membranes were 
washed in TBS/Tween and incubated with horseradish peroxidase (HRP)-coupled IgG secondary 
antibody for 1h at room temperature. Membranes were washed in TBS/Tween and proteins were 
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detected using ECL detection reagent (Thermo Fisher Scientific) in a ChemiDoc™ Touch Imaging 
system (BioRad).  
Antibodies are described in the Supplemental Materials and Methods section. 
 
siRNA transfection 
Cells were reverse transfected at the time of seeding: 1.13 µL siRNA (stock: 5 µmol/L) (Thermo Fisher 
Scientific, Supplemental Materials) were thoroughly mixed with 11.3 µL of Interferin® (Polyplus) in 150 
µL serum-free medium, incubated for 15 minutes at room temperature and added to the wells. Cells 
were detached using 0.05% Trypsin/EDTA (Thermo Fisher Scientific), adjusted to the appropriate 
number and seeded onto the wells. 
 
Caspase activity assay 
Caspase activity was assessed using Caspase-Glo® 3/7 Assay (Promega) according to manufacturer’s 
protocol. In brief, Assay solution was added directly to each well, plate was covered and shaken, 
followed by incubation at room temperature for 45 minutes. Signal was assessed by measuring 
chemiluminescence.  
 
Statistics 
Statistical analysis was performed using GraphPad Prism 7. Welch’s two-tailed test and Mann-Whitney 
test were used for comparisons. Statistical significance was given at p<0.05. 
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Figure legends 
Figure 1: NOXA is upregulated after silencing of PAX3-FOXO1 
A. Comparative RNA-Seq expression data. FPKM values were analyzed and compared from both 
Rh4shsc (x-axis) and Rh4shP3F (y-axis) cells 48h after induction of shRNA with 0.1 µg/mL doxycycline. 
PMAIP1 (NOXA) indicated as green dot, MDM2 indicated as red dot. Lower panel: Change of FPKM 
values for MDM2 (red), PMAIP1 (NOXA, green), and MYCN (blue) in Rh4shsc and Rh4shP3F cells after 
48h B. Relative mRNA expression of NOXA in Rh4 shsc or shP3F 48h after induction of shRNA with 
0.1 µg/mL doxycycline. Gene expression was normalized to GAPDH. Mean of two independent 
experiments performed in triplicates; bars, SD; Welch’s two-tailed t-test; **, P ≤ 0.01 C. Immunoblot for 
NOXA protein levels in both Rh4 shsc and Rh4 shP3F cells 48h after induction of shRNA. 
Representative blot of at least three independent experiments D. NOXA protein expression in the given 
cell lines with scrambled shRNA (shsc) or shRNA targeting PAX3-FOXO1 (shP3F), 48h after induction 
of shRNA (+) or non-induced control (-). Upper panel: Immunoblots for NOXA and GAPDH, lower panels: 
relative densitometric quantification of protein bands, relative to GAPDH. E. Immunoblots for lysates of 
MAST118 cells stably expressing either shLuciferase (shluc) or shP3F inducible constructs. 48h after 
induction or no induction. 
 
Figure 2: NOXA expression is not regulated by FOXO1 but by MYCN 
A. ChIP-Seq analysis of protein binding at the PMAIP1 locus. DNA from both Rh4 and MAST118 cells 
was isolated and incubated with the respective antibodies to immunoprecipitate bound DNA motifs. 
Sequencing analysis for enriched binding of the histone mark or protein at the PMAIP1 locus. PAX3-
FOXO1: red lane, all other lanes: from Rh4: MYCN: dark blue lane, Pol II: Polymerase II B-C. 
Immunoblots for lysates from Rh4shP3F (B) or RHJTshP3F (C) cells 48h after induction of shP3F (+) or 
no induction (-). Additionally, cells were transfected with siRNA targeting FOXO1, MYCN (N-MYC) or 
not targeting (scr). D-E. Relative caspase 3/7 activity measured by Caspase 3/7 Glo® in Rh4sh cells 
(D) or RHJTsh cells (E) 48h after induction of shRNA (+) or no induction (-). Additionally, cells were 
transfected with siRNA against FOXO1 or MYCN, or with either non-targeting siRNA (scr) or no 
transfection at all (Ctrl). Mean of four independent experiments performed in triplicates; bars, SD; Mann-
Whitney-test, *, p < 0.05 
 
Figure 3: MDM2 is a potential new target gene of PAX3-FOXO1 
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A. MDM2 mRNA expression is reduced after silencing of PAX3-FOXO1. mRNA expression was 
analyzed by qRT-PCR in transgenic 5 cell lines either expressing scrambled shRNA (dark red) or shP3F 
(light red) 48h after induction with 0.1 µg/mL doxycycline. Values indicate the fold-change compared to 
uninduced control. Mean of three independent experiments performed in triplicates; bars, SD; Mann-
Whitney-test; *, p < 0.05; **, p < 0.01 B. Immunoblots for the same cell lines 48h after shRNA induction. 
C. ChIP-Seq analysis of the gene locus. Upper panel: chromosome map indicating the location of the 
MDM2 gene. Lower panel: enrichment of histone marks or protein binding indicated by peaks, red: 
PAX3-FOXO1 (from cells as indicated), all other lanes from Rh4: dark blue: MYCN, Pol II: Polymerase 
II. D. Immunoblot for MDM2, NOXA and GAPDH of lysates from both Rh4shP3F and RHJTshP3F cells 
with or without induction of shRNA as indicated. Additionally, cells were transfected with siRNA against 
MDM2 or non-targeting siRNA (scr) E-H. Immunoblots of lysates from PDX-derived cells (E+F), Rh4 cell 
line (G), or immortalized myoblasts (H). Cells were treated for 48h with increasing concentrations of 
Idasanutlin. 
 
Supplemental Figure 1 
A-B. RNA-Seq data from aRMS cell lines expressing either scrambled shRNA (shsc) or shRNA against 
PAX3-FOXO1 (shP3F) 24h after shRNA induction with 0.1 µg/mL doxycycline.  A. Rh4 cells B. Rh30 
cells. Right panels: individual change of FPKM values for the respective genes after 24h in Rh4 cells 
(A) or Rh30 cells (B). 
 
Supplemental Figure 2 
A. Immunoblot of Rh4shP3F (left panel) and RHJTshP3F cells (right panel) 48h after shRNA induction 
(+) or no induction (-). Additionally, cells were transfected with either non-targeting siRNA (siscr) or 
siRNA targeting p53. B-C. Caspase activity in Rh4shP3F cells (B) or RHJTshP3F cells (C) 48h after 
induction of shRNA (black bars) or no induction (white bars). Additionally, cells were transfected with 
the given siRNAs or siRNA combinations. Mean of two experiments performed in triplicates; bars, SD. 
 
Supplemental Figure 3 
A. Immunoblot to confirm siRNA-mediated knockdown of MDM2 in Rh4shP3F or RHJTshP3F cells, 
respectively. Ctrl: untreated cells (no siRNA). 48h after induction of shRNA with doxycycline (+) or no 
induction (-). B. Binding motif of PAX3-FOXO1 
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Supplemental Material and Methods 
Antibodies 
Antigen  Manufacturer   Host (Clone)  Dilution 
Cl. CASP7  Cell signaling  rb poly (D198)  1:1000 
FOXO1   Santa Cruz  rb poly (H-128)  1:500 
GAPDH  Cell signaling  rb mono (14C10) 1:1000 
MDM2   Genetex  rb poly (100653) 1:500 
MYCN   Cell signaling  rb mono  1:1000 
NOXA   Cell signaling  rb mono (D8L7U) 1:1000 
P21   Cell signaling  rb mono (12D1) 1:1000 
P53   Thermo Fisher Sc ms mono (DO-1) 1:1000 
PARP   Cell signaling  rb poly   1:1000 
 
TaqMan probes 
All probes were ordered as Assay-on-Demand mix (Thermo Fisher Scientific) containing specific primers 
and FAM/BHQ-1 probe. 
Gene Assay ID 
PAX3-FOXO1 Hs03024825 
GAPDH Hs02758991_g1 
PMAIP1 (NOXA) Hs00560402 
MYCN Hs00232074 
MDM2 Hs01066930 
 
Small interfering RNAs 
All siRNAs were ordered from Thermo Fisher Scientific (Cat# 4392420) as lyophilized samples. They 
were resuspended to a concentration of 5 µmol/L for subsequent experiments. 
Target siRNA Assay ID 
FOXO1 s5258 
FOXO3a s5261 
MDM2 s8630 
MYCN s526554 
TP53 s607 
non-targeting (scr) AM4611 
 
shRNA constructs 
In advance we tested three different shP3F sequences targeting the breakpoint region for knockdown 
efficiency and toxicity and continued with shP3F #3. 
Targeting sequences 
#1 CCTCTCACCTCAGAATTCAAT 
#2 CTCTCACCTCAGAATTCAATT 
#3 GGCCTCTCACCTCAGAATTCA 
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7. DISCUSSION 
Optimizing therapy to improve patient outcomes still remains the major challenge in pediatric cancer. 
Conventional chemotherapy and radiation come with the risk of severe adverse effects for the health 
and the proper development of children. Insight into the key dependencies of each individual cancer can 
help tailor new targeted therapy strategies. Our focus of interest is alveolar rhabdomyosarcoma (aRMS), 
an aggressive cancer with myogenic characteristics. While overall survival of RMS patients increased 
with the implementation of the VAC regimen, the curve of cure rates has reached a plateau over the last 
decades, indicating a lack of new therapy options.84,111 In addition, disseminated aRMS still has an 
overall 5-year survival of only around 11%.77 Here, conventional therapy fails and new approaches are 
desperately needed.  
To this end, we aimed to further elucidate the mechanism by which the fusion protein PAX3-FOXO1 
prevents cell death in aRMS tumors and to convert this knowledge into a combination therapy approach 
targeting PAX3-FOXO1 biology and simultaneously priming the cancer cell to a cell death pathway. 
 
7.1 THE ROLE OF NOXA IN PAX3-FOXO1 DEPENDENT CELL DEATH 
Using a CRISPR-mediated knockout screen, we demonstrated that, upon loss of PAX3-FOXO1, aRMS 
cells undergo intrinsic apoptosis that is dependent on NOXA (M1, Fig.1E). To underline this finding, 
another hit in this screen was HUWE1, also known as MCL-1 ubiquitin-ligase E3 (MULE). Depletion of 
this gene led to a partial rescue from cell death, suggesting an involvement in cell death after loss of 
PAX3-FOXO1 (M1, Fig.1E). However, as the name suggests, HUWE1, or MULE, regulates the anti-
apoptotic BCL-2 family member MCL-1 by facilitating its proteasomal degradation.402 MCL-1 in turn is 
the canonical inhibitor of NOXA.153 In our model this would implicate that knockout of HUWE1 leads to 
higher levels of MCL-1, which would in turn lead to reduced NOXA function, thus preventing the cells 
from initiating apoptosis after loss of PAX3-FOXO1. We could extend our knowledge on the regulatory 
mechanisms of cell death by not only identifying the primary pro-apoptotic factor in this context, but, with 
HUWE1, also identify a potential indirect regulator of this factor. Interestingly, despite this role of the 
NOXA-MCL-1 axis in our experiments, we demonstrated that not inhibition of MCL-1 most efficiently 
primed cells for cell death (M1, Suppl. Fig.2O), but rather inhibition of BCL-xL. Treatment with ABT-263 
proved the most efficient approach. Furthermore, we could demonstrate that the effect of ABT-263 is 
NOXA-dependent (M1, Fig. 2G). Although direct interactions between BCL-xL and NOXA have been 
described,197,403 they still remain the exception, suggesting that interaction between NOXA and BCL-xL 
is not direct. BCL-xL has been described as PAX3-FOXO1 target gene,144 which would explain the 
sensitivity of aRMS cells to treatment with ABT-263.  
Interestingly, upregulation of MCL-1 has been described as mechanism of ABT-737/ABT-263 resistance 
in certain cancer types.404 Thus, we could conclude that the NOXA-dependent mechanism of action of 
ABT-263 can be counteracted by MCL-1 overexpression, and additional inhibition of MCL-1 might even 
further enhance the efficiency of ABT-263 treatment. Indeed, inhibition of MCL-1 has been shown to 
overcome resistance against ABT-263 in cancer cells.405 In non-small cell lung cancer, a study could 
show that NOXA displaces and destabilizes MCL-1 and thereby modulates sensitivity of the cells 
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towards ABT-737.406 These findings also underscore the importance of NOXA and MCL-1 levels for 
ABT-263/ABT-737 treatment. In line with these findings, in aRMS, treatment with an mTOR-inhibitor 
reduced MCL-1 expression and sensitized cells to treatment with ABT-737.145 
A major drawback of the clinical translation of ABT-263 was the occurrence of severe side effects, like 
thrombocytopenia in some patients, probably through on-target activity of ABT-263 on BCL-xL.407,408 
Therefore, in our in vivo studies, we regularly assessed weight loss of the mice as an indicator of 
perturbed well-being of the mice. No increased weight loss, could be observed, indicating that the dosing 
was well tolerated (M1, Suppl. Fig. 7B-C). 
Mechanistically, the regulation of NOXA expression appears to be more obscure. We found no evidence 
for a direct transcriptional regulation of PAX3-FOXO1 on the PMAIP1 locus (M2, Fig. 2A). Indirect 
regulation can be facilitated through a large variety of factors, which would require large scale unbiased 
screening approaches for complete coverage. In our experiments we demonstrated that neither 
MDM2/p53 nor wild-type FOXO1 contribute to NOXA expression. We did find though, that MYCN 
regulates NOXA expression in aRMS cells (M2 Fig. 2C-D) and could confirm MYCN binding to the 
PMAIP1 locus by ChIP-Seq data. This finding confirms a recent study showing NOXA upregulation by 
MYCN in MYCN-amplified neuroblastoma.409 Furthermore, this regulation confirms a recent finding, that 
NOXA expression is high in aRMS147. Since MYCN is a known target gene of PAX3-FOXO1,96 
paradoxically, MYCN-dependent regulation of NOXA expression would suggest that NOXA expression 
should decrease upon loss of PAX3-FOXO1 due to concomitant loss of MYCN. However, our 
observations instead show upregulation of NOXA after silencing of PAX3-FOXO1 (M2, Fig. 1). While 
high basal levels of NOXA in aRMS have already been described147, our data indicate that there must 
be other factors involved in NOXA expression which are suppressed under basal conditions by PAX3-
FOXO1. As NOXA is a universal stress sensor, there is a plethora of factors, other than p53 and MYCN, 
known to regulate NOXA expression, for instance HIF-1α, E2F1, c-myc, p73, SalI, ATF3, or c-Jun.410,411 
To unravel the exact mechanism of NOXA regulation after silencing of PAX3-FOXO1 one would need 
to screen for the potential of each factor individually. In addition, one would need to take into account 
the innate role in regulating several critical processes that some of these factors possess. 
Lastly, in the screen to identify drugs enhancing viability loss after silencing of PAX3-FOXO1 (M1, Fig.2), 
we could observe that not only BH3-mimetics are potent drugs to further sensitize aRMS cells to cell 
death, but also Aurora kinase A inhibition resulted in loss of viability. PAX3-FOXO1 has been described 
to be critical for G2/M checkpoint adaptation by which cells can overcome G2/M blockade in case of 
incomplete DNA damage repair. Aurora kinase A was shown to be essential for checkpoint recovery.334 
Inhibition of Aurora kinase A results in mitotic arrest or senescence.347 Indeed, we observed an 
accumulation of cells in G2/M after treatment with the Aurora kinase A inhibitor Alisertib (M1, Fig. 5F). 
Thus, loss of both fusion protein and Aurora kinase A activities potentiate the cell cycle arrest. In this 
case, untreated control cells would outgrow treated cells resulting in lower viability in the screen readout.  
Furthermore, Aurora kinase A has been implicated in regulation of anti-apoptotic BCL-2 proteins. 
Indeed, inhibition of Aurora kinase A has been described to induce downregulation of BCL-xL in cancer 
cells by affecting signaling,374 and to shift the Bax/BCL-2 ratio.375 Such effects, in particular those on 
BCL-xL activity could explain why Aurora kinase A inhibition sensitizes to NOXA-dependent cell death 
in our model. 
 115 
 
In conclusion, our findings demonstrate the importance of NOXA in cell death after silencing of PAX3-
FOXO1, and identify a novel treatment strategy. Treatment efficiency might even be enhanced in MCL-
1 low expressing aRMS tumors or with simultaneous pharmacological inhibition of MCL-1, which could 
also reduce side effects in patients due to lower drug dosing.412 
 
7.2 REGULATION OF PAX3-FOXO1 STABILITY BY AURORA KINASE A 
In this thesis, we can demonstrate that Aurora kinase A regulates PAX3-FOXO1 stability and that 
inhibition of the former reduces fusion protein levels in aRMS cells (M1, Fig.3).  
While we observed reduced PAX3-FOXO1 protein levels with all Aurora kinase A inhibitors tested, the 
extent of reduction varied significantly. This variation can be explained by different pharmacodynamic 
parameters (i.e. binding affinity) for each drug. With 100 nmol/L the drug concentrations for the screen 
were chosen to be on the lower end in order to reduce unspecific effects possibly occurring at high 
concentrations. 
The first question that arose with these results was whether Aurora kinase A exerts direct effects on 
PAX3-FOXO1 and thus would be a novel putative interactor of the fusion protein. However, co-
immunoprecipitation (co-IP) experiments both for PAX3-FOXO1 and for Aurora kinase A showed no 
interaction between these two proteins (data not shown). Nevertheless, kinase-protein interactions are 
known to be transient413 and thus, co-IP protocols might not suffice to capture all interaction partners of 
Aurora kinase A. Recent mass spectrometric analysis (unpublished results), of interaction partners of 
PAX3-FOXO1 did not reveal Aurora kinase A as an interaction partner of the fusion protein. In an 
approach to also capture weak and transient interaction partners, we established the BioID / BirA 
proximity ligation protocol.414,415 Here, the bait protein, in our case PAX3-FOXO1, is fused to a bacterial 
biotin-ligase and incubation of the cells with biotin results in ligation of biotin to any proteins in close 
proximity of the bait (i.e. interacting proteins). Biotinylated proteins can be purified by streptavidin pull-
down. BioID experiments in HEK293T cells, ectopically expressing the PAX3-FOXO1-BioID fusion 
revealed biotinylation of PLK1 which was already described as an interactor before.150 Importantly, also 
Aurora kinase A was biotinylated, indicating that there might indeed be interaction with PAX3-FOXO1. 
The BioID method however, is prone to errors and heavily relies on adequate controls, as spatial 
interaction versus direct interaction cannot be distinguished.416 Thus, our current data does not allow us 
to distinguish between these possibilities. The lack of Aurora kinase A as a hit in former interaction 
studies hints more towards a potential indirect regulation of PAX3-FOXO1 by Aurora kinase A. 
Aurora kinase A activates PLK1 by phosphorylation at Thr210 (Figure 13B). Since PLK1 is known to 
directly phosphorylate and thereby stabilize PAX3-FOXO1, we assume that at least part of the effect of 
Aurora kinase A on the fusion protein depends on PLK1 as a downstream target. Indeed, we could 
observe that inhibition of Aurora kinase A leads to decreased PLK1 phosphorylation at position Thr210.  
Interestingly, we also found that Aurora kinase A activity correlated with levels of PAX3-FOXO1 
phosphorylation at Ser437. This residue so far has not been implicated in fusion protein turnover. The 
site corresponds to Ser256 in wild-type FOXO1, which is known to be phosphorylated by AKT. In other 
studies, it could be shown that loss of Aurora kinase A leads to reduction in phosphorylated Ser256 
levels of FOXO1, thus linking Aurora kinase A expression or activity to FOXO1 phosphorylation.417 
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These findings are in line with our data on the fusion protein, where Ser437 was less phosphorylated 
after inhibition of Aurora kinase A.  
In wild-type FOXO1, phosphorylation at Ser256 is preceded by acetylation at Lys245 and Lys248, and 
results in nuclear exclusion and degradation of the protein (Figure 16A).102 Conversely, while 
acetylation of PAX3-FOXO1 at the corresponding lysine residues Lys426 and Lys429 has been 
demonstrated, it was shown to stabilize the protein, indicating that acetylation and phosphorylation might 
have opposite effects both in wild-type FOXO1 and the fusion protein (Figure 16B).104 Along this line of 
thought, we assumed that following acetylation of the respective residues phosphorylation of Ser437 
would lead to stabilization of PAX3-FOXO1, as opposed to the destabilizing effect of Ser256 
phosphorylation in wild-type FOXO1. However, this phosphorylation so far has not been studied in 
PAX3-FOXO1. Here, for the first time, we established that phosphorylation of Ser437 indeed increases 
fusion protein stability and that lack of this phosphorylation results in decreased stability (Figure 16B).  
Since in wild-type FOXO1 Ser256 is phosphorylated by AKT, we can assume that AKT also is 
responsible for phosphorylation of Ser437 in PAX3-FOXO1 (Figure 16B). Indeed, in several studies 
AKT activity was shown to be regulated by Aurora kinase A, and consequently inhibition of the latter led 
to reduced AKT activity.418–420 Loss of AKT activity after Aurora kinase A inhibition could thus explain 
loss of phosphorylation of Ser437 in PAX3-FOXO1 and its decreased stability. Conversely, this 
mechanism of regulation contradicts data showing that AKT decreases PAX3-FOXO1 activity, albeit at 
unknown phosphorylation sites.421,422 Here, further validation of our data is needed to prove that AKT 
indeed phosphorylates Ser437 and thus enhances fusion protein stability. 
Lastly, it cannot be excluded that Ser437 is a potential new interaction site for PLK1. Indeed, phospho-
site prediction using the GPS 3.0 tool423 indicates possible binding of PLKs to that site (data not shown). 
However, as no further literature exist on PLK1 phosphorylating either wild-type FOXO1 or PAX3-
FOXO1, this mode of interaction is less likely. 
Recently, we demonstrated that PLK1 phosphorylation at Ser503 protects PAX3-FOXO1 from 
proteasomal degradation.150 As for the phosphorylation of Ser437 we so far did not demonstrate a similar 
mechanism. Here, it would be important to show exactly how Ser437 phosphorylation contributes to 
fusion protein stability, irrespective of which kinase is responsible for phosphorylation. 
 
In conclusion, we observed that pharmacological inhibition of Aurora kinase A results in reduced PAX3-
FOXO1 protein levels, making it an attractive target for precision therapy. On the one hand this was 
explained by loss of PLK1 activity but also by reduced PAX3-FOXO1 phosphorylation at Ser437, which 
is another site important for fusion protein stability. 
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Figure 16: Regulation of FOXO1 and PAX3-FOXO1 through phosphorylation and acetylation. A) FOXO1 is first 
acetylated at lysines 245 and 248 which allows for AKT-mediated phosphorylation at serine 256. This results in 
nuclear exclusion and subsequent degradation. B) PAX3-FOXO1 is also acetylated at the corresponding lysines 
(K426/K429) which here stabilizes the fusion protein, potentially through Aurora kinase A regulated phosphorylation 
of serine 437 by AKT (faded purple) 
 
7.3 THE POTENTIAL OF CDK9 INHIBITION TO INTERFERE WITH PAX3-FOXO1 
A second set of hits from the library screen, able to reduce PAX3-FOXO1 protein levels were CDK9 
inhibitors. All three CDK9 inhibitors decreased PAX3-FOXO1 protein levels down to approximately 60-
75%.  
CDK9 is the catalytic core subunit of the positive transcription elongation factor b (P-TEFb). It interacts 
with the C-terminus of RNA polymerase II, thereby stimulating transcription after initiation.424 Thus, 
CDK9 has a critical role in driving gene transcription of a cell. 
Our observation that inhibition of CDK9 leads to reduced PAX3-FOXO1 could therefore hint at a 
transcriptional inhibition of fusion gene expression. So far, information on transcriptional control of 
PAX3-FOXO1 is sparse. While, regulatory enhancers are known for PAX3 expression, these have not 
been validated for PAX3-FOXO1.95 With CDK9 inhibition we would thus have the opportunity to target 
the fusion protein already at a transcriptional level (Figure 9B). However, our findings would first need 
to be validated in order to see whether reduced CDK9 activity indeed leads to reduced PAX3-FOXO1 
expression. The problem here is, that just like epigenetic modifiers such as HDAC inhibitors, the 
downstream effects would affect a large variety of genes and pathways. This might prove true in 
particular for CDK9, as it is known to be a universal factor needed for gene transcription. Here it might 
be difficult to discern potential direct from secondary effects. Secondary effects could comprise 
decreased expression of direct regulatory factors influencing expressing or stability. Despite many 
potential off-target effects due the biology of CDK9, the inhibitor Alvocidib has been approved by the 
FDA as an orphan drug.425 
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Thus, if validated further, CDK9 inhibition might be a potential new strategy to target PAX3-FOXO1 
biology through transcriptional downregulation of the fusion gene.  
 
7.4 SYNERGISTIC EFFECTS OF AURORA KINASE A INHIBITION AND BH3-
MIMETICS 
The effects of Aurora kinase inhibition on cell viability can be explained by loss of PAX3-FOXO1 but in 
addition there are other factors contributing to this outcome. First, Aurora kinase A regulates MYCN by 
protecting it from proteasomal degradation (see Fig. 14). MYCN in turn, a potent oncogene, is a known 
target gene of PAX3-FOXO1144 and in addition is amplified in 28% of aRMS cases86, underscoring its 
importance for this disease. The dependence of tumors on MYCN and the detrimental effects of Aurora 
kinase A inhibition in that regard have already been established, for instance in MYCN-amplified 
neuroblastoma.409 Inhibition of Aurora kinase A thus contributes via several pathways to decreased 
viability in aRMS tumors. On the one hand, it decreases PAX3-FOXO1 stability, thereby altering MYCN 
expression. On the other hand, Aurora kinase A inhibition directly targets MYCN stability, thus 
potentiating the first effect. 
 
Taken together, the high synergy between Aurora kinase A inhibitors and ABT-263 in aRMS can be 
explained by the several mechanisms by which the combination targets the cancer cell. First, there is 
loss of PAX3-FOXO1 stability through Aurora kinase A inhibition. Second, as mentioned above, there 
are direct and indirect effects on MYCN levels, an important oncogene. Third, apart from effects on the 
oncogene stability, Aurora kinase A inhibition has been shown to induce senescence or mitotic arrest 
and thus stop cancer cells from proliferating. Loss of PAX3-FOXO1 in this scenario prevents the cell 
from undergoing G2/M checkpoint adaptation to proceed through the cell cycle. Fourth, ABT-263 has 
been proposed as a senolytic drug to drive the senescent cells into apoptosis.260,395 This effect is 
dependent on BCL-xL which is highly expressed in aRMS cells, as it is a target gene of PAX3-FOXO1.144 
Furthermore, inhibition of Aurora kinase A has been shown to downregulate BCL-xL374, thus shifting the 
balance on the mitochondrial membrane even more towards apoptosis and making ABT-263 treatment 
even more efficient.  
These multifaceted mechanism of action makes this combination so potent against fusion-positive 
aRMS tumors. While the combination of Alisertib and ABT-263 does also show synergy in fusion-
negative eRMS cells, it is not as strong as in aRMS cells. This observation can be explained by the 
combination of mechanisms explained above, which are independent of PAX3-FOXO1. These 
mechanisms of action can affect cancer cells irrespective of fusion status and thus were expected to 
have effects. Importantly though, non-cancer cells like fibroblasts or myoblasts were not affected, giving 
hope for potential therapeutic options with this combination. In addition to that, our in vivo studies 
showed that overall the combination treatment was well tolerated by the mice. 
In conclusion, using Aurora kinase A inhibition and BH3-mimetics, we found a potent combination 
therapy approach, that shows high synergy in vitro and in vivo. 
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7.5 THE ROLE OF AURORA KINASE A IN OTHER TRANSCRIPTION FACTOR 
DRIVEN CANCERS 
The importance of Aurora kinase A in sarcomas has only been sparsely investigated. However, there is 
a clear correlation of Aurora kinase A expression and overall survival in several sarcomas as can be 
found seen in Figure 17. Unfortunately, no such data exists for RMS patients but an equally dire 
prognosis for Aurora-high patients can be predicted. This estimation is supported by the important role 
of Aurora A in stabilizing PAX3-FOXO1 and MYCN, which is amplified in almost one third of aRMS 
cancers86. Thus, Aurora kinase A has an important role in aRMS that potentially results in worse 
prognosis as well and would provide a new target for targeted therapy approaches. 
 
 
Figure 17: Overall survival rates of patients with different pediatric cancers, divided into Aurora kinase A high and 
low expressing groups. Data obtained from the R2: Genomics Analysis and Visualization Platform (http://r2.amc.nl) 
 
Figure 17 exemplifies the bad prognosis for Ewing’s sarcoma patients if Aurora A is highly expressed. 
This is particularly interesting, as Ewing’s sarcoma, just like aRMS, is also driven by an oncogenic 
transcription factor (EWS-FLI1), as a result of a chromosomal translocation. Here it would be interesting 
to establish whether Aurora kinase A could contribute to EWS-FLI1 stability in a similar manner as we 
demonstrated with PAX3-FOXO1. These insights might reveal general mechanisms how Aurora kinase 
A contributes to stability of fusion protein transcription factors irrespective of the cancer type. However, 
such contribution of Aurora kinase A in other sarcomas has not been established so far. In Ewing’s 
sarcoma it could be shown that Aurora kinase A is a target gene of EWS-FLI1 but no direct interaction 
or effect on stability was demonstrated.426 Also, in synovial sarcoma, another transcription factor-driven 
disease, regulation of Aurora kinase A and the fusion protein SS18-SSX has not been investigated so 
far. Although, as with PAX3-FOXO1 in aRMS, it has been established also here that the fusion proteins 
are critical for maintenance of their respective sarcomas,427,428 the pitfalls when targeting a transcription 
factor remain. Thus, further knowledge of the biology of these oncogenic transcription factors could 
provide new targets for precision medicine and maybe Aurora kinase A, as potential interactor, could be 
a worthy option in these cancers.  
However, while our data raise hopes for a potential new therapy in children and adolescents with aRMS, 
numerous past studies show that the clinical efficacy of this approach remains to be demonstrated. 
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7.6 THE ROLE OF MDM2 AS A POTENTIAL TARGET GENE OF PAX3-FOXO1 
Lastly, during our studies, we found hints that MDM2 potentially may be a novel target gene of PAX3-
FOXO1. The first indications were derived from transcriptome analyses comparing aRMS cells before 
and after silencing of PAX3-FOXO1. Here, we observed a reduction of MDM2 expression of around 
70% in the PAX3-FOXO1-silenced cells. To validate this finding, we analyzed five different cell lines by 
qRT-PCR and Western Blot. Indeed, we found that both MDM2 mRNA and protein expression were 
reduced upon shRNA-mediated silencing of PAX3-FOXO1. Though these findings indicate a regulatory 
connection between PAX3-FOXO1 and MDM2, they allow no further conclusions whether the regulation 
is direct or indirect. To further investigate this regulation, we analyzed data from ChIP-Seq experiments. 
Indeed, in the Rh4 cell line we found PAX3-FOXO1 to be enriched at the promoter region of MDM2. In 
addition to that, the epigenetic signature at this position hinted at active transcription. However, as this 
result was only obtained from one cell line, it needs to be validated in additional cells, such as those 
from PDX material, and functional tests are required to confirm MDM2 as a target gene of PAX3-FOXO1. 
MDM2 was not connected to NOXA expression in our cell line models. However, most cell lines become 
deficient for p53 activity or signaling as an adaption to the culture conditions.429 Typically, aRMS tumors 
are not deficient for p53 and thus, in primary cell models MDM2 might contribute to NOXA expression.  
The importance of MDM2 as an oncogene in RMS to disrupt p53 function is further supported by the 
fact that amplification of the MDM2 locus is commonly observed in eRMS while p53 is almost never 
mutated (Figure 8).85 In aRMS PAX3-FOXO1 mediated expression of MDM2 could ensure reduced 
activity of p53. These findings could indicate that pharmacological disruption of the MDM2/p53 
interaction could provide a new means of targeting RMS cells. Already in 2009 a pre-clinical study 
demonstrated that treatment with Nutlin-3 induced cell death in rhabdomyosarcoma cell lines, supporting 
this hypothesis.430 Nutlins are a class of small molecule inhibitors, disrupting the MDM2/p53 interaction, 
thus stabilizing the tumor suppressor in cancer cells.431 
In line with these findings, we observed that cells derived from the aRMS patient-derived xenografts 
MAST60 and MAST118 express wild-type p53. Consequently, treatment with Idasanutlin resulted in 
increased p53 levels and caspase activity, reflecting their sensitivity towards this mechanism of action. 
Here, we demonstrate, for the first time, sensitivity of patient-derived aRMS cells to MDM2/p53 
disruption. It would be interesting to investigate whether this sensitivity was also given in both Ewing’s 
sarcoma and synovial sarcoma, the other transcription factor-driven sarcomas. Here knowledge of the 
p53-status could provide new treatment options with Nutlins. 
Nutlins and other small molecule antagonists of MDM2 are used in pre-clinical studies and a few early 
clinical trials give hope that this therapy might in the future progress further into the clinic.432,433  
In conclusion, we found evidence of a PAX3-FOXO1-dependent regulation of MDM2 expression, though 
we cannot conclude direct activity of the fusion protein on the MDM2 promoter. Furthermore, we 
demonstrated for the first time, sensitivity of PDX-derived “primary” aRMS cells to pharmacological 
MDM2 inhibition. 
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7.7 CONCLUSION 
Overall, our studies presented in this thesis are summarized in the graphical scheme of Figure 18. We 
demonstrate that loss of PAX3-FOXO1 in aRMS cells results in intrinsic apoptosis that is dependent on 
NOXA. NOXA expression is regulated by MYCN, a target gene of PAX3-FOXO1. Furthermore, we show 
a novel important role for Aurora kinase A in aRMS cells. Inhibition of Aurora kinase A led to reduced 
stability of PAX3-FOXO1 facilitated by loss of phosphorylation at Ser437. In accordance with published 
literature, Aurora kinase A inhibition also reduced MYCN protein stability. In a search for a combination 
therapy approach, based on our findings, we found that treatment with Alisertib and ABT-263 
synergistically induced cell death in vitro and with lasting effects delayed tumor growth in vivo. 
Furthermore, we found that primary aRMS cells can also be sensitized to cell death using Idasanutlin. 
Thus, this thesis sheds light onto how PAX3-FOXO1 biology prevents cell death in aRMS, thereby 
contributing to malignancy of the disease. In addition, we introduce a novel combination therapy 
approach in aRMS that might provide new chances in the fight against a dreadful disease of the young.  
 
 
 
 
 
 
 
Figure 18: A) 
Regulatory 
network around 
PAX3-FOXO1 
and Aurora 
kinase A, 
including 
transcriptional 
activity of MCYN 
on NOXA. B-C) 
Activities of pro-
apoptotic BCL-2 
proteins (blue) 
and anti-apoptotic 
BCL-2 proteins at 
the mitochondrial 
membrane. 
NOXA displaces 
MCL-1 and 
Navitoclax can 
inhibit BCL-xL, 
allowing for pore 
formation and 
release of 
cytochrome c 
(red dots) into the 
cytosol. Red 
inhibitory arrows 
indicate 
pharmacological 
intervention. 
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